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ABSTRACT 
Background  
The optimal exercise load/intensity for exercise programs for individuals with metabolic 
syndrome (MetS) has not been investigated. One method of determining optimal exercise 
load is to measure the blood lactate transition threshold (BLTT), referred to as the 
anaerobic threshold (AT). The first part of this thesis (study 1) investigated the 
reproducibility of BLTT testing and the consequent determination of AT via the Mader 
method (Mader et al. 1986) and a modified form of the ADAPT method (Cheng et al. 
1992) in patients with MetS. Furthermore, a comparison of the reproducibility of the AT 
determination using the Mader et al. (1986) method as opposed to the ADAPT method 
has not been investigated in MetS patients. 
 
The effect of specific exercise protocols on the different components of MetS has also not 
been investigated. Therefore, the second study in the thesis compared the effects on the 
components of the MetS of an exercise program that uses BLTT (specifically, the AT) to 
those of a comparable exercise program (not using AT) taken from the literature. The 
main aim of the study was to design an exercise program that optimized exercise 
responses and may thus improve metabolic characteristics in individuals with MetS.  
 
The third part of the thesis (study 3) focused on the relationship between cardio-
respiratory fitness and the components of the metabolic syndrome. This study developed 
multiple regression models to find the principal variables that associated with peak 
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oxygen consumption (VO2 peak) and AT in persons with MetS. Regression models were 
also developed to investigate whether these variables were associated with the individual 
metabolic and cardiovascular components of the metabolic syndrome. 
Methods  
In study 1, fifteen male patients diagnosed with MetS (age: 43.5 ± 7.52 years) and fifteen 
healthy, male participants (age: 44.1 ± 6.08 years) each performed a peak oxygen 
consumption and BLTT test simultaneously using an incremental protocol to exhaustion 
on a treadmill, at the same daily times, on three different days. 
 
Study 2 used three subject groups. One group consisted of ten participants (male, age: 
48.3 ± 7.32 years) with MetS that exercised using the walking program of Leon et al. 
(1979) (MetSL). A second group consisted of ten participants (male, age: 40.8 ± 8.21 
years) with MetS that exercised using velocity at AT to set training intensities (MetSV). 
A third group consisted of ten participants (male, age: 40.2 ± 7.90 years) without MetS 
that exercised using velocity at AT to set training intensities (Non-MetSV). Training 
durations and frequency varied from 20 – 90 minutes and 3 -5 days per week 
respectively.  Height, body mass, waist circumference, blood pressure, fasting plasma 
triglyceride, total cholesterol, HDL-, LDL- cholesterol, insulin levels, VO2 peak and 
BLTT were measured in all groups before, during and after twenty weeks of exercise. In 
addition, oral glucose tolerance tests (OGTT) were administered to all participants. 0 
min, 30 min and 2 hours plasma glucose and insulin levels were measured during the 
OGTT. HOMA-IR and insulinogenic indices were also calculated.  Nutritional data were 
recorded at week 0, 8 and 20 of training.  
vii 
 
 
In study 3, thirty-one males diagnosed with MetS and twenty-four healthy male 
participants each performed a VO2 peak and a BLTT test. Height, mass, waist 
circumference, blood pressure, fasting plasma triglyceride, total cholesterol, HDL-
cholesterol and insulin levels were also measured. In addition, oral glucose tolerance tests 
(OGTT) were administered to all participants and HOMA indices were calculated.  
Results  
There was no significant difference in treadmill velocity at AT determined by the Mader 
method or the Modified ADAPT method within both groups of study 1 (p > 0.05). The 
mean treadmill velocity at AT was higher in the healthy compared to the MetS group 
using both the Mader and the ADAPT method. Regression analysis and ANCOVA in 
study 1 demonstrated that this difference was largely due to a higher VO2 peak in the 
healthy group. The study also found an association between VO2 peak and waist 
circumference. The coefficient of variation of repeat measurements for both the Mader 
method and the Adapt method was less than 4% indicating good reproducibility. This was 
confirmed by the typical error method of Hopkins (2000). 
 
Study 2 showed that body mass, BMI and waist circumference decreased significantly in 
all training groups with the training program using AT and the program not using AT 
showing similar outcomes in these variables among persons with MetS. Velocity at AT 
also improved in all training groups. While VO2 peak increased (p < 0.05) in both the 
MetS groups, it did not change significantly in the group without MetS. Similarly, the 
blood pressure response was favourable in the groups with MetS yet absent in the group 
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without MetS. The training group with MetS that used AT was the only group to show 
significant, positive changes in any of the metabolic parameters (fasting insulin and 
HOMA). This group also showed the greatest change in the incidence of MetS. 
 
In study 3, presence of MetS, waist circumference and AT were found to associate with 
VO2 peak and VO2 peak was strongly correlated with AT. Age and body mass were found 
to correlate with fasting glucose, whilst only age correlated with HDL-cholesterol. Age 
and VO2 peak both correlated with systolic blood pressure but only VO2 peak had a 
significant association with diastolic blood pressure.   
Conclusions  
Study 1 demonstrated that BLTT tests are reproducible in persons with MetS.  Study 2 
demonstrated that an endurance exercise program using AT to set intensity is effective in 
eliciting favourable responses in individuals diagnosed with MetS. In addition, the 
training program using AT elicited the responses with a reduced exercise frequency and 
intensity. It also improved insulin sensitivity which was not affected by the walking 
program. The response to the exercise program that used AT was similar in persons with 
MetS and in persons without MetS, except in the central cardio-vascular adaptations of 
VO2 peak and in the metabolic parameters of fasting insulin and the HOMA index. Study 
3 found that the lower VO2 peak of participants with MetS is associated with their higher 
waist circumference. The VO2 peak, in turn, was shown to correlate with anaerobic 
threshold. Therefore, reducing waist circumference in persons with MetS needs to be a 
focus of intervention programs for such a group. This study also found that both diastolic 
and systolic blood pressures were associated with cardio-respiratory fitness (VO2 peak). 
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This further supports the benefit of increasing cardio-respiratory fitness in persons with 
MetS. 
 
The results of these studies showed that BLTT tests are simple, low-cost, reproducible 
ways of setting exercise intensity for persons with MetS that can be incorporated in the 
routine cardio-respiratory fitness assessment of an individual. Furthermore, the 
determination of AT from such tests can be used to design an individualized exercise 
program that can “reverse” the effects of MetS. 
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CHAPTER 1 
INTRODUCTION AND AIMS 
 
Metabolic syndrome (MetS) or Syndrome X is a complex of interrelated risk factors for 
cardiovascular disease (CVD) and diabetes. The National Cholesterol Education Program 
(NCEP) Expert Panel in 2002 (NCEP, ATP III, 2002) defined it as a cluster of three or 
more of the following: 
a)  fasting plasma glucose concentration > 6.1 mmol.L-1; 
b)  serum triglyceride concentration > 1.69 mmol.L-1;  
c)  serum high-density lipoprotein (HDL) cholesterol concentration lower than 1.04 
mmol.L-1;  
d) blood pressure > 130/85 mmHg or controlled with medication  
e) waist circumference of more than 88 cm in women and 102 cm in men. 
 
In April 2005, the International Diabetes Federation (IDF) introduced an alternative 
definition (Alberti et al. 2005) which stated that patients must have central obesity 
(defined as waist circumference > 94 cm for Europid men and > 80 cm for Europid 
women , >90 cm for Asian men and >80cm for Asian women); with any two of the 
following: 
a) serum triglyceride concentration > 1.7 mmol.L-1 
b) high-density lipoprotein (HDL) concentration < 1.03 mmol.L-1 for men, and  
< 1.29 mmol.L-1 for women 
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c) blood pressure: > 130/85 mmHg 
d) previously diagnosed Type 2 diabetes or a raised fasting plasma glucose 
concentration > 5.6 mmol.L-1  
 
Recently an attempt was made to resolve the differences between definitions of MetS.  
It was agreed that abdominal obesity (waist circumference) should not be a prerequisite 
for diagnosis but that it is one of the five criteria. When an individual has any three of the 
five risk factors, a diagnosis of MetS can be made (Alberti et al. 2009). This definition 
agrees with the NCEP ATP III (2002) definition stated above. According to the American 
College of Sports Medicine (ACSM) guidelines, the NCEP ATP III definition is the most 
commonly used for diagnosis (ACSM, 2013). 
 
Physical activity has been identified as a therapeutic goal and is recommended for the 
management of MetS (Carroll et al. 2004; Eckel, 2005; Hafidh et al. 2005; Liberopoulos 
et al. 2005; Stone et al. 2005). Currently exercise guidelines for MetS are the same as 
those for obesity with consideration given to the presence of any CVD risk factors 
(ACSM, 2013). Yet, MetS is a multi-faceted disease and the effect of specific exercise 
protocols on the different components of MetS has not been investigated. Therefore, the 
main aim of this PhD study was to design an exercise program to optimize exercise 
responses and improve metabolic characteristics in individuals with metabolic syndrome.  
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The blood lactate transition threshold (BLTT) referred to as the anaerobic threshold (AT), 
was used to optimize the exercise response. The AT was used since it is a point of 
optimal exercise overload. Overload is a critical principle of physical training in exercise.  
 
In order to determine this point, the AT needs to be measured. Therefore, the first part of 
this PhD (Study 1) aimed to investigate the reproducibility of blood lactate testing and the 
determination of AT via the Mader (Mader et al. 1986) and ADAPT (Cheng et al. 1992) 
methods in patients with MetS. Furthermore, since the BLTTs of patients with MetS have 
not been described by previous studies, Study 1 also aimed to describe the BLTT of such 
patients. 
 
The hypotheses tested in Study 1 were: 
       a) Blood lactate transition thresholds are reproducible in patients with Met S. 
       b) The ADAPT method of determining blood lactate transition thresholds is         
       comparable to the Mader (4 mmol.L-1) method of determining blood lactate   
       transition thresholds. 
 
The second part of the PhD (Study 2) compared how individuals with MetS respond to 
two different exercise programs. One exercise program has been validated in a previous 
study (Leon et al. 1979) using obese participants and does not use AT to set exercise 
intensity. The other exercise program used AT to set exercise intensity. The Leon et al. 
(1979) study was chosen since obesity is a component of MetS and the study showed 
improved metabolic profiles at high exercise volumes. The exercise program using AT 
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uses a moderate exercise volume. The intention of using AT was to individualize the 
exercise program and optimize the improvements in metabolic characteristics at lower 
exercise volumes. In addition, previous studies had not investigated the metabolic 
improvements that could result by training at AT. The aim of Study 2 was to show that 
patients will achieve greater responsiveness in their MetS profile (i.e. improve the 
“cluster” of MetS risk factors) when exercise intensity is set using velocity at AT.  
 
The third part of the thesis focused on the relationship between cardio-respiratory fitness 
and the components of  the metabolic syndrome. The role of cardio-respiratory fitness in 
the attenuation of MetS has been noted in the literature (Carroll et al. 2004; Katzmarzyk 
et al. 2003; Katzmarzyk et al. 2004). However, the determinants of cardio-respiratory 
fitness measurements such as VO2 peak and anaerobic threshold (AT) have not been 
identified in persons with MetS. This study developed multiple regression models to find 
variables that correlate with VO2 peak and AT, in persons with MetS. Regression models 
were also developed to investigate whether cardio-respiratory fitness measurements were 
associated with the individual metabolic and cardiovascular components of the metabolic 
syndrome. The hypothesis tested in study 3 was that cardio-respiratory fitness 
measurements are correlated to the individual components of MetS and thus physical 
activity may be the mechanism for reversing the syndrome. 
 
The aims of this thesis can therefore be summarised as: 
(a) to assess the reproducibility and levels of blood lactate transition thresholds in persons 
with MetS. 
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(b) to assess the effectiveness of an exercise program using BLTT in persons with MetS. 
(c) to find the variables that correlate with cardio-respiratory fitness in persons with MetS 
and investigate the association of components of the MetS with cardio-respiratory fitness 
measurements.  
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LITERATURE REVIEW 
 
1.1 Association of Metabolic Syndrome with Diabetes and Cardiovascular Disease 
MetS has been identified as a major health challenge of the 21st century (Alberti et al. 
2009; Chan et al. 2005; Wilson et al. 2003) and is currently used extensively as a 
significant predictor of CVD and type 2 diabetes mellitus (Carroll et al. 2004; Chan et al. 
2005; Eckel et al. 2005; Malik et al. 2004; Meigs 2004; Reaven, 1995; Wannamethee et 
al. 2005; Wilson et al. 2003).  
Nesto (2005) cites the Kuopio study which found the risk of cardiovascular death with 
MetS to be 10% at 10 years after the diagnosis of MetS and correspondingly the risk of 
nonfatal MI, stroke, or all-cause death was 18%. Ninomiya et al. (2004) also reported an 
association between metabolic syndrome and myocardial infarction and stroke. Meigs 
(2002), showed that individuals exhibiting metabolic clustering related to insulin 
resistance have a 4 - 11 fold increased relative risk for type 2 diabetes and a 2 – 4 fold 
increased risk of cardiac mortality compared with individuals without this syndrome. In 
addition, Girman et al. (2004) showed that patients with metabolic syndrome had 
increased risk of CVS events regardless of Framingham risk category. 
 
In contrast, data from the San Antonio Heart Study showed that the MetS was inferior to 
established prediction models for prediction of either type 2 diabetes or cardiovascular 
disease (Stern et al. 2004). The American Diabetes Association have also identified eight 
major concerns regarding the clinical value of the diagnosis of MetS (Kahn et al. 2005).   
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Furthermore, Sattar et al. (2008) showed that fasting plasma glucose is as good as a 
diagnosis of MetS for predicting diabetes. Their analysis also showed that a diagnosis of 
the MetS has negligible association with risk of cardiovascular disease. However, Kahn 
(2008) comments that the syndrome’s greatest strength is that its identification will 
improve patients’ outcomes. Also, that people with MetS are at an increased risk of 
cardiovascular disease does not mean that the construct is useful for risk prediction. Kahn 
(2008) concludes that more research is needed to understand risk factor clustering and the 
pathogenesis of insulin resistance rather than seeking a diagnosis of the metabolic 
syndrome. 
 
1.2 The Pathophysiology of Metabolic Syndrome 
Researchers have acknowledged insulin resistance as the central component of MetS (De 
Fronzo et al. 1991; Eckel, 2005; Nesto, 2005). In this regard, Eckel (2005) have proposed 
the following model for the pathophysiology of MetS: free fatty acids (FFA) are released 
from an enlarged adipose tissue mass. In the liver, these FFAs cause hepatic insulin 
resistance that in turn causes an increased production of glucose, triglycerides and 
secretion of very low density lipoproteins (VLDL). Associated abnormalities include 
reductions in HDL cholesterol and an increased density of low density lipoproteins 
(LDL). In muscle, FFAs also reduce insulin sensitivity by inhibiting insulin-mediated 
glucose uptake (Eckel, 2005). Associated problems with this include a reduction in 
glucose partitioning to glycogen and increased lipid accumulation as triglyceride. 
Increases in circulating glucose and to some extent FFA increase pancreatic insulin 
secretion resulting in hyperinsulinaemia. Hyperinsulinaemia may result in increased 
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sodium reabsorption and increased sympathetic nervous system activity (Eckel, 2005). 
This may contribute to the hypertension, as might increased levels of circulating FFAs. 
 
In addition, contributory to the insulin resistance produced by excessive FFAs is the 
paracrine and endocrine effect of the proinflammatory state. A variety of adipose tissue 
cells (eg. adipocytes and monocyte-derived macrophages) increase secretion of 
interleukin-6 (IL -6) and tumor necrosis factor alpha (TNF-Į) (and others), which result 
in increased insulin resistance and lipolysis of triglyceride stores to circulating FFAs. The 
increased circulating IL-6 and other cytokines enhance hepatic glucose and VLDL 
production and insulin resistance in muscle (Eckel, 2005). Cytokines and FFAs also 
increase the production of hepatic fibrinogen and plasminogen activator inhibitor-1 
(PAI-1) that complements the overproduction of PAI-1 by adipose tissue. Furthermore, 
the production of the insulin - sensitizing and anti-inflammatory cytokine, adiponectin, is 
reduced. Finally, IL-6 has also been shown to promote synthesis of C-reactive protein 
(CRP) (Reaven, 2005) and high CRP levels have been associated with a state of chronic 
inflammation (Alberti et al. 1998). All the above-mentioned factors contribute to the pro-
thrombotic/ inflammatory state associated with MetS. 
 
The pathogenesis of insulin resistance as a linking factor for MetS though remains 
unclear (Alberti et al. 2005; Eckel, 2005). An alternative concept has been suggested by 
Unger (2003) citing leptin resistance as the linking factor. Recently though Peterson et al. 
(2007) investigated the hypothesis that insulin resistance in skeletal muscle promotes the 
development of artherogenic dyslipidemia associated with MetS, by changing post-
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prandial energy storage. These researchers showed that insulin resistance in skeletal 
muscle promotes dyslipidemia by changing the pattern of the metabolism of ingested 
carbohydrates away from skeletal muscle glycogen synthesis toward hepatic lipogenesis 
which results in an increase in plasma triglyceride levels and a decrease in plasma high-
density lipoproteins levels. This study also showed that insulin resistance was 
independent of changes in plasma TNF-Į; IL-6 (and other plasma adipocytokine) levels 
or intra-abdominal obesity, suggesting that these factors are not influential in the 
development of insulin resistance during the early stages of MetS. The researchers 
suggested that abdominal obesity and non-alcoholic fatty liver disease appears later in the 
course of MetS and is more likely a consequence of skeletal muscle insulin resistance 
rather than a primary cause of insulin resistance and dyslipidemia.  
 
Although it has been suggested that insulin resistance is the central etiological factor for 
the MetS, epidemiological data do not support the idea that this can account for all of the 
cluster abnormalities. Studies have suggested that hyperleptinemia (leptin resistance) 
rather than hyperinsulinemia may play a central role in the genesis of the risk factor 
cluster that constitutes MetS (Zimmet et al. 1999). Hyperleptinaemia and leptin resistance 
may contribute to hypertension, impaired glucose metabolism, and pro-atherogenic state 
in MetS (Marcelo et al. 2006). Furthermore, leptin-resistance has been associated with 
elevated neuropeptide Y levels (Marcelo et al. 2006) and elevated neuropeptide Y levels 
have been shown to lead to obesity and the MetS (Kuo et al. 2008). 
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Furthermore, glucocorticoid (GC) excess has also been associated with the MetS (Wang, 
2005). A good correlation was observed between total urinary GC metabolites and the 
number of features of the MetS in an elderly cohort of patients (Andrew et al. 2002). 
Additional studies have also suggested correlation of increased GC activity with insulin 
resistance, hyperglycemia and hypertension (Filipovsky et al. 1996; Walker et al. 1998). 
The following have been cited as mechanisms for the metabolic effects of glucocorticoids 
on features of MetS:  
x In the liver, GCs increase the activities of enzymes involved in fatty acid 
synthesis and promote the secretion of lipoproteins (Diamant et al. 1975; Itoh et 
al. 1977). Liver fat also appears to be involved in the negative regulation of 
hepatic insulin sensitivity (Samuel et al. 2004) and is associated with certain 
features of the MetS (Seppala-Lindrood et al. 2002). Therefore, liver fat 
accumulation promoted by GCs is likely to contribute to the pathophysiology of 
the MetS. 
x GCs also induce the hepatic gluconeogenic pathway via the activation of the rate-
limiting enzymes in gluconeogenesis, phosphoenolpyruvate carboxykinase and 
glucose-6-phosphatase (Friedman et al. 1993), which results in increased hepatic 
glucose output and hyperglycemia.  
x In adipose tissue, GCs promote the differentiation of pre-adipocytes to adipocytes, 
which leads to increased body fat mass (Hauner et al. 1989). Furthermore, once 
differentiated, the adipocytes develop insulin resistance in the presence of GCs 
(Olefsky, 1975).   
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x GCs may also induce insulin resistance in skeletal muscle (Dimitriadis et al. 
1997).  
x In addition, GCs reduce GLUT4 translocation in adipose and skeletal muscle 
tissue that contribute to peripheral insulin resistance (Wang, 2005). 
x Furthermore, GCs are agonists of the mineralocorticoid receptor (MR), which 
upon activation may lead to renal salt retention and elevated blood pressure 
(Lloyd-MacGlip et al. 1999).  
 
Tooke (1998) has suggested that vascular changes occur prior to the emergence of 
Type 2 diabetes and act to increase vascular resistance at the arteriolar level. All of 
the individual components of the MetS appear to have an adverse effect on the 
endothelium and its capacity to vasodilate or may be caused by endothelial 
dysfunction. Endothelial dysfunction is manifested by impaired vasodilatation in 
response to stimulators of endothelium-derived nitric oxide synthesis. Evidence that 
insulin’s vasodilating effect is mediated by nitric oxide (Steinberg et al. 1994) has led 
to research suggesting that insulin resistance may be caused by inadequate blood flow 
to skeletal muscle and resulting diminished glucose extraction. 
 
Endothelin-1 (ET-1), a potent vasoconstrictor peptide, may also contribute to 
endothelial dysfunction through its inhibitory effects on nitric oxide (NO) production 
(Kalani, 2008). Furthermore, ET-1 reduces insulin sensitivity and may take part in the 
development of the metabolic syndrome (Kalani, 2008). 
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Evidence also exists to support a genetic basis of the syndrome including single gene 
defects in lamin A/C, 1-acylglycerol-3-phosphate, O-acyltransferase, and seipen (Hegele, 
2003). Genome-wide scan analysis has shown strong signals linked to all traits of MetS 
on chromosomes 1, 2 and 16, also suggesting possible harbouring of major genes for this 
syndrome (Chan et al. 2005). In addition, these researchers proposed that a central neuro- 
hormonal dysregulation is characterised by activation of stress–related hormones such as 
cortisol and catecholamines and an age-associated decline in sex hormones and growth 
hormone. These changes might lead to increased deposition of visceral adiposity 
associated with insulin resistance and MetS. 
 
MetS can also be accompanied by other alterations not included in the diagnostic criteria. 
These include increases in apolipoprotein B and Apolipoprotein C-111, uric acid, 
prothrombotic factors, serum viscosity, homocysteine, white blood cell count; the 
presence of microalbuminuria, non-alcoholic fatty liver disease, obstructive sleep apnoea 
and polycystic ovarian disease (Eckel, 2005). 
 
It can therefore be seen that the aetiology of MetS is still not fully understood and is an 
area of intensive research. Furthermore, MetS is related to other areas of metabolic 
dysfunction other than those used in its diagnosis. It is possible that future research will 
lead to the extension of the criteria for MetS diagnosis to these other metabolic variables.   
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The National Cholesterol Education Program have suggested increased physical activity 
as the basis of therapy for MetS (NCEP, 2002). Yet protocols for an effective training 
program for this syndrome have not been devised. Furthermore, MetS is a multi-faceted 
disease and the effect of specific exercise protocols on the different components of MetS 
have also not been investigated. Study 2 of this thesis investigated an exercise program 
that uses blood lactate transition thresholds (BLTT, specifically the anaerobic threshold 
(AT)) to optimize exercise responses and thus improve metabolic characteristics in 
individuals with MetS. The review will thus now focus on research involving BLTT 
testing and then the use of BLTT in the design of training programs.  
   
1.3 Blood Lactate Transition Threshold Testing 
Measurement of BLTTs in conjunction with heart rate, oxygen consumption (VO 2), and 
workload have been used in athletes: 
a) as more sensitive indicators of training adaptations (Denis et al. 1982; Edwards et 
al. 2003; Gollnick et al. 1986; Karlsson et al. 1982; Kohrt et al. 1989; Sjodin et al. 
1982; Tanaka et al. 1986). 
b) as better indicators of endurance performance (Bishop et al. 1998; Coyle et al. 
1991; Farrell et al. 1979; Faude et al. 2009; Heck et al. 1985; Karlsson et al. 1982; 
Sjodin et al. 1982; Sjodin et al. 1985; Tanaka et al. 1983; Weltman et al. 1987; 
Weltman 1995; Yoshida et al. 1987); and of prolonged, high intensity, intermittent 
running performance in team sports (Sirotic et al. 2007). There is also evidence to 
suggest that any point used consistently in the lactate curve during exercise can be 
used as an index of performance (Tokmakidis et al. 1998). 
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c) as best indices for setting the exercise intensities of training programs (Coen et al. 
1991; Sjodin et al. 1982; Stegmann et al. 1982; Weltman et al. 1992; Weltman 1995; 
Yoshida et al. 1982). 
The AT has been used in prescribing exercise intensity among healthy, non-athletes 
(Weltman et al. 1992) and among adults with cardiac disease (Coyle et al. 1983). Blood 
lactate measurement, integrated with the objectives above, has not been investigated and 
applied to exercise programming for MetS. 
 
Furthermore, automated blood lactate analysers have made lactate measurement 
uncomplicated and accessible, whilst many individuals find the VO2 peak tests 
uncomfortable and difficult. Many are claustrophobic and cannot perform a VO2 peak test 
easily (i.e. the maximal exercise criteria of the test cannot be attained). In addition, VO2 
peak tests require exercising to exhaustion. In a clinical setting this is not desirable due to 
risk and is difficult to attain (Faude et al. 2009). Lactate measurements are easier to 
administer because they can be performed during sub-peak exercise, are cheaper to 
administer and do not need highly specialized staff. 
 
Shifts in the blood lactate – work intensity curves of BLTTs can also be used to assess 
exercise adaptations on a more regular basis than that of peak VO 2 testing (Weltman, 
1995). It is generally accepted that a down- and rightward shift of the lactate curve 
denotes an improved endurance capacity (Acevedo et al. 1989; Bosquet et al. 2002; 
Yoshida et al. 1990); is a marker of cellular adaptations to exercise; and reflects training 
adaptations with greater sensitivity than VO 2 max or VO2 peak (Coen et al. 1991). This 
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allows for regular feedback to patients, which in turn helps adherence and exercise 
program adjustment. An even more practical option could be to perform a single bout of 
exercise at a constant speed/pace/power output and monitor the blood lactate 
concentration at the end of the bout. The blood lactate concentration at the end of an 
exercise bout should decrease with each testing session (Costill et al. 1985). 
 
One problem in interpreting literature about BLTT that many terms have been used to 
describe the thresholds. This research will utilise the following two terms to describe the 
two thresholds that have been found in the blood lactate response during incremental 
exercise: 
1) The Lactate Threshold (LT): The lactate threshold is defined as the first 
workload at which there is a sustained increase in blood lactate levels above 
resting levels. This point generally occurs at blood lactate levels below  
2 mmol.L-1. Other descriptions given to this threshold include:  
o Aerobic Threshold - fixed at 2mmol.L-1 (Bourdon, 2000; Faude et al. 
2009). 
o The workload preceding a nonlinear rise in blood lactate during 
progressive work (Bourdon, 2000; Weltman, 1995) 
o The workload preceding a 0.4mmol.L-1 rise in blood lactate above the 
baseline (ADAPT method) (Bourdon, 2000). 
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(Figure taken from Bourdon, 2000) 
o Maximal Steady State – fixed 2.2 mmol.L-1 value (Bourdon, 2000). 
o Onset of Plasma Lactate Accumulation – Exercise intensity that elicited a 
blood lactate concentration 1.0 mmol.L-1 greater than baseline (i.e. lactate 
at low intensity corresponding to 40-60% VO2 max) (Bourdon, 2000; 
Faude et al. 2009). 
 
(Figure taken from Bourdon, 2000) 
o The workload 0.2mmol.L-1 (the error of lactate analysers), above the 
lowest exercise lactate value (Faude et al. 2009). 
o  The workload at which blood lactate increases 0.5 mmol.L-1 above 
resting concentration (Faude et al. 2009). 
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o The workload at which there is a rise in the relationship of blood lactate 
between two consecutive workloads and the work intensities of those 
workloads (Farrell et al. 1979). 
2) The Anaerobic Threshold (AT): The workload marked by a rapid rise in blood 
lactate denoting the upper limit of equilibrium between lactate production and 
clearance. This point occurs at blood lactate levels between 3 and 5.5 mmol.L-1 
(Heck et al. 1985). Other descriptions given to this point are: 
o Aerobic-Anaerobic threshold; Onset of Blood Lactate Accumulation (OBLA); 
4 mmo/L threshold. All these terms are used to describe the workload causing 
a fixed 4 mmol.L-1 blood lactate level (Heck et al. 1985; Mader et al. 1986; 
Sjodin et al. 1985). OBLA has been shown to be related to average power 
output during time-trials (Bishop et al. 1998; Sjodin et al. 1981). In contrast, 
Bentley et al. (2001) showed that OBLA was not related to the average power 
output during a 20 minute or 90 minute cycle time-trial. Some studies have 
used 3.5 mmol.L-1 instead of 4 mmol.L-1 (Denadai et al. 2005). 
o Dmax (Cheng et al. 1992) – The point on the lactate curve at maximal 
distance from the line connecting starting and finishing lactate levels.  
 
(Figure taken from Bourdon, 2000) 
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McGehee et al. (2005) showed that running velocity and other parameters 
at AT determined via this method were significantly lower than those 
determined using the 4 mmol.L-1 threshold method. Yet Bishop et al. 
(1998; 2000), found that Dmax and OBLA were the two variables that 
were most related to the average power output achieved during 60 minutes 
of cycle exercise in female cyclists. Also, Bentley et al. (2001) found that 
90 minute time-trial performance is highly related to this Dmax. To 
eliminate the influence of the start point of the test on the Dmax method, 
Bishop et al. (1998) connected the LT (i.e. workload preceding a 
0.4mmol.L-1 rise in blood lactate above the baseline) with the end-point 
of the lactate curve (i.e. the finishing lactate level). 
o Anaerobic Threshold (ADAPT method) (Bourdon, 2000) – Modified Dmax 
utilizing LT instead of the first workload as the start point. 
 
(Figure taken from Bourdon, 2000) 
o Anaerobic Threshold (Kindermann et al. 1979) - Part of exponential increase 
in lactate concentration, approximately 4 mmol.L-1. 
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o The individual anaerobic threshold – Calculated as the tangent to the blood 
lactate curve from recovery curve where blood lactate is equal to the value at 
the end of the test (Stegmann et al. 1981; McLellan et al. 1992) 
 
(Figure from Bourdon, 2000) 
o Maximal Steady State Workload – Workload at fixed 3 mmol.L-1 blood 
lactate level (Bourdon, 2000). 
o Lactate Minimum test (Tegtbur et al. 1993): Starts with a short supramaximal 
bout of exercise and is followed by an incremental exercise test. The lactate 
minimum speed is the lowest point on the lactate curve. 
o Maximal Lactate Steady State (MLSS): The highest constant workload that 
still leads to equilibrium between lactate production and elimination (Faude et 
al. 2009). This is determined by performing several constant load trials, at 
least 30 minutes long, on different days, at various intensities (50-90% VO2 
max). An increase in blood lactate of not more than 1 mmol.L-1 between the 
10th and 30th minute of the trial determines the MLSS workload. MLSS has 
also been termed as the individual anaerobic threshold (IAT) (Weltman, 
1995). 
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(Figure from Weltman, 1995) 
The disadvantage of this determination is that the athlete has to come to the 
laboratory for several days. Some studies have shown that the MLSS 
corresponds to a concentration of 4 mmol.L-1 (Jones et al. 1998; Poole et al. 
1988), yet wide individual variability has been observed (Denadai et al. 2005). 
Denadai et al. (2005) also found no significant difference between OBLA and 
MLSS and between OBLA and determination of critical velocity. 
 
In addition to the terminology debate, there is the debate of the best fitting procedure for 
the determining of these BLTTs. Bishop et al. (1998), describes the most commonly used 
methods for the determination of the above-mentioned BLTTs. Exponential and 3rd -
degree polynomial fitting procedures are the most commonly used fitting procedures. The 
best fitting procedure for obtained blood lactate data has not yet been established (Faude 
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et al. 2009). Therefore, the data fitting procedures in research should be reported, since 
they influence interpretation of results. 
 
This study will compare two of the methods used in the determination of BLTTs: 
a) The MADER model (Mader et al. 1986): Identifies only the AT. This is the 
workload associated with the fixed blood lactate concentration of 4 mmol.L-1.  
This is the most frequently used method (Faude et al. 2009). 
b) The ADAPT method (Bourdon, 2000): Uses both LT and AT. LT is the workload 
preceding a 0.4mmol.L-1 rise in blood lactate above the baseline; and AT is 
determined using the modified Dmax method as described above. 
 
The Mader method was chosen for this study since it is the most extensively used method 
and the Lactate Scout blood lactate analyser software that was used in this study utilises  
the Mader method of determining AT.  
Heitkamp et al. (1991) investigated the reproducibility of the Mader model. These 
researchers found a good reproducibility of the AT for untrained women and an even 
higher reproducibility for trained women. However, no studies have investigated the 
reproducibility of the 4 mmol.L-1 AT in MetS patients. Furthermore, the 4 mmol.L-1 
determination method has been shown to have large individual variation (Weltman, 
1995); and to underestimate (in anaerobically trained individuals) or overestimate (in 
aerobically trained athletes) endurance capacity (Stegmann et al. 1981;1982). Fixed blood 
lactate concentrations, such as those used by the Mader model, are also strongly 
influenced by nutritional and training/recovery state (Dotan et al. 1989; Hughes et al. 
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1982). Therefore, individually based methods of determining BLTT have been 
developed. 
 
The ADAPT method of BLTT determination uses one such individually based threshold 
method calculated from the shape of the lactate – work intensity curve. Frohlich et al. 
(1989) found that nutritional factors (glycogen depletion as a result of dietary or training 
manipulations) did not alter the shape nor the slope of the lactate - work intensity curve. 
Therefore, BLTT determined via fixed blood lactate levels in a glycogen depleted state 
will overestimate endurance capacity, while individually based thresholds determined 
from the shape of the lactate-work intensity curve are hardly changed. This may be the 
reason for this thesis choosing to also investigate the ADAPT method of BLTT 
determination. 
The technical error of measurement (TEM: also called the standard error of 
measurement) for BLTT determination using the ADAPT method has been shown to 
have good precision for athletes tested at the South Australian Sports Institute (Bourdon, 
2000). No study has investigated the applicability of this method in the clinical 
environment. 
 
It has been argued that blood lactate concentrations increase continuously rather than 
show a clear threshold. Similarly, the contribution of oxygen independent (anerobic) and 
dependent (aerobic) pathways to energy production show a continuous transition, not a 
sudden change. The processes of these energy pathways, simultaneously contribute to 
energy production during both low and high intensity exercise. Therefore, the term 
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“threshold” might be misleading (Faude et al. 2009). However, the review of Faude et al. 
(2009) aimed to integrate all the different BLTT concepts into a framework that was 
originally called the aerobic-anaerobic transition (i.e the intensity range between LT and 
AT (MLSS) ) (Kindermann et al. 1979; McLellan, 1981). These researchers noted that 
the model is valuable from a practical and didactical point of view and that it illustrates 
the physiological relevance of the blood lactate transition thresholds (Faude et al. 2009). 
 
In setting up protocols for BLTT determination, the following factors should be noted: 
x Sampling site 
BLTT determined from differing sample sites (i.e. blood vessel types) or differing 
automated lactate analysers, are not comparable. Samples taken from the earlobe 
have been shown to result in lower blood lactate values than those taken from the 
fingertip (Faude et al. 2009). Whole blood lactate concentrations are between 10 – 
30% lower than plasma values (Bourdon, 2000; Faude et al. 2009). Sweat 
contains lactate therefore the sampling site must be cleaned with water first before 
the blood sample is taken. 
x Test protocol workload and rest duration 
A number of studies have noted that exercise periods of at least 4 –7 minutes are 
required to attain steady-state blood lactate concentrations and a more consistent 
indication of the relationship between muscle and blood lactate concentrations 
(Bourdon, 2000; McNaughton et al. 2006; Weltman, 1995). Also, Weltman et al. 
(1990a) found no differences in the determination of LT and AT when using a 
continuous, 3 minute stage treadmill protocol compared to a discontinuous 10 
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minute stage protocol. Thus, there seems to be disagreement on the optimal 
workload time. Therefore, this PhD study used a 4 minute workload test protocol 
to make sure that the workload was longer than the minimum research period. The 
periods in between work-bouts to allow for blood sampling, must also be kept to a 
minimum, with 1 minute as a maximum (Bourdon, 2000). Work intensity 
increments should be small and 6 – 8 workloads are sufficient (Bourdon, 2000). 
x Ergometer type 
The choice of test ergometer should be dictated by the principle of training 
specificity. 
x Substrate availability 
AT can be altered by changes in substrate availability. Ivy et al. (1981) 
determined AT on a cycle ergometer under 3 conditions: control; glucose trial 
(ingesting 75g of glucose 30 minutes before the exercise test); elevated free fatty 
acids state (by administration of heparin). No differences existed in AT between 
the control and glucose trial when adjusted for baseline blood lactate 
concentrations. A significant reduction in blood lactate occurred in the elevated 
free fatty acid trial and AT occurred at a higher % VO2 max in this condition. 
Hughes et al. (1982) found that AT occurs at a lesser workload in a glycogen-
depleted state. Yoshida (1984), observed that the workload at AT was 
significantly reduced after a high compared to a low carbohydrate diet. In 
contrast, Quirion et al. (1988) reported that changing the diet had no effect on AT. 
x Environmental factors 
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Altitude and external temperature can also affect the blood lactate response to 
exercise. Blood lactate transition threshold values are reduced with increasing 
altitude or temperature (Weltman, 1995). 
x Training Status 
There is a decrease in blood lactate concentration at a given workload following 
endurance training. It has been suggested that this may be related to the finding 
that training reduces carbohydrate utilization and muscle lactate accumulation 
during exercise (Saltin et al. 1976). Increases in skeletal muscle mitochondrial 
density (Holloszy, 1967; Holloszy et al. 1984) and improved fatty acid oxidation 
(Hickson et al. 1997; Rennie et al. 1976) after endurance training have been 
identified as mechanisms in explaining the reduced carbohydrate utilization 
during exercise after training. Increases in mitochondrial density and 
mitochondrial enzyme activity, allows for greater ATP production via oxidative 
processes and thus would decrease glycolytic flux and lactate formation. Also, the 
improvement in fat oxidation as an adaptation to endurance training would 
decrease the need for ATP formation via glycolysis and thus decrease the rate of 
lactate production. In addition, Holden et al. (1992) showed that the reduced 
blood lactate concentration after training is the combined result of the reduced 
rate of lactate appearance and improvement in the rate of lactate clearance. This 
factor is influential in this study and will be further investigated. 
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BLTT tests are influenced by many factors, yet if standardized they are reproducible. The 
first study of this thesis hypothesized that reproducibility could be attained in patients 
with MetS. 
 
1.4 The Effects of Endurance Training on Blood Lactate Transition Thresholds 
Endurance training substantially reduced blood lactate concentrations at any given VO2 
(MacRae et al. 1992; Stanley et al. 1985). These researchers suggested that training 
results in a diminished blood lactate response during exercise by decreasing the rate of 
lactate production or increasing the rate of lactate clearance or both. The decrease in 
blood lactate production may be related to the reduced carbohydrate utilization during 
exercise after endurance training (Saltin et al. 1976). Coggan et al. (1992) investigated 
the glucose and glycogen metabolism at a given intensity after training and concluded 
that the individuals with a higher LT (more metabolically fit) used less muscle glycogen 
during an exercise bout and had more favourable glucose turnover during exercise. This 
supports the concept that the skeletal muscle capacity is related to the blood lactate 
response to exercise and is a major determinant of the metabolic response to exercise 
(Weltman, 1995). 
 
Many studies have also reported that the workload and VO2 associated with blood lactate 
parameters improve to a greater degree with training than does VO2 max (Denis et al. 
1982; Hurley et al. 1984; Yoshida et al. 1982; Sjodin et al. 1982; Weltman et al. 1992). 
These data also provide evidence that the blood lactate response to exercise and VO2 max 
are affected by differing mechanisms. It is suggested that VO2 max is dependent on 
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cardiovascular (central) factors such as 1) maximal cardiac output; 2) pulmonary 
diffusing capacity; 3) oxygen carrying capacity of the blood (Basset et al. 2000); and that 
the blood lactate response to exercise is dependent on muscle (peripheral) factors such as 
number and size of mitochondria or muscle fiber type (Weltman, 1995). 
 
The blood lactate threshold will change with training primarily for three reasons: 1) 
lactate utilization increases, 2) lactate production declines and/or 3) lactate clearance 
increases (Olbrecht, 2000). The flow diagram below will be used to explain the 
adaptations: 
 
1) Lactate utilization increases: 
Training can affect lactate utilization in two different ways:  
a) Oxygen utilization – Training adaptations within the muscle fiber allow it to 
utilize more of the available oxygen. These adaptations include an increase in 
number and size of mitochondria and an increase of oxidative enzyme 
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concentration in the mitochondria. This higher utilization of oxygen means more 
of the pyruvate will be used for aerobic energy, thus less of the pyruvate will be 
converted to lactate and the blood lactate threshold will occur at a higher work 
output. (“1” in the diagram above refers to the processes discussed). 
b) Better oxygen delivery – Training adaptations allow the cardiovascular system to 
deliver more oxygen to the muscle, at a faster rate. The greater the amount of 
oxygen delivered, the greater the amount of pyruvate that will be used in the 
aerobic process and thus less will be converted to lactate. (These processes are 
represented in “2” in the diagram above). Some training adaptations that improve 
oxygen delivery are an increase in skeletal muscle capillarization; increase in the 
proportion of red blood cells to plasma in the blood and an increased cardiac 
output. 
2) Lactate production declines: 
a) Improved fat oxidation - The higher utilization of fat means there is less need for 
glycolysis and consequently less pyruvate and less lactate is produced. The 
increase of oxidative enzyme concentration in the mitochondria of the muscle 
fiber is a training adaptation that promotes this shift of energy source during 
exercise. (These processes are represented in “3” in the diagram above). 
b) Lower anaerobic capacity – Endurance training may change the anaerobic 
capacity. This may be the main reason for short term changes in the lactate 
threshold (Olbrecht, 2000). The lactate threshold will automatically change 
because pyruvate production is changed. When the anaerobic capacity is lowered 
less pyruvate is produced for a given effort level. Thus, the lactate threshold will 
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increase without any change in the ability of the body to process aerobic energy or 
to shuttle lactate. The lactate threshold is always an equilibrium between lactate 
production and lactate elimination. (“4” on diagram above). 
3) Lactate clearance increases: 
Training allows the body to become more efficient at removing lactate from the 
producing muscles and shuttling it to other parts of the body where it can be used. This 
eases the acid levels in the producing muscles and thus lets them operate at a higher 
energy level before producing the acidosis levels that slow down energy production. 
(Process “5” in the diagram above). Also training can help the lactate shuttle as the 
increased capillary system will help clear the lactate out of producing muscles and into 
the blood stream. The same adaptation facilitates the transfer of lactate from the blood to 
other muscles for elimination.  
Buffering: 
The muscles can be trained to buffer some of the acid accumulating in the lactate 
producing muscles. The hydrogen ions causing the problems with contraction are 
neutralized and this allows even more lactate to be produced before there are problems 
with contraction. However, it probably does not affect the threshold since it does not slow 
down lactate production (Olbrecht, 2000). (Process “6” in diagram above). 
 
1.5 Blood Lactate Threshold Testing and the Prescription of Exercise 
Studies have suggested that training intensity be based on the VO2 at AT (determined by 
a BLTT test); or the velocity of movement at AT (Coen et al. 1991; Coyle et al. 1983; 
Heck et al. 1985; Karlsson et al. 1982; Kindermann et al. 1979; Stegmann et al. 1982; 
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Sjodin et al. 1982; Tanaka et al. 1986; Weltman et al. 1992; Weltman 1995; Yoshida et 
al. 1982). These studies have also suggested that improvement in such blood lactate 
parameters are more important than elevating VO2  peak for enhancing endurance 
performance. A major underlying mechanism for this is the strong association between 
muscle respiratory capacity and VO2 at AT (Ivy et al. 1980; Sjodin et al. 1982).  
The review by Jacobs (1986), notes that prescribing exercise intensity as a function of 
lactate concentration may prove to be a means of obtaining a homogeneous training 
adaptation in a group of participants. In addition, this review also noted that lactate 
response to supramaximal exercise is a sensitive indicator to “sprint training” adaptation 
and is correlated with supramaximal exercise performance.  
 
Blood lactate levels have also been associated with exercise durations for different 
exercise intensities. Exercise intensities only slightly above the LT result in elevated but 
constant blood lactate levels during steady-state exercise and can be maintained for ~ 4 
hours (Faude et al. 2009). At exercise intensities corresponding to AT (MLSS), exercise 
can be maintained for 45- 60 minutes (Urhausen et al. 1993). 
 
Significant correlation exists between the response of plasma lactate during a running 
training program and the percentages of speed at the AT determined on a treadmill (Coen 
et al. 1991). This forms the basis for using BLTT treadmill tests to set exercise 
intensities. Coen et al. (1991) showed that AT determined during a treadmill BLTT test 
allows for precise setting of training recommendations for both endurance runs 
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performed at different intensities and for 1000m interval training programs (external 
conditions must also be considered). 
 
Another reason for using blood lactate to set exercise intensity is that exercise with no 
significant accumulation of lactate results in only a slight increase in sympathetic activity 
and to moderate adaptation of regulatory hormones. At intensity close to 100% of AT, 
sympathetic activity increases (Coen et al. 1991). High correlations between 
catecholamine concentrations and blood lactate concentrations during exercise have been 
reported (Podolin et al. 1991). It should be noted that it is speculation that training at AT 
increases sympathetic activity, but no links between lactate, glucose metabolism and 
sympathetic activity have been found. It has also been suggested that a training intensity 
which approximates AT would be optimal in eliciting the local training adaptation 
changes in muscle metabolism (Kindermann, 1979). Sjodin et al. (1982) investigated this 
area with trained runners. The trained runners incorporated training at an exercise 
intensity corresponding to AT (4 mmol.L-1 blood lactate) once a week for 20 minutes. 
These researchers found that the rate of glycogenolysis during exercise was slower post-
training and that the potential to oxidize pyruvate and lactate increased. Improved 
intracellular oxidative capacity was also indicated by measurement of muscle enzymes in 
the vastus lateralis. Velocity and VO2  at AT also increased significantly after this type of 
training.  
 
Tanaka et al. (1986) also showed that the addition of a run lasting longer than 60 minutes 
at, or slightly above AT to other training may be effective in improving both endurance 
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performance and AT for middle-distance runners. The mechanism for such alterations, 
proposed by these researchers, is supported by the findings of Sjodin et al. (1982) i.e. an 
increased activation of relatively more slow-twitch fibers at AT and /or improved oxygen 
extraction in skeletal muscle. 
 
The study of Lucia et al. (1999) also supports the concept of a transitional exercise 
intensity that is required to produce exercise adaptations. These researchers showed that 
changes in electro-myographical activity of the rectus femoris and vastus lateralis 
muscles were coincidental with the aerobic (LT) - anaerobic (AT) transition in elite 
cyclists.  
 
Weltman et al. (1992) showed that training using BLTT is effective in improving VO2 
and velocity at LT and at fixed blood lactate concentrations of 2, 2.5 and 4 mmol.L-1. For 
the first 4 months, training at LT (approximately 55% of VO2 max) or training at above 
LT (approximately 81% of VO2 max) resulted in similar training adaptations in the 
previously untrained women. However, for continued training adaptations (after the 4 
months), some exercise was required at an intensity above the LT. Participants in this 
study trained 6 times per week. These researchers concluded that the increase in physical 
activity associated with the onset of endurance training is sufficient to elicit a training 
effect provided the initial training intensity is at or above LT. However this data also 
suggests that training above LT is more effective than training at LT for longer term 
improvements. It is speculated that such intensities may induce an increase in the 
oxidative metabolism of muscle cells (Kindermann et al. 1979). 
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Yoshida et al. (1982) monitored untrained males that trained 15 minutes a day, 3 days a 
week, for 8 weeks at an intensity corresponding to AT (Mader method). The change in 
VO2 at LT after training compared to the change in VO2 max led the authors to conclude 
that training at an intensity corresponding to AT may be one of the most effective 
methods for endurance training.   
 
Keith et al. (1992) investigated two groups of athletes. One group trained at AT for 30 
minutes. The other group divided the 30 minute workout into four intervals, each seven 
and a half minutes long. Two of the intervals were performed above AT, while the other 
two were carried out below AT. Each group trained four times a week. Both groups 
showed similar increases in VO 2 max and velocity at AT. It must be noted though, that 
the AT group had 120 weekly minutes of quality exertion and the non-AT group had 60 
weekly minutes of quality work. Thus, BLTT determination may be important for 
exercise prescription if long-term exercise adaptations are desired. Hollman et al. (1981) 
also showed that training at AT for 30 min, 5 times weekly will significantly increase 
velocity at AT, yet training at a higher exercise intensity results in no changes after 6 
weeks of training.  
 
In addition, exercising above the MLSS (AT) has been associated with an excess 
excretion of stress hormones (e.g. plasma epinephrine and plasma cortisol) (Urhausen et 
al. 1994) and of immunological markers (e.g. monocytes, lymphocytes, neutrophils) 
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(Gabriel et al. 1997). Therefore, establishing the AT from blood lactate testing may be 
important in preventing over-reaching during endurance exercise. 
 
Weltman et al. (1989), found that for sedentary women, heart rates of 75% MHR and 
55% of HRR were required for most to be above LT. For blood lactate concentrations of 
4mmol.L-1 (AT), heart rates in excess of 95% MHR were required. 
 
The work of Alois Mader and Jan Olbrecht (Mader et al. 1986; Mader, 1991; Olbrecht, 
2000), introduced a technique that has been used to train world champion athletes. This 
theory considers the contributions of both the aerobic and anaerobic systems separately, 
instead of focusing on the AT. This concept emphasizes the importance of the lactate 
production process (glycolysis) and how it can be modified in athletes ranging from 50m 
freestyle sprinters to Ironman triathletes. This system aims to fine-tune the innate 
anaerobic capacity level to a desired level at race time. Blood lactate testing is used to 
monitor anaerobic capacity level. This training concept however, views blood lactate 
testing in a different light. It notes that raising anaerobic capacity will lower the AT for 
traditional endurance testing. Lowering anaerobic capacity will raise the AT of endurance 
tests because there is less lactate to deal with at the same effort level. In each case, the 
aerobic capacity may not have changed but traditional analysis may assume that there is a 
decrease in aerobic endurance in the first situation and an increase in the second one. In 
both situations the wrong training may then be prescribed. Thus, this concept cautions 
that the aerobic system may seem improved in traditional lactate testing, by temporarily 
suppressing the anaerobic capacity.   
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In summary, Weltman (1995) notes that there exists a lack of scientific consensus about 
the best way to use blood lactate levels for designing and altering training programs. One 
of the questions that this PhD study attempts to answer is whether training based on the 
blood lactate response to exercise is more effective than one other training techniques. 
Furthermore, this training methodology has not been investigated in a clinical setting. 
The second study of this PhD examines this question in persons with MetS. 
 
1.6 Exercise Intervention Programs for the Reduction of Progressive Disease Risk 
Factors and Effects on Components of the Metabolic Syndrome 
Many studies have shown that low levels of physical activity and low cardiorespiratory 
fitness are associated with increased risk of CVD, cancer and all cause mortalities (Blair 
et al. 1989; Blair et al. 2009; Lakka et al. 1994; Lee et al. 1995; Mark et al. 2003; 
Paffenbarger et al. 1983). Regular physical activity has also been shown to lead to a 
reduced risk of cardiovascular disease in men (Bassuk et al. 2005; Katzmarzyk et al. 
2004; Sesso et al. 2000). In addition, a dose-response relationship exists between physical 
activity and coronary heart disease and type 2 diabetes (DHSSPS, 2011).  
 
Impaired glucose tolerance is a component of the MetS, and is associated with a high risk 
of developing type 2 diabetes. Studies have investigated the effect of exercise and/or diet 
in preventing type 2 diabetes in this at risk population. Such studies include the Diabetes 
Prevention Program (Knowler et al. 2002), that showed modest increases in physical 
activity can reduce the incidence of diabetes by 58%. The intervention, (diet counselling 
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and 150 minutes of moderate intensity exercise per week) - was nearly twice as effective 
as metformin therapy in preventing the progression to diabetes in an at-risk population.                          
The DA Qing IGT and Diabetes Study (Pan et al. 1997), randomised participants into a 
control group, diet only group, exercise only group and a diet + exercise group. The 
exercise program was based on increasing the amount of leisure physical activity (30 
minutes of mild exercise or 20 minutes of moderate exercise or 5 - 10 minutes of 
vigorous exercise per day), rather than using a formal exercise prescription. The 
incidence of diabetes in this study decreased by 33% and 47% in the diet only and 
exercise only groups respectively, when compared to the control group. The incidence 
reduced by 38% in the diet + exercise group. This study noted that the efficacy of diet 
was similar to that of exercise and that no additional benefit was gained from combining 
the two interventions. 
 
Laaksonen et al. (2005) found that increasing total leisure time physical activity (> 4 
hours/wk of moderate exercise) and modifying diet, reduced risk of developing diabetes 
by 58% (even after adjusting for confounding parameters). McAuley et al. 2002 showed 
that 5 weekly, 20 minute exercise sessions at 80 – 90% maximal heart rate attained a 
greater improvement in insulin sensitivity than modest lifestyle changes among 
overweight insulin-resistant normoglycaemic adults. 
 
A Cochrane review (Oronzo et al. 2009) on preventing type 2 diabetes showed that 
physical activity interventions (on average, at least 150 minutes each week of brisk 
walking, cycling, jogging) with diet modification reduced incidence of diabetes by 37% 
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in high-risk groups such as people with MetS. Favourable effects were also shown on 
body mass, waist circumference and blood pressure. The review did conclude that more 
evidence is required on the effects of exercise alone. 
 
Leon et al. (1979) used a 16-week walking program to train obese men aged 19 – 31 
years (without MetS). These researchers showed that the walking program reduced body 
mass (4.9 – 6kg), increased the high-density lipoprotein (HDL),/ low density lipoprotein 
(LDL) ratio; reduced fasting blood glucose and reduced the ratio of plasma insulin / 
glucose concentrations. These effects indicate an increase in tissue sensitivity to insulin, 
which should aid in the prevention of type 2 diabetes and reduce the risk of vascular 
disease. Thus, exercising 5 times per week, 7.5h/wk, at an intensity eliciting 1100 
kcal/session (4603 kJ/session), suggests a reversal of metabolic disease. A limitation of 
this study is that no control group was investigated. Study 2 of this PhD, applied the Leon 
et al. (1979) exercise program to persons with MetS, in comparison to an exercise 
programme using less volume and using AT to set intensity. 
 
Contradictory evidence exists regarding the optimal amount and intensity of exercise 
needed for health benefits. Some international organisations suggest 30 minutes of 
moderate intensity exercise (in minimum bouts of 10 minutes), 5 days/wk or 75 minutes 
of vigorous intensity exercise. These organisations also suggest minimizing sitting time 
(American College of Sports Medicine, 2006; DHSSPS, 2011). Other organisations 
suggest 60 minutes of exercise per day. Some studies showed that vigorous activity is 
required to achieve a reduction in cardiovascular events (Lakka et al. 1994; Lee et al. 
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1995). Other studies have indicated that only moderate activities are sufficient (Shaper et 
al. 1991; Slattery et al. 1989). Some researchers have shown that for metabolic benefits, 
regular exercise should be performed more frequently (3 -5 day/wk) and for a longer 
duration (60 minutes) at a lower intensity (40 – 60% VO2 max) than typically prescribed 
for improvements in cardiorespiratory fitness (Buemann et al. 1996; Despres et al. 1997). 
 
Few, randomized, controlled studies exist in this area of optimal amount and intensity of 
exercise. The STRRIDE study (Slentz et al. 2005; Slentz et al. 2007a) is one such study. 
The study investigated the effect of different exercise amounts and intensities. Four 
groups were used in the STRRIDE study. 1) A control group; 2) A low amount, moderate 
intensity exercise group, (40 -55% of peak VO2 , exercise energy expenditure of 14 
kcal.kg body mass-1.wk-1); 3) A low amount, vigorous intensity exercise group, (65 -
80% of peak VO2, exercise energy expenditure of 14 kcal.kg body mass-1.wk-1); 4) A 
high amount, vigorous intensity exercise group, (65 – 80% of peak VO2, 23kcal.kg body  
mass-1.wk-1). Central obesity (determined from abdominal fat measurements) was used 
since it has been linked to risk of disease (Kissebah et al. 1994; Lemieux et al. 2000). The 
STTRIDE study showed that body mass and visceral fat responded in a dose-response 
manner. Thus the greater the amount of exercise (23 kcal.kg-1.wk-1), the greater the 
decrease in these parameters. Body mass decreased by 2.31 kg and peak VO2 increased 
by 17.9% with the above exercise prescription. An exercise expenditure of 14 kcal.kg-
1.wk-1or 1200 kcal.wk-1 (19.2 km.wk-1) maintained body mass and visceral fat. This 
study also noted that exercise intensity did not appear to have any effect on body mass or 
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abdominal fat responses. However, other studies have found that exercise intensity is 
important in determining training adaptations (Gibala et al. 2012; Rynders et al. 2014).  
 
Duscha et al. (2005) analysed the STRRIDE study with respect to the exercise effect on 
VO2 peak. The researchers found that VO2 peak also responded in a dose-response 
manner. Other published findings from this cohort also showed improvements in lipids, 
lipoproteins, and insulin sensitivity (Houmard et al. 2004; Kraus et al. 2002; Slentz et al. 
2004; 2007a). The relative improvement in the insulin sensitivity index was greater in the 
low exercise volume/moderate intensity (40-50% VO 2 peak) and in the high volume/high 
intensity (65-80% VO 2 peak) groups than in the low volume/high intensity group 
(Houmard et al. 2004). The improvements on the lipoprotein profiles were influenced by 
amount and intensity of exercise (Slentz et al. 2007b).  Therefore, the above-mentioned 
exercise programme suggests a prescription for reversing metabolic disease. 
 
Commenting on the STRRIDE studies, Slentz et al. (2007a) noted that the theoretical 
minimal physical activity level for body mass maintenance occurs at around  
12.8 km.wk-1 (or 14 kcal.kg -1 .wk -1). At 17.6 - 27.2 km.wk-1, a beneficial effect occurs 
on lipoproteins and lipoprotein particle size and number (Slentz et al. 2007b). The article 
also highlighted that the theoretical minimal amount of exercise is different for each 
individual – i.e. some proportion of individuals would still gain body mass when doing 
the minimal amount (12.8 km.wk-1) of exercise. This PhD study used BLTT to 
individualize the exercise response. 
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Both the STRRIDE and the Leon et al. (1979) studies did not influence caloric intake of 
the participants. The participants were asked not to diet and not to change their eating 
habits for, and during the duration of the exercise period. A limited number of 
randomised, controlled trials have investigated exercise-induced reductions in visceral fat 
among groups that did not change dietary habits. One such study, Ross et al. (2000), 
showed that an exercise program designed to increase energy expenditure by 700kcal/day 
(2928J/day) in men for 12 weeks, resulted in a decrease of visceral fat of 6.9cm2 per 
kilogram of body mass loss (28% decrease). The diet–only group in this study had a 
similar decrease (5.9 cm2 per kg mass loss). 
 
A review of the treatment of obesity (McQueen, 2009), suggested that exercise at  
55 - 69% of MHR, 5-7 days per week, 45 - 60 min duration is needed.  A dosage of 250 - 
300 minutes per week was suggested for long-term body mass-loss and for prevention of 
body mass regain. This review also states that the value of intermittent exercise bouts is 
as yet inconclusive and that resistance training in the obese subject does not influence 
energy expenditure or absolute mass loss. 
 
The above-mentioned exercise prescriptions rely on peak VO2 testing to set exercise 
intensity. Peak VO2 tests (and equipment) are expensive and the former are difficult to 
conduct, especially in the clinical environment. Furthermore, two tests were required to 
set the exercise intensity. A maximal and sub-maximal test to determine the work rate 
that required a particular oxygen consumption (Slentz, 2007b). Therefore, this PhD study 
aimed to utilise a cheaper, easier test of setting exercise intensity – BLTT.  In addition, 
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the studies described above used exercise programs that were not periodized. A ramp 
period was used and thereafter participants exercised at a constant intensity and volume 
for 6 -8 months. Furthermore, the participants used in the studies mentioned above were 
not diagnosed with MetS – the participants were overweight, yet healthy. The presence of 
the components of the syndrome may influence the effect of exercise.  
 
This review has focused only on studies that used cardio-pulmonary exercise. The 
Canadian and American Diabetes Associations recommend combined cardio-pulmonary 
and resistance exercises for at-risk individuals (Sigal et al. 2004).  Studies that have 
investigated combined cardio-pulmonary and resistance exercises and type 2 diabetes 
have shown increases in aerobic capacity and an increase in muscular strength (Maiorana 
et al. 2002; Oberbach et al. 2006; Tokmakidis et al. 2004). Mathieu et al. (2008) further 
added flexibility and balance to a cardio-pulmonary and resistance program for type 2 
diabetics. The combined 10 week program showed a 1.1kg body mass - loss, decreases in 
waist circumference (2.5cm) and increases in cardiovascular capacity and HDL-C. No 
changes were shown in total cholesterol, triglycerides or LDL-C. The study however had 
the limitations of an absence of a control group, a small number of participants, 
heterogeneity of participants and the absence of food intake monitoring. 
 
In summary, the beneficial effect of regular exercise on CVD, type 2 diabetes and 
cardiovascular risk factors is evident. The effect of exercise alone on the simultaneous 
reduction of multiple, clustered risk factors (as they appear in persons with MetS) will 
now be discussed. 
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1.7 Exercise Intervention Programs for Persons with Metabolic Syndrome  
The National Cholesterol Education Program suggested body mass loss and increased 
physical activity as the basis of therapy for MetS (Haffner et al. 2003). The Kuoppio 
Study (Laaksonen et al. 2002), showed that men who engaged in moderate intensity (>4.5 
METs) leisure time physical activity of < 1 h.wk-1 were 60% more likely to have MetS 
than those engaging in > 3 h.wk-1 even after adjustment for confounding variables.  In 
addition, men with a VO2 max < 29.1 ml.kg-1.min-1 were almost 3-4 times more likely 
to have MetS than those with a VO2 max >35.5 ml.kg-1.min-1 (Lakka et al. 2003).  
 
Rennie et al. (2003) also found an indirect association between moderate and vigorous 
physical leisure-time activity and risk of being classified with MetS. Reduced body mass 
index and increased cardio-vascular fitness were cited as important mediators of this 
association. 
 
Other researchers have also shown an inverse relationship between cardio-respiratory 
fitness and the incidence of MetS (Carroll et al. 2000; Irwin et al. 2002; Kullo et al. 2002; 
LaMonte et al. 2005; Whaley et al. 1999). Katzmarzyk et al. (2004) showed that 
cardiorespiratory fitness has a strong protective effect against all-cause and 
cardiovascular disease mortality in healthy men and in men with MetS. 
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As discussed in section 1.6 and 1.7, physical exercise has been shown to reduce individual cardiac risk factors, yet few controlled 
studies have reported the effect of exercise alone on the reduction of several risk factors simultaneously, as is the case in individuals 
with MetS. The table below summarises some of the research studies within this field. 
 
Table 1 Particulars of studies investigating exercise effects on Metabolic Syndrome 
STUDY PARTICIPANT GROUP
S 
EX.PROGRAM 
DURATION 
EX. 
INTENSITY 
EX. 
DURATION 
EX. 
FREQUEN
CY 
EX. 
MODE 
RESULTS TYPE OF 
STUDY/ 
LIMITATIONS 
The Heritage 
Family  
Study  
(Katzmarzyk 
et al. 2003) 
17-65 yrs 
healthy, 
sedentary 
n=621 
105 with 
MetS; 
516 
without 
MetS 
20weeks  
Endurance 
program 
55% VO2 
max. 
Increase 
every 2 weeks 
30 min. 
Increase to 50 
min for final 6 
weeks 
Three times 
per week 
Cycle 
Ergo 
30.5% decrease 
in persons with 
MetS. Exercise 
improved 
“cluster” of risk 
factors 
simultaneously. 
No control group 
  No 
change in 
life-style 
or diet 
levels 
 Up to 75% 
VO2 max. for 
final 6 weeks 
   VO2 max 
increased by 
16.3%  
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STUDY PARTICIPANT GROUPS EX.PROGRAM 
DURATION 
EX. 
INTENSITY 
EX. 
DURATION 
EX. 
FREQUEN
CY 
EX. 
MODE 
RESULTS TYPE OF 
STUDY/ 
LIMITATIONS 
Smutok et 
al. 1993 
50yrs(+9yrs), 
sedentary males 
n=37 
Strength 
training 
(ST); 
aerobic 
training 
(AE)& 
control. 
No change 
in diet. 
20 weeks ST: 12-15 
RM max; 11 
exercises 
AT: 50% 
MHR reserve 
increased to 
75-85% 
AT: 30 min Three times 
per week 
Tread-
mill 
ST and AE 
improved 
glucose tolerance 
and insulin 
response to 
OGTT. AE: 19% 
increase in VO2 
max. Body fat 
decreased. 
Randomised, 
controlled 
        No significant 
changes in body 
mass, lipoprotein 
profile or blood 
pressure
 
Katzel et al.  
1997 
Obese, sedentary 
46 -80yrs men 
n=67 
One 
exercising 
group, 
given a 
diet 
Nine months, 
then a nine 
month body mass 
intervention 
program included 
Start at 50-
60% HR 
Reserve- 
increased to 
70 – 80% 
45 min Three times 
per week 
Tread-
mill, 
cycle ergo 
 Exercise alone: 
No change in 
OGTT, blood 
pressure, lipid 
profile. Vo2 max 
increased 14%. 
No control group 
        Post ex. Program 
body mass 
intervention: 
improved OGTT  
response, 
lipoprotein 
profile and body 
mass. 
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STUDY PARTICIPANT GROUPS EX.PROGRAM 
DURATION 
EX. 
INTENSITY 
EX. 
DURATION 
EX. 
FREQUEN
CY 
EX. 
MODE 
RESULTS TYPE OF 
STUDY/ 
LIMITATIONS 
Dengel et 
al. 1998 
50 -70yrs. Obese,  
hypertensive 
sedentary, insulin-
resistant men with 
MetS 
n=17 
MetS 
group and 
a control 
group. 
Given a 
diet 
Six months 
aerobic ex. + 
mass-loss 
Started 50-60 
% HR 
reserve- 
increased to 
75-85% HR 
reserve 
40 minutes 3 – 4 times 
per week 
Tread-
mill, 
Cycle 
ergo 
Decrease in body 
mass, waist girth, 
blood pressure, 
cholesterol, TG. 
Increase in VO2 
max, HDL 
Improved GTT 
response 
Small sample size 
Katriina 
et al. 2005 
Middle-aged, obese 
men. 
n= 90 
Walking 
(W) 
resistance 
(ST) and 
control 
Six months with 
dietary advice 
W: 60-70% 
VO2 max 
ST: 60-
80%1RM; 6 
ex. eight reps; 
three sets 
45 minutes Three times 
per week 
Walk Modest changes 
in the 
components of 
metabolic 
syndrome. 
Improved OGTT 
response, HDL, 
Randomized , 
controlled 
        Exercise did not 
add any 
additional effect 
to that of diet 
counsel alone. 
 
Watkins 
et al. 2003 
Men and women, 
older than 29yrs 
with MetS 
n=53 
 
Ex only 
(EX), EX 
+ body 
mass-loss 
program 
(BM) 
control 
group 
26 weeks 70-85% HR 
reserve 
10 min cool-
down and 
warm-up and 
35 minute in 
target zone 
3 -4 times 
per week 
Tread-
mill walk/ 
Jog 
Cycle 
ergo 
EX and EX+WT: 
Improved insulin 
response to 
OGTT. EX+WT: 
Decrease in 
DBP. No 
changes in 
lipoprotein 
profile 
Randomized, 
controlled 
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STUDY PARTICIPANT GROUPS EX.PROGRAM 
DURATION 
EX. 
INTENSITY 
EX. 
DURATION 
EX. 
FREQUEN
CY 
EX. 
MODE 
RESULTS TYPE OF 
STUDY/ 
LIMITATIONS 
Anderssen 
et al. 1995 
The Oslo 
Diet and 
Exercise 
Study 
Males and 
females, 40 yrs, 
sedentary, 
overweight, 
dyslipidemic, 
hypertensive 
n=92 
Exercise 
(EX); 
Exercise+
diet(EX+
D); 
Diet(D); 
Control 
One year 60-80%MHR 60 minutes Three times 
per week 
Aerobics, 
circuit, 
brisk 
walk, 
jogging 
Diet and exercise 
affected lipid 
profile and blood 
pressure 
markedly; 
affected 
hemostasis and 
fibrinolytic 
components 
moderately. 
EX+D often 
superior in effect. 
Randomised, 
controlled 
Kraus et al. 
2002 
STRRIDE 
study 
Male and female, 
aged 40-65yrs, 
sedentary, 
overweight, 
dyslipidemic 
n=84 
Three 
exercise 
groups(1,2
,3) ; 
control 
group 
Six months 1) High 
amount/ High 
int:65-80% 
VO2 max; 
174min/wk 
1) 45.8 min 3.8 times per 
week 
Treadmill 
cycle 
ergo; 
elliptical 
Exercise group 1) 
had the greatest 
influence on 
lipoprotein 
profile (with the 
least body mass 
loss) 
Randomised, 
controlled 
    2) Low 
amount/ High 
int:65-80% 
VO2 max; 
117min/wk 
2) 39 min Three times 
per week 
 Improvements to 
lipoprotein 
profile were 
related to amount 
and not intensity 
of exercise. 
Effect on body 
mass and fat was 
dose related. 
 
    3) Low 
amount/mod 
int: 40-55% 
VO2 max;  
3) 52 min 
176 min per 
week 
3.4 times per 
week 
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STUDY PARTICIPANTS GROUPS EX.PROGRAM 
DURATION 
EX. 
INTENSITY 
EX. 
DURATION 
EX. 
FREQUEN
CY 
EX. 
MODE 
RESULTS TYPE OF 
STUDY/ 
LIMITATIONS 
Juneau et 
al. 1987 
Men and women; 
middle-aged; 
healthy; sedentary 
n=57 
Control; 
exercise 
Six months 
235-345 kcal 
expenditure per 
session 
60-80% MHR 40 – 50 min Three times 
per week 
Home-
based, 
walk, 
slow jog 
VO2 max 
increased by 9-
15%. Body mass 
decreased in men 
only. No changes 
in lipoprotein 
profile.  
Randomised, 
controlled 
Eriksson 
et al. 1998 
Male and female. 
Mean age: 60yrs; 
Impaired glucose 
tolerance 
n=14 
Aerobic 
ex(AE); 
Circuit 
train.(CT)
Control  
Six months 60%MHR 60-90min Three times 
per week 
Walk, 
jog, 
swim, 
cycle 
AE: Increased 
VO2 max, HDL. 
No change in 
insulin 
sensitivity, 
CT: Increased 
insulin sensitivity 
Randomised, 
controlled 
(small sample 
size) 
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STUDY PARTICIPANTS GROUPS EX.PROGRAM 
DURATION 
EX. 
INTENSITY 
EX. 
DURATION 
EX. 
FREQUEN
CY 
EX. 
MODE 
RESULTS TYPE OF 
STUDY/ 
LIMITATIONS 
Wing et 
al. 1998 
Male and female 
40-55yrs, 
overweight, family 
history of T2D 
n=57 
Diet(D); 
Exercise 
(EX); 
D+EX;  
Comtrol 
24 months 
 
Moderate 50-60 min 
(4.8km) 
1500kcal/wk 
energy 
expenditure 
Five times 
per week 
Brisk 
walk 
Initial: Wt loss; 
decrease in 
glucose, insulin, 
cholesterol, trigs, 
LDL, SBP; 
increase in HDL 
greatest in D and 
D+EX. At 2 yrs 
no between 
group differences 
were maintained. 
Wt loss of 4.5kg 
in 2 yrs 
decreased risk of 
T2D by 30% 
Randomised, 
controlled 
Lavrencic 
et al. 2000 
Male and female, 
40-65yrs, sedentary, 
with MetS 
n=29 
Exercise 
(EX);  
control 
12 weeks 80% MHR 20 min w/up; 
30 min ex. 
Three times 
per week 
Cycle 
Ergo 
18% increase in 
fitness in EX 
group; enhanced 
flow-mediated 
dilation 
(endothelial 
function); no 
change in body 
mass index; 
blood pressure, 
lipid profile; 
insulin resistance 
Randomised  
controlled 
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STUDY PARTICIPANTS GROUPS EX.PROGRAM 
DURATION 
EX. 
INTENSITY 
EX. 
DURATION 
EX. 
FREQUEN
CY 
EX. 
MODE 
RESULTS TYPE OF 
STUDY/ 
LIMITATIONS 
Nieman et 
al. 2002 
Female, 
overweight, 25-
75yrs;  
n=43 
Exercise 
(EX); 
Exercise+
diet(EX+
D); 
Diet(D); 
Control 
12 weeks 60-80% MHR 45 minutes Five times 
per week 
Walk (D) and (EX+D): 
Decrease in 
mass, 
triglycerides, 
cholesterol. No 
changes in the 
(EX)  
Randomised, 
controlled 
Stenvold 
et al. 2012 
Men and women,  
sedentary with 
MetS 
n=31 
Aerobic 
interval 
training 
(AIT); 
strength 
(ST); 
control 
12 weeks AIT: 4x4 min 
@ 90%MHR; 
3 min rest @ 
70%MHR; 
ST: 
80%1RM;  
AIT: 43 min 
total with 
w/up + 
cool/down 
ST: 40 min 
Three times 
per week 
Treadmill,
cycle 
AIT and ST: 
decrease in fat 
mass; AIT 
associated with a 
more favorable 
inflammatory 
status. 
Small sample size, 
randomized, 
controlled 
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The studies appearing in the tables above show the efficacy of exercise in improving a 
cluster of risk factors simultaneously and the metabolic profile of individuals with 
metabolic syndrome. Yet, there seems to be contradictory evidence with some studies 
showing exercise alone to having an effect on components of MetS and others showing 
no effect. 
 
Carroll et al. (2004), in their review of metabolic abnormalities and exercise, applied 
meta-analyses and a fixed-effects model to analyse randomised controlled trials. The 
review concluded that there is now more evidence that long-term exercise, without body 
mass reduction, modestly decreases abdominal adipose tissue and improves insulin action 
among overweight/obese adults. In addition, exercise alone is effective in improving 
impaired glucose control and reducing the incidence of type 2 diabetes in both sexes. 
Furthermore, exercise alone was associated with modest but clinically relevant 
lipoprotein profile improvements in raising HDL-C and lowering triglycerides. More 
often than not, though, exercise did not alter total cholesterol and LDL-C concentrations. 
The review also found that exercise alone modestly reduces blood pressure with greatest 
changes evident in overweight individuals with hypertension. The majority of the 
randomised controlled studies that Carroll et al. (2004) analysed have suggested aerobic 
endurance activity, 3-5 days per week, 30-60 minutes per session at moderate to 
moderately vigorous intensity (40-80% VO 2 max; median weekly energy expenditure of 
1600 kcal.wk-1). The authors did however state that more trials are needed to establish 
the lower threshold for exercise amount and intensity for metabolic outcomes.  
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Yamaoka et al. (2012) also performed a systematic review and meta-analysis of lifestyle 
modification interventions (LMI) effects on individuals with MetS. Their analysis 
however included “diet only” and “diet and exercise” randomised, controlled trials as 
opposed to the Carroll et al. (2004) review that analysed “exercise only” interventions. 
Like the Carroll et al. (2004) review, the Yamaoka et al. (2012) review also showed that 
LMI decreases the prevalence of MetS and associated abnormalities of MetS. Yamaoka 
et al. (2012) though suggested that their review (when compared to the Carroll et al. 
(2004) review) indicates that “dietary modifications” may be more effective than 
“exercise interventions”. 
 
1.8 Conclusion  
The reliability and use of BLTT has been extensively investigated with athletes, yet the 
use of BLTT in exercise prescription for individuals with MetS has not been researched. 
The first study of this PhD investigated this topic. Furthermore, there is a lack of research 
data on the effect of exercise programs on the diagnosis of MetS. The second study of 
this thesis thus investigated an exercise program that used BLTT to optimize the effects 
of exercise on the metabolic profile of persons with MetS.  
 
There is concensus that long-term lifestyle modifications (diet alone, exercise alone or 
diet and exercise combined) are effective in reducing the prevalence of MetS, the risk of 
type 2 diabetes and simultaneously improving the cluster of risk factors associated with 
MetS. The review by Yamaoka et al. (2012) indicated that dietary interventions may be 
more effective than exercise interventions in the outcomes needed to influence MetS. 
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However, there is a large individual variation to the response to exercise programs. There 
is a lack of data with respect to individualizing exercise programs for persons with MetS 
in order to optimize the improvements in metabolic characteristics at lower exercise 
volumes. This PhD will aim to add knowledge to this area by using AT to individualize 
the exercise program. Furthermore, since improving cardio-respiratory fitness is an 
important part of the lifestyle modifications for MetS, this study will try identify the 
variables that are strongly related to cardio-respiratory fitness parameters. 
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CHAPTER 2 
REPRODUCIBILITY AND LEVELS OF BLOOD LACTATE TRANSITION 
THRESHOLDS IN PERSONS WITH METABOLIC SYNDROME 
 
2.1 Abstract 
Background  
The optimal exercise load/intensity for exercise programs for individuals with metabolic 
syndrome (MetS) has not been investigated. One method of determining optimal exercise 
load is to measure the blood lactate transition threshold (BLTT), referred to as the 
anaerobic threshold (AT). This study investigated the reproducibility of BLTT testing and 
the consequent determination of AT via the Mader method and a modified form of the 
ADAPT method in patients with MetS.  
Methods  
Fifteen, male patients diagnosed with MetS and fifteen healthy, male participants each 
performed BLTT measurements on a treadmill at the same daily times on three different 
days. Peak oxygen consumption was also determined during testing.  
Results 
 There was no significant difference in treadmill velocity at AT determined by the Mader 
method or the Modified ADAPT method within both groups (p > 0.05). Both methods 
yielded good coefficients of variation. When combining both groups, the typical error 
also demonstrated good reproducibility. The mean treadmill velocity at AT was higher in 
the healthy compared to the MetS group using both the Mader and the ADAPT method. 
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Regression analysis and ANCOVA demonstrated that this difference was largely due to a 
higher VO2 peak in the healthy group. The study also found an association between VO2 
peak and waist circumference. 
Conclusion 
 This study demonstrated that BLTT tests are reproducible in persons with MetS. The 
Modified ADAPT method may be the preferred method of determining treadmill velocity 
at AT since fewer factors are known to influence its determination.  
 
2.2 Introduction 
The metabolic syndrome has been identified as a major health challenge (Alberti et al. 
2009; Chan et al. 2005; Wilson et al. 2003) and has been shown to be a significant 
predictor of cardiovascular disease (CVD) and type 2 diabetes mellitus (Meigs. 2004; 
Wannamethee et al. 2005; Wilson et al. 2003). In addition, the syndrome confers 
additional risk to those accounted for by traditional CVD scoring paradigms (Carroll et 
al. 2004). 
 
Lifestyle changes, most especially following a controlled exercise program have been 
shown to play a major role in the therapeutic management of MetS (Carroll et al. 2004). 
To maximise the exercise response for any person involved with a training program 
(including persons with MetS), one needs to identify an individual’s optimal exercise 
load (exercise intensity), duration of exercise and exercise frequency. While standards 
have been set for the last two (Wallace, 2006), it is more difficult to determine the first.  
Blood lactate transition thresholds have been shown to be the best indices for setting 
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exercise intensity (Coen et al. 1991; Coyle et al. 1983; Stegmann et al. 1982; Weltman et 
al. 1992; Weltman, 1995; Yoshida et al. 1982). It has been shown that an increase in 
physical activity is sufficient to elicit a training effect provided that the initial training 
intensity is at or above the anaerobic threshold (Weltman et al. 1992). It is speculated that 
at intensities close to100% of AT, sympathetic activity increases to a level that results in 
adaptive changes of regulatory hormones and muscle metabolism (Coen et al. 1991; 
Kindermann et al. 1979). This method of exercise intensity determination has not been 
applied to training programs for individuals with MetS. Optimizing exercise results for 
MetS patients may also be important in improving exercise adherence levels, which are 
low in individuals with this syndrome (Magkos et al. 2009). 
 
Therefore, the main aim of this study was to investigate the most appropriate method of 
determining BLTT in persons with MetS.  Most BLTT methods can be broadly classified 
into two categories: those using fixed blood lactate concentrations (e.g. the Mader 
method); and those using individualized lactate and anaerobic thresholds (e.g. the 
Automatic Data Analysis for Progressive Tests (ADAPT) method). In order to use BLTT 
for determining the appropriate exercise intensity to be used in participants with MetS it 
is necessary to determine the best method for measuring BLTT in such participants, as 
this has not previously been attempted. In addition, since the BLTT of patients with MetS 
has not been measured in other studies, this investigation aimed to determine the BLTT 
of such patients. Furthermore, the study aimed to assess the variables that most strongly 
correlate with VO2 peak and AT. 
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2.3 Methods 
The Human Ethics Committee of the University of the Witwatersrand, Gauteng, accepted 
the study protocol (MO61104). 
 
2.3.1 Participants and definition of metabolic syndrome 
Fifteen male patients diagnosed with MetS and fifteen healthy participants each 
performed three BLTT tests. All healthy participants were age-matched with the patient 
group and had one or no components of MetS. Patients were diagnosed with MetS by 
clinicians using the harmonised guidelines (Alberti, 2009). The presence of any 3 of the 5 
criteria denoted below constituted a diagnosis of MetS: waist circumference (>94 cm); 
triglycerides (>1.7 mmol.L-1) or drug treatment for high triglycerides; HDL-cholesterol 
(<1.0 mmol.L-1) or drug treatment for reduced HDL-cholesterol; elevated blood pressure 
(> 130/85) or on anti-hypertensive drug treatment; elevated fasting glucose   
(> 5.6 mmol.L-1) or drug treatment for glucose intolerance. 
 
2.3.2 Measurements 
All participants underwent an oral glucose tolerance test (OGTT) for the detection of 
undiagnosed diabetes. Fasting and two hour plasma glucose levels were measured using a 
glucose oxidase method (Roche Diagnostics, Mannheim, Germany) whilst fasting serum 
triglyceride, total cholesterol and HDL-cholesterol levels were assayed using enzymatic 
assay methods (Roche Diagnostics, Mannheim, Germany). 
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The following were determined on the first day of laboratory testing: height (measured to 
the nearest millimetre by a Seca Stadiometer [Hamburg, Germany]); body mass 
(measured to the nearest gram by a Charder electronic scale [Taiwan, China]); waist 
circumference (taken as the greatest reading around the girth, midway between lateral 
lower ribs and the iliac crests); blood pressure (measured by a Honsun 
sphygmomanometer [Shanghai, China]; sitting; average of two readings) and a BLTT test 
was performed and the time of day was noted. 
 
2.3.3 Blood lactate transition threshold (BLTT) test 
The BLTT test was repeated at the same time of day a total of three times, with one day 
rest in between tests. As in the study of Heitcamp et al. (1991), participants did not vary 
their usual dietary habits, exercise or leisure time activities between the three tests. All 
participants did not exercise for 12 hours before the testing sessions. The BLTT test used 
an initial treadmill speed of 2.5 kph at a 5% gradient with speed increments of 0.5 kph 
every 4 minutes. (This was within the recommended 4-7 minute period for steady state to 
be attained). The treadmill speed was modified depending on the response of a participant 
to ensure the collection of at least six blood samples for lactate analysis (i.e. if the blood 
lactate value remained low after 3 workloads, the speed was increased by 1 kph). After 
signalling impending exhaustion, participants were encouraged to continue to complete 
the 30 seconds period already begun. 
 
Electrocardiographic responses and oxygen consumption (VO2) were measured at the 
same time (Cortex Biophysik Metalyzer 3b CPX system, Leipzig, Germany). The 
 80
electrocardiogram (ECG) was used to monitor electrocardiographic responses during 
testing of the participants. Testing was stopped if any ECG abnormalities were observed. 
VO2 at exhaustion was recorded as the VO2 peak. No abnormalities in ECG readings 
were observed. This protocol was designed taking into consideration the low level of 
physical conditioning of patients with MetS. 
 
Lactate concentration was measured from whole-blood samples taken from the fingertip 
using the Lactate Scout automated analyser (Lactate Scout, SensLab, Leipzig). The error 
of measurement for repeated measures on the same blood sample using the Lactate Scout 
is 0.5 mmol.L-1 (Tanner et al. 2010). Blood samples (collected from finger capillary 
vessels using a lancet) were taken at the end of each 4 minute exercise period within 30 – 
40 seconds of the participants standing still on the treadmill. The fingertip was first wiped 
with water to remove the sweat and then it was dried before the blood sample was 
collected. The participant continued exercising within one minute of standing. 
 
2.3.4 Determination of the BLTT 
The BLTT that was determined for each participant will be defined in this study, for 
purposes of terminology, as Anaerobic Threshold (AT). AT, in this study, will be defined 
as the workload (treadmill velocity given as km.h-1) marked by a rapid rise in blood 
lactate denoting the upper limit of equilibrium between lactate production and clearance 
(Bourdon, 2000). The treadmill velocity at AT for each BLTT test was determined using 
two methods: the Mader method and the ADAPT method, as these are the two most 
frequently used and recognised methods for assessing AT.  
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The Mader method determines AT as the workload that corresponds to the fixed blood 
lactate level of 4 mmol.L-1 (Mader et al. 1986). This was calculated using the Lactate 
Scout software. The software fits the data with a third degree polynomial regression 
curve and then determines the velocity at 4 mmol.L-1 blood lactate  
 
The ADAPT method determines AT from the individual shape of the velocity – blood 
lactate curve (not from a fixed blood lactate concentration). The ADAPT method is based 
on the Dmax mod method (Cheng et al. 1992). It determines AT by calculating the 
workload corresponding to the greatest perpendicular distance from a regression curve 
relating workload to blood lactate and a straight line formed by the first and last points of 
the curve. When using the ADAPT method the Australian Sports Commission modified 
the Dmax mod analysis by defining the first point as the workload preceding a  
0.4mmol.L-1 rise in blood lactate above the baseline (Bourdon, 2000). However the use 
of a particular data point on the curve to determine the first point is artificial and 
arbitrary, and this study re-defined this point as the lowest point on the curve. This point 
was then connected to the last point of the curve which was defined as the lactate 
concentration measured at VO2 peak (Fig.1). The modified ADAPT method used in this 
study allows for a consistent and reproducible first and last point of the curve. A two 
phase exponential regression was fitted to the data points in our modification of the 
ADAPT method (GraphPad Prism Version 3.02) (Fig.1). The regression curves fitted to 
our data yielded high correlations (R2 = 0.9691 to 0.9995). 
 82
 
0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 4.5 5.0 5.5 6.0 6.5 7.0 7.5 8.0 8.5 9.0
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
4.5
5.0
5.5
6.0
6.5
7.0
7.5
8.0
8.5
9.0
9.5
10.0
10.5
11.0
11.5
12.0
12.5
Velocity km/h
B
lo
od
 L
ac
ta
te
 m
m
ol
/L
 
 
Figure 1. The modified ADAPT method, using the lactate value at VO2 peak as the end point and 
the lowest point on the curve as the first point, to measure AT. The vertical line (with arrow) 
indicates the velocity at the point that is the greatest perpendicular distance from the curve and a 
straight line formed by the end and the lowest points of the curve. 
 
The % VO2 peak at AT was calculated by first determining the VO2 at AT. This was 
determined in the same way described above (ADAPT method), but with VO2 on the x-
axis as opposed to velocity. The VO2 at AT was then expressed as a percentage of VO2 
peak. The % VO2 peak was calculated using the ADAPT method, since no significant 
difference was found between the two methods and and the ADAPT method was going to 
be used in study 2 of the thesis. 
 
2.4 Statistical analysis 
Data distribution was analysed using Shapiro-Wilk’s W test, and any variables that were 
found to be significantly skewed were log transformed to normality i.e. p>0.05 by 
Shapiro-Wilk’s W test. Coefficients of variation [CV = (SD / MEAN) x 100] were 
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calculated between testing sessions for the two groups. We confirmed our findings by 
also using the typical error technique as reported by Hopkins (Hopkins, 2000). 
 The Bland – Altman method was used to assess agreement between the Mader and 
modified ADAPT methods. The average values of the two groups were compared using 
the independent t statistic. Pearson correlation analyses were used to determine the 
principal correlates of the VO2 peak and the AT. Variables that gave a p<0.10 in the 
univariate analyses were then used as independent variables in two separate multiple 
regression models in which VO2 peak and AT were the dependent variables. Collinearity 
was assessed by calculating the variance inflation factors (VIFs) and variables with a 
VIF>10 were excluded from the initial regression models. Backward, stepwise regression 
analysis was then performed until only variables with p<0.05 remained in the model. 
One-way ANOVA and ANCOVA were then used to confirm the data from the regression 
models. The results of the multiple regression models were the same for AT measured 
using the ADAPT or Mader methods.  
 
2.5 Results 
2.5.1 Participants 
Table 2 depicts the physical characteristics of the participants. There were significant 
differences between the groups in waist circumference, high-density lipoprotein, 
triglycerides, systolic blood pressure and VO2 peak. Fasting and 2 hour glucose levels, 
total cholesterol, diastolic blood pressure, body mass and age were not significantly 
different between the groups. No undiagnosed diabetic participants were detected.  
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The percentage of VO2 peak associated with AT was 73.4 ± 7.8% in the group with MetS, 
and 75.8 ± 8.8% in the group without MetS. This difference was not significant (p > 
0.05). 
 
 
 
Table 2 Mean ± SD levels of the physical characteristics of study participants 
PARAMETER METABOLIC 
SYNDROME (N=15) 
HEALTHY 
(N=15) 
Age (Yrs) 43.5 ± 7.52 44.1 ± 6.08 
Body Mass (kg) 103.3 ± 13.93 94.2 ± 15.22 
Body Mass Index (kg.m-2) 32.1 ± 3.2 29.2 ± 4.5 
Waist Circumference (cm) 112.4 ± 8.43 102.3 ± 12.37* 
Serum High Density Lipoprotein 
(mmol.L-1) 
0.9 ± 0.19 1.1 ± 0.18* 
Serum Triglycerides (mmol.L-1) 1.87 ± 0.45 1.38 ± 0.55
* 
Serum Total Cholesterol (mmol.L-1) 5.72 ± 1.41 5.63 ± 1.07 
Systolic Blood Pressure (mmHg) 135.8 ± 12.02 122 ± 10.34* 
Diastolic Blood Pressure (mmHg) 86.7 ± 5.34 82.7 ± 7.06 
Fasting Plasma Glucose (mmol.L-1)  5.2 ± 0.6 5.0 ± 0.3 
Two Hour Plasma Glucose (mmol.L-1) 5.3 ± 1.5 5.2 ± 1.1 
VO2 Peak (ml.min-1.kg-1) 30.3 ± 6.6   42.7 ± 11.3
* 
*p< 0.05 versus metabolic syndrome 
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2.5.2 Comparison of the Mader and modified ADAPT method 
There was no significant difference (p > 0.05) in velocity at AT determined by the Mader 
method or the modified ADAPT method, in both participant groups. Both methods of 
determining velocity at AT yielded good (< 4%) coefficients of variation (CV). There  
was no statistical difference between the coefficients of variation of the two groups 
(Table 3). 
Table 3 Mean ± SD and coefficient of variation (CV) for velocity at anaerobic threshold (AT) 
 METABOLIC 
SYNDROME 
(N=15) 
HEALTHY 
(N=15) 
 
 Mader 
Method 
Modified 
Adapt 
Method 
Mader 
Method 
Modified 
Adapt 
Method 
Coefficient of 
Variation (%) 2.61 3.52 2.97 3.44 
Mean of Velocity at  
AT (km.h-1) 6.78 ± 0.19* 5.87 ± 0.21* 8.62 ± 0.26 7.89 ± 0.26 
*p<0.05 versus healthy males 
 
The healthy males attained a significantly higher velocity at AT than that attained by the 
males with MetS for both the Mader method (P < 0.05) and the modified ADAPT method 
(P < 0.05) (Table 3).  
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Our findings of good reproducibility were confirmed when we used an alternate method 
of calculating reproducibility i.e. the typical error technique reported by Hopkins 
(Hopkins, 2000), which gave values of 3.1%; 0.29km.h-1 and 4%; 0.27km.h-1 for the 
Mader and modified ADAPT methods respectively. The Bland-Altman plot was used for 
determining the level of agreement between the 2 methods (Fig. 2) and demonstrated that 
the Mader method gave a higher value than ADAPT, with a mean difference of 0.82 ± 
0.37 km.h-1 (p=0.03). 
 
 
Figure 2. Bland Altman comparison between the Mader method and the modified ADAPT 
technique (data for the two groups of participants have been combined). The two horizontal lines 
depict the 95% limits of agreement (from 0.09 to 1.55), with a mean difference of 0.82 ± 0.37 
km.h-1 (p=0.03). 
 
In addition, this study found a close exponential relationship between treadmill speed and 
plasma lactate concentration using a two-phase exponential regression fit to the blood 
lactate values (R2 = 0.96 to 0.99). 
 
 
 87
2.5.3 Determinants of VO2 peak and the AT 
Pearson correlation analysis demonstrated that the VO2 peak and the AT both correlated 
with each other and with the following variables: BMI, body mass, waist circumference, 
diastolic and systolic blood pressure and 2 hour plasma glucose levels. These variables, 
as well as coding variables for the presence/absence of metabolic syndrome, were then 
included as independent variables in two separate backward, stepwise regression models 
in which VO2 peak and AT were the dependent variables. In both models, BMI and waist 
had a VIF>10 and therefore BMI was excluded from each of the initial regression 
models. In the first regression model, waist circumference and metabolic syndrome were 
found to correlate with VO2 peak (see Table 4). These data suggest that the lower VO2 
peak of participants with metabolic syndrome is associated with their higher waist 
circumference. This was confirmed in an ANCOVA comparing VO2 peak between the 2 
participant groups, where waist circumference was added as a covariate. This attenuated 
the F-value from 11.4 to 4.34 and the p-value from 0.002 to 0.05. In the second 
regression model, body mass and VO2 peak were found to correlate with AT (see Table 
4). This suggests that the lower AT of participants with the metabolic syndrome may be 
due to differences in body mass and/or VO2 peak. This hypothesis was tested by 
comparing AT in control and metabolic syndrome patients using ANCOVA adjusted for 
either mass or VO2 peak. Adjusting for body mass attenuated the F value from 7.49 to 
4.46 and the p-value from 0.01 to 0.04, whereas adjusting for VO2 peak attenuated the F-
value to 0.0006 and the p-value to 0.98. This demonstrates that the lower AT values in 
participants with the metabolic syndrome is largely associated with their lower VO2 peak 
levels. 
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Table 4 Results of backward, stepwise multiple regression analyses for isolating principle 
determinants of VO2 peak and anaerobic threshold (AT)  
 
REGRESSION 
MODEL 
NUMBER 
DEPENDENT 
VARIABLE 
INDEPENDENT VARIABLES 
WITH STANDARDISED BETA 
COEFFICIENT (P-VALUE) 
R2 FOR FULL 
MODEL (P-
VALUE) 
1 VO2 peak (log) Waist: -0.82 (<0.0001) 
Metabolic syndrome†: -0.22 (0.02) 
0.85 (<0.0001) 
2 Anaerobic 
threshold (log) 
Mass: -0.61 (<0.0001) 
VO2 peak (log): 0.38 (0.007) 
0.84 (<0.0001) 
†Presence of the metabolic syndrome was coded as 1 and absence was coded as 0 
  
2.6 Discussion 
The MetS group in this study had higher waist circumference; higher triglyceride levels 
and lower HDL-cholesterol levels when compared to the healthy group. These results 
agree with the definition used in this study to classify MetS.   
 
Considering body mass and age were not different between the two groups, the lower 
VO2  peak found in the MetS group agrees with the Kuoppio study (Lakka et al. 2003) 
that found directly determined VO2 max to be lower in persons with MetS. Also, 
Laaksonen et al. (2002) showed that men with a VO2 max of < 29.1 ml.min-1.kg-1 were  
3 – 4 times more likely to have MetS than those with VO2 max of  35.5ml.min-1.kg-1. 
The difference in VO2 peak between the 2 groups cannot be due to the healthy group 
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training more than the MetS group, because all participants in the study had not exercised 
regularly for a minimum of 4 weeks prior to the testing.  
 
Multiple regression analysis suggested that the lower VO2 peak of MetS participants is 
associated with their higher waist circumference. This is an original finding and it 
highlights the importance of reducing waist circumference in individuals with MetS, in 
order to improve energy production and health. It is interesting to note that both 
longitudinal (Eisenmann et al. 2005) and cross sectional studies (Jago et al. 2010) have 
shown that, of all anthropometric variables measured, only waist circumference was 
negatively correlated with level of fitness. It is not known why waist circumference 
specifically influences VO2 peak. However, waist circumference is a proxy indicator of 
visceral fat mass (Pouliot et al. 1994) and this body fat depot is a negative regulator of 
whole body insulin sensitivity (Ross, 2002) and may therefore limit glucose metabolism 
in skeletal muscle. 
 
To our knowledge, no other study has shown that the velocity at AT is lower in patients 
with MetS and that this was largely associated with their lower VO2 peak. This finding 
supports the notion of a lower level of aerobic fitness in patients with MetS, as has been 
demonstrated in other studies (Church, 2009; Eisenmann, 2007). Also, the higher velocity 
attained at AT by the healthy participants when compared to the participants with MetS, 
confirms the observation that persons with MetS exhibit a lower level of physical 
conditioning than their healthier counterparts (Lakka et al. 2003). 
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The percentage of VO2 peak associated with AT (% VO 2 peak @ AT) is not significantly 
different in the group with MetS when compared to the group without MetS. It is 
believed that the % VO 2 peak @ AT and VO 2 peak are determined by different factors, 
with VO 2 peak being dependent on cardiovascular factors, such as cardiac output, stroke 
volume and the % VO 2 peak @ AT being dependent on peripheral factors such as 
number of mitochondria and muscle fiber type (Weltman et al. 1992; Weltman, 1995).  
This suggests that the MetS group had a lower performance in an index of central, 
cardiovascular function yet similar characteristics in peripheral muscle morphology when 
compared to individuals without MetS.  
 
 The Mader method of determining AT yielded good reproducibility in this study (see 
Table 3). Heitkamp et al. (1991) used correlation coefficients for treadmill speed, and 
also found good reproducibility of AT at 4 mmol.L-1 for the Mader method. Coefficients 
of variation for velocity at AT determined by the modified ADAPT method in our study 
were not different to those yielded by the Mader method (Table 3). 
 
The advantage of the ADAPT method is that it calculates AT from the shape of the 
lactate-work intensity curve. Frohlich et al. (1989) found that nutritional factors 
(glycogen depletion as a result of dietary or training manipulations) did not alter the 
shape nor the slope of the lactate- work intensity curve. In contrast, nutritional and 
training/recovery factors will influence the calculation of AT when fixed blood lactate 
levels are used, as is the case with the Mader method (Bourdon, 2000). Urhausen et al. 
(1992) also showed that AT determined via fixed blood lactate levels in a glycogen 
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depleted state will overestimate endurance capacity, while this threshold determined from 
the shape of the lactate-workload curve is hardly changed. Furthermore, some individuals 
with very low levels of conditioning do not reach 4 mmol.L-1 lactate but one can still use 
the shape of their curve to determine AT. Furthermore, the Bland-Altman analysis 
showed that when data from the two subject groups was combined the Mader method 
gave a higher value for the AT compared to the ADAPT method, with a mean difference 
of  0.82 ± 0.37 km.h-1. The Mader method uses a fixed blood lactate level of 4 mmol.L-1 
yet mean maximal steady state exercise blood lactate values range from 3.0 to 5.5 
mmol.L-1 (Weltman, 1995).  In view of our results, it is possible that a fixed lactate level 
of 4 mmol.L-1 is too high and more studies need to be performed to determine if this 
fixed level of lactate is appropriate for determining AT.  
 
The technical error of measurement (TEM: also called the standard error of measurement: 
6di 2 / 2n) for AT determination using the ADAPT method has been shown to have 
good precision for athletes tested at the South Australian Sports Institute (TEM%= 1.5%) 
(Bourdon, 2000). No study has investigated the applicability of this method in the clinical 
environment. This study found that the modified ADAPT method can be used in the 
clinical environment with good reproducibility. This finding was also confirmed by the 
method that Hopkins (Hopkins, 2000) has set up to test reliability of data. The typical 
error obtained via this method also shows good reproducibility of velocity at AT using 
both the Mader and the modified ADAPT methods.  
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Swart et al. (2004) reviewed the reliability and accuracy of the Accusport and Lactate Pro 
portable blood lactate analysers. These researchers stated that the changes in blood lactate 
concentration at threshold that occur with training (approximately 0.7 mmol.L-1), might 
be of a smaller magnitude than the level of error inherent in the portable blood lactate 
analysers (up to 0.35 mmol.L-1 at 5mmol.L-1 or 0.7 mmol.L-1 at 10 mmol.L-1). This 
study used the ADAPT method and velocity at AT in determining BLTT, and found the 
level of error inherent in the Lactate Scout (0.27-0.29 km.h-1) is smaller than the changes 
that can occur with training (0.5 – 1.6 km.h-1) (Bourdon, 2000). Thus, the use of 
treadmill speed (work load), rather than blood lactate concentration to denote the 
threshold has improved the reliability of the BLTT. 
 
The AT has been used in prescribing exercise intensity among healthy, non-athletes 
(Weltman et al. 1992) and among adults with cardiac disease (Coyle, 1983). As far as the 
authors are aware, this is the first study to investigate AT among adults with MetS. 
Measuring AT on a regular basis in such individuals is straight forward. The test takes 
only 20-30 minutes to complete and automated blood lactate analysers have made lactate 
measurement simple and accessible. Most patients find the VO2 peak tests uncomfortable 
and difficult to perform. Lactate measurements are easier to administer because they can 
be performed during sub-peak exercise, and do not require highly specialized staff. In 
addition, regular monitoring of changes in AT motivates individuals by showing their 
improvement in endurance capacity as their BLTT curve shifts to the right. 
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Typical changes in blood lactate levels during exercise range from 1.2 mmol.L-1 to 11 
mmol.L-1 for athletes (Bourdon, 2000); 5 mmol.L-1 in heart disease patients (Coyle et al. 
1983); 8 mmol.L-1 in healthy subjects (Coyle et al. 1983; Weltman et al. 1992; Weltman, 
1995). The changes are similar across different modes of activity (running, cycling, arm 
ergometer) (Weltman, 1995). 
 
The current study shows that AT measurements can be used to establish an exercise 
prescription for persons with MetS. This can be accomplished by firstly asking the 
subject to exercise for 20 minutes at 85% of the treadmill velocity at which AT occurred. 
This would slowly be increased over 12 weeks to 45 minutes at 100% of the treadmill 
velocity at which AT occurred (if a cycle is used, watts will be used instead of velocity). 
The intention of using AT to prescribe exercise is to prevent an exercise load that is too 
small or too strenuous. 
 
2.7 Conclusions 
x This study showed that the BLTT is reproducible in persons with metabolic 
syndrome, and that BLTT tests can be used to set the exercise load for persons 
with MetS.  
x The Mader and ADAPT methods of determining the AT were similarly 
reproducible. The ADAPT method may be preferable because fewer factors 
influence its determination.  In addition, our modifications to the ADAPT method 
yielded acceptable reproducibility.  
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x In addition, this study found that the lower VO2 peak and velocity at AT in 
individuals with MetS was associated with a greater waist circumference and a 
lower VO2 peak respectively.  
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CHAPTER 3 
EFFECT OF EXERCISE INTERVENTION PROGRAMS ON PHYSICAL, 
PHYSIOLOGICAL AND BIOCHEMICAL PARAMETERS OF PERSONS WITH 
AND WITHOUT METABOLIC SYNDROME 
 
3.1 Abstract 
Background  
Protocols for an effective exercise program for treating metabolic syndrome (MetS) have 
not been devised. Furthermore, MetS is a multi-faceted disease and the effect of specific 
exercise protocols on the different components of MetS has also not been investigated. 
Therefore, this study compared the effects on the components of the MetS of an exercise 
program that uses blood lactate transition thresholds (specifically, the anaerobic threshold 
(AT)) to the same measurements obtained in an exercise program (not using AT) 
appearing in the literature. The main aim of the study was to design an exercise program 
that optimized exercise responses and may thus improve metabolic characteristics in 
individuals with MetS.  
Methods  
Ten participants with MetS exercised using the walking program of Leon et al. (1979) 
(MetSL). Ten participants with MetS exercised using velocity at AT to set training 
intensities (MetSV). Ten participants without MetS also exercised using velocity at AT to 
set training intensities (Non-MetSV). Physical, physiological and metabolic parameters 
were measured in all groups before, during and after twenty weeks of exercise. 
Nutritional records were collected at week 0, 8 and 20 of training.  
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Results  
BMI and waist circumference decreased significantly in all training groups with the 
training program using AT and the program not using AT showing similar outcomes in 
these variables among persons with MetS. Body mass, Velocity at AT also improved in 
all training groups yet body mass and VO2 peak did not change significantly in the group 
without MetS. Similarly, the blood pressure response was favourable in the groups with 
MetS yet absent in the group without MetS. The training group with MetS that used AT 
was the only group to show significant, positive changes in any of the metabolic 
parameters (fasting serum insulin and HOMA). In addition, the training program using 
AT had a greater effect on the incidence of MetS than the training program not using AT.  
Conclusion  
An endurance exercise program using AT to set intensity is effective in eliciting 
favourable responses in individuals diagnosed with MetS and in reducing the incidence of 
MetS. The training program using AT elicited the responses with a reduced exercise 
frequency and intensity. It also improved insulin sensitivity which was not affected by the 
walking program of Leon et al. (1979). The response to the exercise program that used 
AT was similar in persons with MetS and in persons without MetS, except in the central 
cardiovascular adaptations of VO2 peak and in the metabolic parameters of fasting insulin 
and the HOMA index.  
 
3.2 Introduction 
The National Cholesterol Education Program suggested body mass - loss and increased 
physical activity as the basis of therapy for MetS (NCEP, 2001). Yet protocols for an 
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effective training program for this syndrome have not been devised. Furthermore, MetS is 
a multi-faceted disease and the effect of specific exercise protocols on the different 
components of MetS have also not been investigated. Therefore, the main aim of this 
study is to design an exercise program that uses blood lactate transition thresholds 
(BLTT, specifically the anaerobic threshold (AT)) to optimize exercise responses and 
thus improve metabolic characteristics in individuals with MetS. 
 
The intention of using AT is to individualize the exercise program and optimize the 
improvements in metabolic characteristics. The AT has been suggested as a point of 
optimal exercise overload (Coen et al. 1991; Sjodin et al. 1982; Yoshida et al. 1982). 
However, it should be noted that other studies have suggested this may not be the case 
(Gibala et al. 2012; Rynders et al. 2014).  Exercise overload refers to exercising at a level 
of intensity higher than is normally performed in order to induce training adaptations. 
Overload is a critical principle of physical training and may need to be determined in 
individuals with MetS in order to influence their metabolic profile. This study will use 
the AT as the point of optimal exercise overload. Previous studies have not investigated 
the metabolic improvements that could result in persons with MetS by training at AT.  
 
In addition, this study will ascertain how individuals with MetS respond to an exercise 
program that has been validated in a previous study that used obese participants (Leon et 
al. 1979). The responses of this group will be compared to the response of individuals 
with MetS using an exercise program incorporating the AT.  
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The hypothesis that will be tested in this investigation is that persons using AT to 
individualize exercise intensity will show greater beneficial changes in their MetS profile 
compared to individuals not using AT in their exercise program. 
 
3.3 Methods 
The Human Ethics Committee of the University of the Witwatersrand, Johannesburg, 
South Africa, approved the study protocol (MO61104). 
 
3.3.1 Subject groups and definition of MetS 
The study investigated three groups: 
a) Ten participants with MetS exercised using the walking program of Leon et al. 
(1979) (Group: MetSL). 
b) Ten participants with MetS exercised using velocity at AT to set training 
intensities (Group: MetSV). 
c) Ten participants without MetS exercised using velocity at AT to set training 
intensities (Group: Non-MetSV). 
 
Subjects were diagnosed with MetS by using the harmonised guidelines (Alberti, 2009). 
The presence of any 3 of the 5 criteria denoted below constituted a diagnosis of MetS: 
waist circumference (>94 cm); triglycerides (>1.7 mmol.L-1) or drug treatment for high 
triglycerides; HDL-cholesterol (<1.0 mmol.L-1) or drug treatment for reduced HDL-
cholesterol; elevated blood pressure (> 130/85) or on anti-hypertensive drug treatment; 
elevated fasting glucose (> 5.6mmol.L-1) or drug treatment for glucose intolerance. 
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Participants were recruited from a physician’s (Dr. F. Fleming) medical practice and from 
advertisements placed in a local newspaper. 
 
3.3.2 Measurements  
Fasting blood samples were analysed by a pathology laboratory (Lancet Laboratories, 
Richmond, Johannesburg) as part of the diagnosis. The following baseline measurements 
were made on every subject before the training program commenced: 
a) Blood serum concentrations of: triglycerides; HDL and total cholesterol were assayed 
using enzymatic assay methods (Roche Diagnostics, Mannheim, Germany), measured on 
the Architect i2000 Abbott autoanalyser. The LDL levels were calculated using the 
method of Friedewald et al. (1972). 
b) An oral glucose tolerance test (OGTT) was performed in a fasting state after 
administering a 75 g glucose load. Fasting, 30 minute and two-hour plasma glucose 
levels were measured on the Architect i2000 Abbott instrument, using a glucose oxidase 
method (Roche Diagnostics, Mannheim, Germany). Serum insulin levels (measured on 
the Architect i2000 Abbott instrument using the Chemiluminescent Microparticle 
Immunoassay) were also measured at each time point. The HOMA-IR (Matthews et al. 
1985) and insulinogenic index (Utzschneider et al. 2009) were calculated to assess insulin 
sensitivity and insulin secretory response, respectively.   
c) Anthropometric variables: height (measured to the nearest millimetre by a Seca 
Stadiometer [Hamburg, Germany]); body mass (measured to the nearest gram by a 
Charder electronic scale [Taiwan, China]); waist circumference (taken as the greatest 
reading around the girth, midway between lateral lower ribs and the iliac crests).  
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d) Blood pressure was measured with a Honsun sphygmomanometer (Shanghai, China) 
in the sitting position and an average taken of two readings. 
e) Peak VO2 and heart rate were measured using the Cortex, Biophysik, Metalyzer 3b 
CPX on-line system (Leipzig, Germany). 
The treadmill protocol was the same as the protocol reported in Chapter 2. 
f) A BLTT test using the modified ADAPT method, was performed at the same time as 
the peak VO 2 test. The protocol was the same as that described in Chapter 2.  
 
3.3.3 Training programs 
The subjects in Group MetSL followed the walking program of Leon et al. (1979) 
outlined below. The program was modified to allow a five-week, instead of a two-week 
adaptation period. Also, the gradient was modified due to the older age-group of the 
participants in this study. Consequently, the training period was extended to 20 weeks 
instead of 16 weeks. The Leon et al. (1979) training program was chosen since it was 
periodized and measured outcomes of components of the metabolic syndrome that this 
study was also measuring. 
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Table 5 Protocol of the 20-week treadmill walking program (Leon et al. 1979). 
 
Week 
 
Day Speed 
(Kph) 
Duration 
(Min) Elevation 
(% grade) 
1 M 2.4 10 + 5 rest + 5 0 
1 T 2.4 10 + 5 rest + 5 2 
1 W 2.4 10 + 5 rest + 10 2 
1 Th 2.4 10 + 5 rest +10 + 5 rest + 5 
4
1 F 2.6 10 + 5 rest +10 + 5 rest + 5 4 
2 M 2.6 10 + 5 rest +10 2 
2 T 2.8 10 + 5 rest +10 + 5rest + 5 2 
2 W 3.0 10 + 5 rest +10 + 5 rest +10 
4
2 Th 3.2 15 + 5 rest +10 + 5 rest +10 4 
2 F 3.4 15 + 5 rest +15 + 5 rest +15 6 
3 M 3.4 15 + 5 rest +10 + 5 rest +10 4 
3 T 3.6          15 + 5 rest + 15 + 5rest +15 4 
3 W 3.8 20 + 5 rest + 15 + 5 rest +15 6 
3 Th 4.0 20 + 5 rest + 20 + 5 rest +15 6 
3 F 4.2 20 + 5 rest + 20 + 5 rest +20 6.5 
4 M 4.2 20 + 5 rest + 20 + 5 rest +15 6 
4 T 4.4 20 + 5 rest + 20 + 5 rest +20  6 
4 W 4.6 25 + 5 rest + 20 + 5 rest +20 6.5 
4 Th 4.8  25 + 5 rest + 25 + 5 rest +20 6.5 
4 F 5.0 25 + 5 rest + 25 + 5 rest +25 7 
5 M 5.0 25 + 5 rest + 25 + 5 rest +20  6.5 
5 T 5.0 25 + 5 rest + 25 + 5 rest +25 6.5 
5 W 5.1 30 + 5 rest + 25 + 5 rest +25 7 
5 Th 5.1 30 + 5 rest + 30 + 5 rest +25 7 
5 F 5.1 30 + 5 rest + 30 + 5 rest +30 7.5 
6 M,T,W,Th,F 5.1 30 + 5 rest + 30 + 5 rest +30 7.5 
7 M 5.1 30 + 5 rest + 30 + 5 rest +30 7.5 
7 T 5.1 30 + 5 rest + 30 + 5 rest +30 8 
7 W 5.1 30 + 5 rest + 30 + 5 rest +30 7.5 
7 Th 5.1 30 + 5 rest + 30 + 5 rest +30 7.5 
7 F 5.1 30 + 5 rest + 30 + 5 rest +30 8 
8 - 20 M,T,W,Th,F 5.1 30 + 5 rest + 30 + 5 rest +30 8 
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The MetSV and Non-MetSV groups followed the 20 week program outlined below: 
 
 
Table 6 The training program for groups using AT to set intensity 
 
Week Duration 
(min/session)
Frequency 
(sessions/week)
Intensity 
(% AnaerobicThreshold) 
1 20 3 90 
2 25 3 90 
3 25 3 95 
4 20 3 95 
5 25 3 100 
6 30 3 100 
7 35 4 100 
8 25  3 100 
9 35 4 100 
10 40 4 100 
11 45 4 100 
12 35 3 100 
13 45 4 100 
14 50 4 100 
15 55 4 100 
16 40 3 100 
17 55 4 100 
18 60 4 100 
 
 
 (Week 19) 
 
Day Duration 
(min/session)
Sessions Intensity 
(% Anaerobic Threshold)
1 40 1 100 
2 35 1 100 
3 30 1 100 
 (Week 20) 
 
Day Duration 
(min/session)
Sessions Intensity 
(% Anaerobic Threshold)
1 25 1 100 
2 20 1 100 
3 15 1 100 
 
A tapering phase was used in the training program using AT to prevent fatigue from 
affecting post-training results and to adhere to periodization principles of exercise 
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prescription. Heart rate was monitored during training sessions with Polar Heart rate 
monitors.  
Training was performed and controlled at the Technogym Wellness Centre, Bryanston, 
using the Technogym key system that records all training sessions. These sessions were 
accessed using the Technogym Wellness System Software (V7) (Technogym,Italy).  
Participants who had downloadable Polar heart rate monitors were able to exercise at 
their own training facility. Their training information was accessed from the Polar web-
site (www.polarmypersonaltrainer.com). 
 
Participants warmed-up and cooled-down at a lower exercise intensity than that set for 
each session for 5 minutes. The training duration and frequency of the program using AT 
was less than the training program not using AT. This is because training at AT is 
considered as quality training and needs to be limited in frequency and duration. It will be 
beneficial for clinical practice to have a training protocol that achieves results with a 
relatively low training duration and frequency. 
 
3.3.4 Medication and Nutrition 
All medications taken by the participants were recorded. No participants used any 
confounding medications (eg. Statins; Glucophage). All participants were given a 
standardised nutrition programme (Document A in Appendix). The nutrition plan was 
given in an attempt to get a similar energy intake across the 3 groups. The Willett food 
frequency questionnaire (Lee, 1996) (Document B in Appendix) in combination with a 
24 hour eating record for 3 days (Document C in Appendix) were used to monitor the 
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energy intake of all participants. These nutritional records were taken at week 0, 8 and 20 
of training. Nutritional records were analysed for caloric content using the site 
www.nal.usda.gov/fnic/foodcomp/search. 
 
All baseline measurements were re-tested in all groups during weeks 12 and 20, with the 
BLTT, VO2 peak test, waist circumference and body mass being measured every 4 
weeks. 
 
Exclusion criteria for the study were: 
x Women  
x Men younger than 25 and older than 55 years of age 
x Any individuals with known cardiovascular or pulmonary disease. 
x Type 1 diabetes 
x Use of confounding medications 
 
3.4 Statistical Analysis 
The n per group for this study was chosen as 10. This was based on convenience and was 
the upper n as determined by infrastructural limitations. A post hoc sample size 
calculation based on the data shown in Table 18 (percentage change in variables for each 
group after 20 weeks of exercise) for waist circumference, assuming a power of 0.80 and 
an Į of 0.05 gave an n for each group of 18. If BMI was used, the n per group was 8. 
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Data distribution was analysed using Shapiro-Wilk’s W test, and any variables that were 
found to be significantly skewed were log transformed to normality. Student’s t-test for 
paired values obtained at week 0 and week 12; and at week 0 and week 20 were used to 
analyse intra-group responses. Inter-group comparisons were made using an ANOVA. If 
the ANOVA analysis found significant differences for confounding variables, an 
ANCOVA analysis was performed adjusting for the confounding variable and a post hoc 
analysis was performed using a Tukey HSD test. Dunnett’s test was used for comparing 
mean values obtained at weeks 4, 8, 12, 16 and 20 with the mean value at week 0. A level 
of P< 0.05 was set as statistically significant.  
 
Pearson correlation analyses were used to determine the principal correlates of the % 
changes in VO2 peak and AT. Variables that gave significant correlations in the 
univariate analyses (p<0.1) were then used as independent variables in two separate 
multiple regression models in which % change in VO2 peak and % change in AT were the 
dependent variables. Backward, stepwise regression analysis was then performed until 
only variables with p<0.10 remained in the model.  
 
The statistics package Statistica version 11 (StatSoft, Tulsa, OK, USA) was used for the 
statistical analysis and sample size calculations. 
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3.5 Results 
3.5.1 Subjects 
Table 7 describes the study’s subject baseline characteristics. Significant intra-group 
differences between the Non-MetSV and MetSL groups were found for waist 
circumference, VO2 peak (p=0.15 between the MetS groups), systolic blood pressure, 
fasting insulin, OGTT insulin level at 30 minutes and HOMA index. Fasting glucose and 
OGTT glucose levels at 2 hours differed between the MetSV and MetSL groups. (Table 
7).  
Twelve (12) participants were originally recruited in the MetSL and in the MetSV groups 
and 15 participants were originally recruited in the Non-MetSV group. These numbers 
were recruited based on an original sample size of 10 per group, to allow for drop outs. 
By week 12, five (5) participants dropped out of the MetSL group (n=7); 3 from the 
MetSV group (n=9) and 6 from the Non-MetSV group (n=9). At week 20, a further 1 
dropped out from the MetSL group (n=6); 4 from the MetSV group (n=5) and 1 from the 
Non-MetSV group (n= 8). The reasons for drop-out were duration of sessions for MetSL 
group were very long (90 minutes); colds and flu; work commitments (4 times/week 
exercise could not be maintained) and birth of a child. There were participants who did 
not have high “readiness to change” level and dropped-out early on in the study. This 
highlights the need to assess psychological aspects and offer support in this area during 
an exercise intervention. This is a limitation of this study. 
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Table 7 Physical and biochemical characteristics of study participants 
Parameter Non-MetS V 
(n=9) 
MetS V 
(n=9) 
MetS L 
(n=7) 
Age (years) 40.2 ± 7.90 40.8 ± 8.21 48.3 ± 7.32 
Body mass (kg)  101 (15.2) 99.8 (29.6) 114 (35.1) 
BMI (kg.m -2 )  31.0 (6.10) 31.8 (4.80) 33.9 (11.1) 
Waist circumference (cm)  104 (13.0) 111 (11.9) 116 (27.2)*
Triglycerides (mmol.L-1)  1.21 (0.45) 1.70 (1.00) 1.28 (0.69) 
Total cholesterol (mmol.L-1)  5.27 ± 1.18 5.48 ± 1.23 5.41 ±1.61 
LDL (mmol.L-1) 3.65 ± 1.19 3.76 ± 0.95 3.65 ± 1.48 
HDL (mmol.L-1)  1.06 (0.20) 0.90 (0.01) 1.00 (0.49) 
Systolic blood pressure 
(mmHg) 
120 ± 11.1 134 ± 14.2 144 ± 8.52** 
Diastolic blood pressure 
(mmHg) 
80.0 ± 6.61 88.3 ± 6.61 89.3 ± 9.32 
Fasting glucose (mmol.L-1) 5.10 (0.40) 4.80 (0.60) 5.90 (0.61)
† 
30 min glucose (mmol.L-1) 7.42 ± 1.64 6.76 ± 2.38 9.16 ± 1.92 
2 hour glucose (mmol.L-1) 6.20 (2.20) 3.80 (2.00) 7.40 (3.30)
† 
Fasting insulin (µU.ml-1) 8.51 ± 1.40 11.1 ± 4.78 14.3 ± 2.82
*
30 min insulin (µU.ml-1) 33.9 (26.4) 73.2 (19.2) 91.3 (38.1)
*
2 hour insulin (µU.ml-1) 31.3 (31.7) 21.9 (24.9) 84.1 (56.1) 
HOMA index  1.97 (0.48) 2.32 (0.97) 3.26 (1.61)*
Insulinogenic index 24.7 ± 19.8 20.8 ± 22.6 28.9 ± 21.9 
VO2 Peak (ml.min-1.kg-1)  33.8 ± 5.14 29.3 ± 7.07 23.5 ± 2.59
*
Velocity at AT (km.h-1) 5.37 ± 0.70 5.27 ± 1.53 5.06 ± 0.65 
Data reported as median (IQR) or mean ± SD  
*p<0.05, **p<0.005 vs Non-MetSV; †p<0.05 vs MetSV. Data from ANOVA with Tukeys post hoc 
test.  
HOMA index = glucose×insulin/22.5.  
Insulinogenic index = (Insulin30 –Insulin0 )/(Glucose30 – Glucose0). 
 
3.5.2 Intra-group comparisons 
Within the Non-MetSV group (Table 8 and 9), body mass did not change significantly at 
any week, with the p- values near significance at weeks 8, 16 and 20 (p= 0.06 - 0.07). 
Waist circumference changed significantly at weeks 16 and 20, yet week 4 had a p-value 
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close to significance (p=0.09).  As opposed to VO2 peak that did not change significantly 
at any week, AT changed significantly at all weeks. The only metabolic parameter in this 
group that got close to a significant change was OGTT glucose level at 2 hours, at week 
12 (p=0.06). 
 
Table 8 Changes in physical and physiological parameters at weeks 4, 8, 12, 16 and 20 for Non-
MetSV group 
Non-MetSV  Comparison of baseline data with weeks 4, 8 and 12 
(n=9) 
Comparison of baseline data with 
weeks 16 and 20 (n=8) 
 Wk0+ Wk4 Wk8 Wk12 Wk0++ Wk16 Wk20 
Body mass (kg) 101 (15.2) 100 (15.3) 97.6 (15.8) 97.0 (15.3) 102 (20.3) 97.6 (16) 98.0 (15.6)
BMI (kg.m -2) 31.0 (6.10) - - 29.3 
(4.70)* 
31.1 (5.80) - 29.9 
(4.30)* 
Waist 
circumference 
(cm) 
104 (13.2) 104 (10.0) 103 (10.5) 103 (8.60) 105 (13.3) 101 (12.0)* 102 (12.7)*
VO2 peak 
(ml.min-1.kg-1) 
33.8 ± 5.10 34.1 ± 4.61 35.6 ± 3.82 36.3 ± 4.21 33.8 ± 5.50 35.9 ± 3.36 37.0 ± 5.32 
Velocity at AT 
(km.h-1) 
5.37 ± 0.74 5.91 ± 
0.69* 
5.95 ± 
0.61* 
6.22 ± 
0.73* 
5.30 ± 0.72 6.22 ± 
0.78* 
6.31 ± 
0.73* 
Systolic Blood 
Pressure 
(mmHg) 
120 ± 11.1 - - 123 ± 10.8 120 ± 11.8 - 120 ± 8.86 
Diastolic Blood 
Pressure 
(mmHg) 
80.0 ± 6.61 - - 79.4 ± 9.50 81.3 ± 5.82 - 78.8 ± 6.41 
* Significant difference at p< 0.05 level 
+ These values used in Dunnett’s tests against week 4, 8 and 12; ++these values used in Dunnett’s tests against weeks 16 
and 20   
Data reported as mean ± SD or median (IQR) 
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Table 9 Changes in metabolic parameters at weeks 12 and 20 for the Non-MetSV group 
 
Non-MetSV Comparison of baseline and week 12 data 
(n=9)
Comparison of baseline and week 20 data 
(n=8) 
 Wk0+ Wk12 Wk0++ Wk20 
Triglycerides 
(mmol.L-1)  
1.21 (0.45) 1.02 (0.37) 1.24 (0.45) 0.94 (0.42) 
Total cholesterol 
(mmol.L-1)  
5.27 ± 1.18 5.25 ± 1.23 5.03 ± 0.09 5.09 ± 1.26 
LDL (mmol.L-1) 3.65 ± 1.19 3.72 ± 1.16 3.42 ± 1.03 3.53 ± 1.36 
HDL (mmol.L-1)  1.06 (0.20) 1.10 (0.20) 1.05 (0.17) 1.20 (0.25) 
Fasting glucose 
(mmol.L-1) 
5.10 (0.40) 5.00 (0.30) 5.15 (0.50) 5.15 (0.15) 
30 min glucose 
(mmol.L-1) 
7.40 ± 1.64 8.07 ± 1.86 7.42 ± 1.76 7.62 ± 1.82 
2 hour glucose 
(mmol.L-1) 
6.20 (2.20) 4.80 (2.20) 5.95 (2.20) 5.20 (1.95) 
Fasting insulin 
(µU.ml-1) 
8.51 ± 1.40 8.01 ± 4.34 8.70 ± 1.37 9.26 ± 5.98 
30 min insulin 
(µU.ml-1) 
33.9 (26.4) 43.0 (39.1) 42.4 (31.8) 59.0 (48.0) 
2 hour insulin 
(µU.ml-1) 
31.3 (31.7) 15.4 (47.0) 31.9 (47.0) 34.3 (47.8) 
HOMA index  1.97 (0.48) 1.65 (0.72) 1.99 (0.57) 1.96 (0.84) 
Insulinogenic index 24.7 ± 19.8 16.7 ± 8.30 26.3 ± 20.5 21.4 ± 110 
+These values used in paired t-tests against week 12  
++These values used in paired t-test against week 20   
Data reported as mean ± SD or median (IQR). No differences were significant 
HOMA index = glucose×insulin/22.5.  
Insulinogenic index = (Insulin30 –Insulin0 )/(Glucose30 – Glucose0). 
 
Results of the MetSV intra-group analysis (Table 10 and Table 11) showed significant 
decreases in body mass at week 4, 16 and 20, with p-values near significance ( 0.07) at 
week 8 and 12. Waist circumference also decreased significantly only at week 4, with p-
values at 0.06 at weeks 8 and 12. VO2 peak and AT changed significantly at all 
measurement points, except for AT at week 4 and 16  (with p-values near significance at 
0.06 for both weeks) and for VO2 peak at week 4 (with p-value near significance at 0.06). 
As opposed to systolic blood pressure, diastolic blood pressure changed significantly at 
weeks 12 and 20. The only metabolic parameters that showed a significant change in this 
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training group were fasting insulin and HOMA index at week 20. Changes in 
triglycerides (at week 20), HDL (at week 12), LDL (at week 20) and OGTT insulin level 
at 30 minutes (at week 20) were marginally not significant (p 0.09). 
 
Table 10 Changes in physical and physiological parameters at weeks 4, 8, 12, 16 and 20 for 
MetSV group. 
MetSV Comparison of baseline data with weeks 4, 8 and 12 
(n=9) 
Comparison of baseline data with 
weeks 16 and 20 (n=5) 
 Wk0+ Wk4 Wk8 Wk12 Wk0++ Wk16 Wk20 
Body mass (kg) 99.8 (29.6) 97.5 
(27.8)* 
96.6 (31.4) 97.0 (32.2) 93.2 (15.6) 90.5 
(16.2)* 
90.0 
(18.2)* 
BMI (kg.m -2) 31.8 (4.80) - - 29.8 
(5.60)* 
29.4 (1.10) - 28.5 
(0.10)* 
Waist 
circumference 
(cm) 
111 (11.9) 110 (14.0)* 107 (10.7) 107 (11.5) 110 (18.6) 107 (14.7) 107 (14.1)
VO2 peak 
(ml.min-1.kg-1)  
29.3 ± 7.10 31.9 ± 6.50 33.9 ± 
6.20* 
36.6 ± 
7.70* 
33.8 ± 5.62 41.3 ± 
6.90* 
44.0 ± 
7.60* 
Velocity at AT 
(km.h-1) 
5.27 ± 1.53 5.60 ± 1.19 6.03 ± 
1.33* 
6.09 ± 
1.34* 
5.94 ± 1.43 6.92 ± 2.02 6.90 ± 
1.64* 
Systolic Blood 
Pressure 
(mmHg) 
134 ± 14.2 - - 128 ± 9.28 132 ± 16.4 - 120 ± 23.5 
Diastolic Blood 
Pressure 
(mmHg) 
88.3 ± 6.61 - - 84.1 ± 
4.70* 
88.1 ± 7.58 - 78.0 ± 
8.37* 
* Significant difference at p< 0.05 level 
+ These values used in Dunnett’s tests against week 4, 8 and 12; ++these values used in Dunnett’s test against weeks 16 
and 20   
Data reported as mean ± SD or median (IQR) 
 
 
The MetSL training group (Table 12 and 13) showed significant changes in body mass at 
weeks 12, 16 and 20 (week 8 had a p-value near significance at 0.06). Waist 
circumference changed significantly at all weeks. VO2 peak changed significantly at only 
weeks16 and 20, with week 12 at a p-value near significance (0.06). AT changed 
significantly at all weeks except at week 4 and 8 with the AT value at week 4 being close 
to significance (p=0.06). Systolic and diastolic blood pressure changed significantly at 
week 12 and week 20. No metabolic parameters changed in this group. Fasting glucose 
(week 12 and 20), fasting insulin and OGTT insulin level at 30 min (at week 12) and 
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HOMA (at week 12) showed p-values that were marginally not significant (p value 
between 0.06 and 0.08). 
 
 
 
 
Table 11 Changes in metabolic parameters at weeks 12 and 20 for the MetSV group 
MetSV Comparison of baseline and week 12 data 
(n=9) 
Comparison of baseline and week 20 data 
(n=5) 
 Wk0+ Wk12 Wk0++ Wk20 
Triglycerides 
(mmol.L-1)  
1.72 (1.02) 1.48 (0.73) 1.32 (1.03) 0.81 (0.35) 
Total cholesterol 
(mmol.L-1)  
5.48 ± 1.23 5.11 ± 1.19 5.79 ± 1.12 4.63 ± 1.04 
LDL (mmol.L-1) 3.76 ± 0.95 3.36 ± 1.05 4.07 ± 0.77 3.19 ± 0.89 
HDL (mmol.L-1)  0.90 (0.01) 1.00 (0.25) 0.90 (0.01) 0.95 (0.01) 
Fasting glucose 
(mmol.L-1) 
4.80 (0.60) 4.70 (0.50) 4.80 (0.60) 4.80 (0.50) 
30 min glucose 
(mmol.L-1) 
6.76 ± 2.38 7.42 ± 1.64 6.83 ± 1.28 9.16 ± 1.92 
2 hour glucose 
(mmol.L-1) 
3.80 (2.00) 4.60 (0.70) 3.70 (0.50) 4.50 (2.60) 
Fasting insulin 
(µU.ml-1) 
11.1 ± 4.78 9.23 ± 3.56 10.27 ± 1.48 7.04 ± 2.56* 
30 min insulin 
(µU.ml-1) 
73.2 (19.2) 40.8 (71.0) 74.0 (34.9) 46.9 (21.6) 
2 hour insulin 
(µU.ml-1) 
21.9 (24.9) 40.4 (50.4) 17.7 (7.40) 15.2 (11.1) 
HOMA index  2.32 (0.97) 1.53 (1.36) 2.09 (0.48) 1.53 (0.26)* 
Insulinogenic index 20.8 ± 22.6 13.5 ± 36.2 33.8 ± 13.9 8.54 ± 47.7 
* Significant difference at p< 0.05 level 
+ These values used in paired t-tests against week 12  
++These values used in paired t-test against week 20   
Data reported as mean ± SD or median (IQR) 
HOMA index = glucose×insulin/22.5.  
Insulinogenic index = (Insulin30 –Insulin0 )/(Glucose30 – Glucose0). 
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Table 12 Changes in physical and physiological parameters at weeks 4, 8, 12, 16 and 20 for 
MetSL group 
MetSL Comparison of baseline data with weeks 4, 8 and 12 
(n=7) 
Comparison of baseline data with 
weeks 16 and 20 (n=6) 
 Wk0+ Wk4 Wk8 Wk12 Wk0++ Wk16 Wk20 
Body mass (kg) 114 (35.1) 111 (30.7) 112 (32.5) 110 (34.2)* 112 (35.1) 105 (35.8)* 104 (34.8)*
BMI (kg.m -2) 33.9 (11.1) - - 32.0 
(11.1)* 
35.9 (11.1) - 33.5 
(11.4)* 
Waist 
circumference 
(cm) 
116 (27.2) 115 (26.1)* 114 (25.3)* 113 (27.5)* 121 (27.2) 115 (28.1)* 114 (27.0)*
VO2 peak 
(ml.min-1.kg-1) 
23.5 ± 2.61 26.8 ± 5.75 27.7 ± 4.62 29.2 ± 5.34 22.8 ± 2.17 29.6 ± 
4.25* 
30.8 ± 
4.90* 
Velocity at AT 
(km.h-1) 
5.06 ± 0.65 5.36 ± 0.79 5.67 ± 0.64 5.93 ± 
0.91* 
4.91 ± 0.56 5.87 ± 
0.53* 
5.89 ± 
0.75* 
Systolic Blood 
Pressure 
(mmHg) 
143 ± 8.52 - - 130 ± 10.6* 144 ± 9.17 - 127 ± 13.3*
Diastolic Blood 
Pressure 
(mmHg) 
89.3 ± 9.32 - - 80.7 ± 
9.76* 
89.2 ± 10.2 - 77.5 ± 
7.58* 
* Significant difference at p< 0.05 level 
+ These values used in Dunnett’s tests against week 4, 8 and 12; ++these values used in Dunnett’s tests against weeks 16 
and 20   
Data reported as mean ± SD or median (IQR) 
 
Table 13 Changes in metabolic parameters at weeks 12 and 20 for the MetSL group 
 
MetSL Comparison of baseline and week 12 data 
(n=7) 
Comparison of baseline and week 20 data 
(n=6) 
 Wk0+ Wk12 Wk0++ Wk20 
Triglycerides 
(mmol.L-1)  
1.28 (0.69) 1.20 (0.58) 1.25 (0.32) 1.14 (0.6) 
Total cholesterol 
(mmol.L-1)  
5.41 ± 1.61 5.09 ± 1.14 5.18 ± 1.64 4.84 ± 1.16 
LDL (mmol.L-1) 3.65 ± 1.48 3.38 ± 1.04 3.45 ± 1.52 3.08 ± 0.94 
HDL (mmol.L-1)  1.00 (0.49) 1.01 (0.55) 1.10 (0.49) 1.13 (0.60) 
Fasting glucose 
(mmol.L-1) 
5.90 (0.60) 5.00 (1.00) 5.90 (0.50) 5.00 (1.40) 
30 min glucose 
(mmol.L-1) 
9.16 ± 1.92 8.39 ± 1.99 9.47 ± 1.97 8.89 ± 1.53 
2 hour glucose 
(mmol.L-1) 
7.40 (3.90) 5.25 (3.70) 7.40 (3.60) 6.30 (1.20) 
Fasting insulin 
(µU.ml-1) 
14.3 ± 2.82 10.3 ± 4.12 14.7 ± 2.93 11.4 ± 5.29 
30 min insulin 
(µU.ml-1) 
91.3 (38.1) 60.7 (15.2) 95.4 (8.40) 99.0 (16.4) 
2 hour insulin 
(µU.ml-1) 
84.1 (56.1) 35.6 (46.8) 81.9 (49.8) 69.5 (55.4) 
HOMA index  3.26 (1.61) 2.29 (0.82) 3.82 (1.61) 2.04 (0.89) 
Insulinogenic index 28.9 ± 21.9 33.6 ± 42.4 30.8 ± 24.1 28.7 ± 17.7 
+These values used in paired t-tests against week 12  
++These values used in paired t-test against week 20   
Data reported as mean ± SD or median (IQR). No differences were significant. 
HOMA index = glucose×insulin/22.5. Insulinogenic index = (Insulin30 –Insulin0 )/(Glucose30 – Glucose0). 
 116
 
 
 
 
3.5.3 Absolute changes in body mass 
Table 14 Absolute changes in body mass (kg) (Mean ± SD) compared to week 0 
Group Week 12 Week 20 
Non-MetSV -3.10 ± 3.60 -3.26 ±3.82 
MetSV -2.18 ±3.06 -4.12 ±1.83 
MetSL -8.79 ±6.57 -1.05 ±6.81 
 
The MetSL group showed the greatest absolute change in body mass (Table 14). 
ANOVA analysis did not find any significant differences between the 3 groups in 
absolute changes in body mass at week 12 or at week 20 (F=3.22, p=0.06 at week 12; 
F=2.18, p=0.15 at week 20). 
 
3.5.4 Inter-group comparison of the % change in variables from week 0 to week 12. 
Analysis of the comparison of the % change in variables from week 0 to week 12 across 
the 3 study groups is depicted in Table 15. This data compares ANOVA results with the 
respective ANCOVA, after adjustment for % change in body mass. The % change in 
body mass across the groups just missed significance (p=0.07, Table 15) however it was 
still included in the ANCOVA as a precautionary measure. It was found to not 
substantially affect any of the ANOVA results (see Table 15). Table 16 shows the results 
of the post hoc analysis of the ANCOVA data.  
The MetSL group showed the greatest decrease in systolic blood pressure (8.8%) (Table 
16). Although systolic blood pressure also decreased in the MetSV group, the % change 
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was only significantly different between the Non-MetSV and MetSL groups (Table 16). 
The only other significant change during this period was the % change in OGTT glucose 
level at 2 hours (Table 16). This value increased in the MetSV group and was 
significantly different to the decrease that occurred in the Non-MetSV and the MetSL 
groups. Body mass decreased in all groups during this period (2% in the MetSV group, 
3.1% in the Non-MetSV group and 6.8% in the MetSL group), however the post hoc 
analysis showed no significant differences between the groups (Table16). 
 
Table 15 ANOVA and ANCOVA results for comparison of percent change in data from week 0 
to week 12 across the three subject groups. 
 
Variables Results of ANOVA Results of ANCOVA  
(adjusted for body mass) 
Body mass (kg) 2.80 (0.07)  
BMI (kg.m-2) 2.43 (0.11)  
Waist circumference (cm) 2.02 (0.16)  
Triglycerides (mmol.L-1) 0.06 (0.94) 0.04 (0.96) 
Total Cholesterol (mmol.L-1) 0.20 (0.82) 0.28 (0.76) 
LDL (mmol.L-1) 0.84 (0.44) 0.82 (0.46) 
HDL (mmol.L-1) 1.38 (0.28) 1.20 (0.32) 
Systolic Blood Pressure 
(mmHg) 
5.66 (0.01) 4.28 (0.01) 
Diastolic Blood Pressure 
(mmHg) 
1.78 (0.19) 1.85 (0.18) 
Fasting glucose (mmol.L-1) 2.30 (0.13) 2.16 (0.14) 
30 min glucose (mmol.L-1) 0.72 (0.50) 0.69 (0.51) 
2 hour glucose (mmol.L-1) 7.07 (0.01) 6.93 (0.02) 
Fasting insulin (ȝU.ml-1) 0.78 (0.47) 0.72 (0.5) 
30 min insulin (ȝU.ml-1)  0.6 (0.56) 0.8 (0.46) 
2 hour insulin (ȝU.ml-1) 2.58 (0.10) 2.56 (0.10) 
HOMA index 0.5 (0.61) 0.41 (0.67) 
Insulinogenic index 0.39 (0.68) 0.37 (0.70) 
VO2 Peak (ml.min-1.kg-1) 1.97 (0.17) 2.18 (0.14) 
Velocity at AT (km.h-1) 0.24 (0.79) 0.20 (0.82) 
Data is given as F-value (p-value); figures in bold are those showing significant trends. See Table 
16 for results of post hoc analysis of ANCOVAs 
HOMA index = glucose×insulin/22.5.  
Insulinogenic index = (Insulin30 –Insulin0 )/(Glucose30 – Glucose0). 
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Table 16 Comparison of Week 0 vs Week 12 percent change data across the three subject groups 
 
Variables Non-MetS V  
(n=9) 
MetS V 
(n=9) 
MetS L 
(n=7) 
Body mass -3.05 (-5.14) -2.0 (-2.52) -6.79 (-10.4) 
BMI  -2.60 (-6.09) -2.05 (-2.38) -6.93 (-10.6) 
Waist circumference  -2.15 ± 2.64 -2.11 ± 2.87 -4.57 ± 2.64 
Triglycerides  -13.1 ± 30.9 -8.37 ± 39.9 -7.49 ± 32.6 
Total Cholesterol  0.08 ± 13.7 -4.92 ± 18.7 -2.96 ± 17.7 
LDL  3.87 ± 18.3 -8.98 ± 20.7 1.76 ± 24.6 
HDL  -3.85 (-7.69) 14.6 (6.74) 0 (-4.17) 
Systolic Blood 
Pressure  
2.97 ± 6.75 -3.69 ± 6.37 -8.76 ± 8.06* 
Diastolic Blood 
Pressure  
-0.31 ± 12.8 -4.56 ± 5.0 -9.32 ± 8.84 
Fasting glucose  -3.85 (-5.56) -2.08 (-6.52) -7.41 (-18.6) 
30 min glucose  6.17 (2.70) -5.80 (-24.6) -12.4 (-23.2) 
2 hour glucose  -12.9 ± 16.7 16.9 ± 23.6* -22.7 ± 25.8** 
Fasting insulin  -7.04 (-29.1) -25.2 (-37.6) -30.1 (-43.6) 
30 min insulin  -3.83 (-49.8) -44 (-55.1) -28.7 (-36.4) 
2 hour insulin  -23.5 (-41.7) 98.6 (16.7) -53.6 (-76.4) 
HOMA index -13.2 (-30.7) -20.7 (-34.9) -30.1 (-51.7) 
Insulinogenic index -21.2 (-62.7) -38.6 (-148) -17.6 (-38.3) 
VO2 Peak  11.1 (6.67) 18.8 (10.3) 15.5 (11.9) 
Velocity at AT  22.2 (15.8) 10.4 (8.33) 17.4 (11.2) 
Data reported as % change and as mean ± SD or median (IQR):*p<0.05 vs Non-MetS V; 
**p<0.005 vs MetS V; data from ANCOVA with adjustment for % change in body mass. 
HOMA index = glucose×insulin/22.5.  
Insulinogenic index = (Insulin30 –Insulin0 )/(Glucose30 – Glucose0). 
 
3.5.5 Inter-group comparison of the % change in variables from week 0 to week 20. 
ANOVA and ANCOVA results for the comparison of the % change in variables between 
week 0 and week 20 is depicted in Table 18. Both body mass and BMI showed 
significant trends across the groups and therefore body mass was adjusted for in the 
ANCOVAs (Table 17). Adjustment for BMI showed very similar effects (data not 
shown). Adjusting for % body mass changes had minimal effects on any of the ANOVA 
data (Table 17). 
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Table 18 shows the results of the post hoc analysis of the ANCOVA for the week 0 to 
week 20 % change data. Body mass decreased in all groups with the highest decrease 
occurring in the MetSL group (8.7%) and this group was the only group that changed 
significantly when compared to the Non-MetSV group (Table 18). Similar results were 
observed for the % change in BMI and the same trend was also shown for systolic and 
diastolic blood pressures, with a significant difference in % change across the Non-
MetSV and MetSL groups. The greatest change in systolic and diastolic blood pressure 
occurred in the MetSL group (11.9% and 12.6% respectively) (Table18). VO2 peak 
increased by 35.3% in the MetSL group; 30.5% in the MetSV group and by 10.7% in the 
Non-MetSV group. The change was only significant across the Non-MetSV and MetSL 
groups (Table 18). Percentage change in OGTT insulin level at 30 minutes decreased 
only in the MetSV group and the % change was near significance across the Non-MetSV 
and MetSL groups (p=0.07) (Table 18).  
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Table 17 ANOVA and ANCOVA results for comparison of the percent change in data from week 
0 to week 20 across the three subject groups 
 
Variables Results of ANOVA Results of ANCOVA 
(adjusted for body mass) 
Body mass (kg) 3.88 (0.04)  
BMI (kg.m-2) 3.88 (0.04)  
Waist circumference (cm) 1.87 (0.19)  
Triglycerides (mmol.L-1) 1.27 (0.31) 1.14 (0.35) 
Total Cholesterol (mmol.L-1) 2.01 (0.17) 1.95 (0.18) 
LDL (mmol.L-1) 1.63 (0.23) 1.63 (0.23) 
HDL (mmol.L-1) 1.15 (0.34) 0.92 (0.42) 
Systolic Blood Pressure 
(mmHg) 
3.59 (0.05) 5.20 (0.04) 
Diastolic Blood Pressure 
(mmHg) 
3.96 (0.04) 6.45 (0.03) 
Fasting glucose (mmol.L-1) 1.38 (0.29) 0.86 (0.45) 
30 min glucose (mmol.L-1) 0.42 (0.67) 0.47 (0.64) 
2 hour glucose (mmol.L-1) 0.83 (0.46) 0.64 (0.54) 
Fasting insulin (ȝU.ml-1) 0.18 (0.84) 0.22 (0.81) 
30 min insulin (ȝU.ml-1)  3.14 (0.07) 3.12 (0.08) 
2 hour insulin (ȝU.ml-1) 0.12 (0.89) 0.11 (0.90) 
HOMA index 0.01 (0.99) 0.02 (0.98) 
Insulinogenic index 0.13 (0.88) 0.18 (0.84) 
VO2 Peak (ml.min-1.kg-1) 4.85 (0.03) 3.95 (0.02) 
Velocity at AT (km.h-1) 0.31 (0.74) 0.61 (0.56) 
Data is given as F-value (p-value); figures in bold are those showing significant trends. See Table 
18 for results of post hoc analysis of ANCOVAs 
HOMA index = glucose×insulin/22.5.  
Insulinogenic index = (Insulin30 –Insulin0 )/(Glucose30 – Glucose0). 
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Table 18 Comparison of Week 0 vs Week 20 percent change data across the three subject groups 
Variables Non-MetS V  
(n=8) 
MetS V 
(n=5) 
MetS L 
(n=6) 
Body mass -3.40 ± 3.61 -4.26 ± 1.36 -8.66 ± 4.99* 
BMI  -3.39 ± 3.42 -4.23 ± 1.36 -8.67 ± 4.97* 
Waist circumference  -3.42 ± 2.45 -3.86 ± 3.05 -6.21 ± 2.94 
Triglycerides  -11.5 ± 33.7 -35.7 ± 35.1 -8.68 ± 21.1 
Total Cholesterol  1.51 ± 16.3 -18.3 ± 19.7 -4.02 ± 16.9 
LDL  3.82 ± 27.3 -20.7 ± 20.4 -5.12 ± 20.9 
HDL  6.16 ± 14.9 16.4 ± 17.7 3.87 ± 10.5 
Systolic Blood 
Pressure  
-0.12 ± 6.85 -9.36 ± 10.1 -11.9 ± 9.79* 
Diastolic Blood 
Pressure  
-3.03 ± 4.66 -11.2 ± 8.92 -12.6 ± 7.58* 
Fasting glucose  1.92 (-0.46) 4.35 (1.92) -11.4 (-17.2) 
30 min glucose  5.48 ± 27.6 -5.17 ± 25.6 -4.97 ± 15.1 
2 hour glucose  -7.79 (-22.1) 21.6 (0) -14.9 (-45.9) 
Fasting insulin  -18.5 (-30.7) -35.3 (-43.8) -33.3 (-39.8) 
30 min insulin  20.4 (-40.8) -31.4 (-42.5) 2.94 (-2.76) 
2 hour insulin  -1.79 ± 47.6 16.6 ± 77.9 8.09 ± 84.9 
HOMA index -18.7 (-31.6) -32.6 (-35.7) -37.7 (-47.5) 
Insulinogenic index -25.8 (-50.8) -39.9 (-125) 44.7 (16.3) 
VO2 Peak  10.7 ± 13.5 30.5 ± 12.8 35.3 ± 18.7* 
Velocity at AT  19.6 ± 7.79 16.1 ± 8.05 20.3 ± 11.8 
Data reported as a % and as mean ± SD or median (IQR): *p<0.05 vs Non-MetS V 
HOMA index = glucose×insulin/22.5.  
Insulinogenic index = (Insulin30 –Insulin0 )/(Glucose30 – Glucose0). 
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3.5.6 Determinants of the percent change in VO2 peak and Velocity at AT 
 
Table 19 Determinants of the % change in VO2 peak and Velocity at AT 
Regression 
model number 
Dependent 
variable 
Independent variables with 
standardised beta coefficient and (p-
value) 
R2 for full 
model with 
(p-value) 
1 % change in VO2 
peak (log) 
Age: -0.03 (0.0004) 
Baseline VO2 peak: -0.03 (0.004) 
% change in WC: -0.04 (0.05) 
% change in insulin (log): -0.15 (0.01) 
0.80 (<0.002) 
2 % change in 
Velocity at AT 
(log) 
Baseline velocity at AT: -0.14 (0.004) 0.56  
(<0.004) 
WC= Waist Circumference 
(Data of week 0 and week 12 were used for the regression model) 
 
Pearson correlation analysis demonstrated that the % change in VO2 peak correlated with 
the following variables: age, baseline VO2 peak, % change in waist circumference, % 
change in systolic and diastolic blood pressure and % change in fasting insulin and 
OGTT 2 - hour glucose level.  Percentage change in velocity at AT correlated only with 
baseline VO2 , baseline velocity at AT and % change in fasting glucose. These variables, 
as well as coding variables for the training groups with metabolic syndrome, were then 
included as independent variables in two separate backward, stepwise regression models 
in which % change in VO2 peak and % change in velocity at AT were the dependent 
variables. In the first regression model age, baseline VO2 peak, % change in waist 
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circumference and % change in fasting insulin levels were found to correlate with the % 
change in VO2 peak (see Table 19). In the second regression model, baseline velocity at 
AT was found to correlate with the % change in velocity at AT (see Table 19).  
 
3.5.7 Exercise energy expenditure 
Table 20 Weekly exercise energy expenditure over 12 weeks (Mean ± SD) 
 
 Non-MetS V MetS V  MetS L 
Average weekly 
expenditure (kcal/wk) 
1110 ± 280* 1238 ± 173* 3994 ± 1089 
*p <0.005 vs MetS L 
(To convert to joules, multiply by 4.184) 
 
 
Table 21 Energy expenditure per kilogram body mass-loss over 12 weeks (Median (IQR)) 
 
 Non-MetS V MetS V MetS L 
Energy expenditure 
(kcal/kg.body mass-
loss) 
286 (166) 399 (251) 358 (292) 
(To convert to joules, multiply by 4.184) 
 
Table 20 reports the weekly exercise energy expenditure of each group. The MetSL 
group expended a greater amount of energy via their exercise program when compared to 
the MetSL and Non-MetSL groups (who were on the same training program). The MetSL 
expended 36.6 kcal/kg.wk-1 and 399 kcal/kg body mass - loss. The MetSV and Non-
MetSV groups expended 19 kcal/kg.wk-1; 399 kcal/kg body mass - loss and 21 
kcal/kg.wk-1; 286 kcal/kg body mass - loss respectively (Table 21). ANOVA analysis did 
not show any significant differences in energy expenditure per kilogram body mass - loss 
between the groups (F=0.49; p=0.62). 
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3.5.8 Nutritional intake 
Table 22 Nutritional intake (kcal) for all groups during the training period 
 
Week 
number 
MetSV 
(n=5) 
Non-
MetSV 
(n=6) 
MetS L 
(n=6) 
Week 0 1826 ± 574 2046 ± 845 1515 ± 362 
Week 8 1642 ± 622 1633 ± 835 1393 ± 341 
Week 20 1688 ± 969 1858 ± 845 1665 ± 456 
 
Data given as mean ± SEM 
(To convert to joules, multiply by 4.184)  
 
An ANOVA showed no significant differences in nutritional intake or the components of 
nutritional intake within each group, across all the weeks. Also, nutritional intake (kcal) 
did not differ across the 3 groups at each week (ANOVA; Table 22).   
3.5.9 Incidence of metabolic syndrome 
 
 
 
Fig 3 Change in components of metabolic syndrome and incidence of metabolic syndrome in the 
MetSV group. 
WC= Waist circumference; TG= plasma triglycerides; HDL-C= plasma high-density lipoproteins; 
BP= Blood pressure. High and low values are based on the diagnosis criteria of MetS. 
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Both metabolic syndrome training groups showed a significant reduction in the incidence 
of the syndrome after the training period (p value for chi-squared < 0.05) (Fig 3 and 4). A 
smaller percent of individuals were still diagnosed with MetS after the training period in 
the MetSV group (1 out of 9; 11.1%), as opposed to the MetSL group (3 out of 7; 42.9%). 
 
 
 
 
Fig 4 Change in components of metabolic syndrome and incidence of metabolic syndrome in the 
MetS L group. 
WC= Waist circumference; TG= plasma triglycerides; HDL-C= plasma high-density lipoproteins; 
BP= Blood pressure. High and low values are based on the diagnosis criteria of MetS. 
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3.6 Discussion 
Body mass decreased significantly in the MetS training groups. BMI and waist 
circumference decreased significantly in all training groups with the training program 
using AT and the one using the method of Leon et al. (1979) showing similar outcomes 
in these variables among persons with MetS. Velocity at AT also improved in all training 
groups yet VO2 peak did not change significantly in the group without MetS. Similarly, 
the blood pressure training response was favourable in the groups with MetS yet absent in 
the group without MetS. The training group with MetS that used AT was the only group 
to show significant, positive changes in metabolic parameters i.e. fasting insulin and 
HOMA, as shown in Table 11. In addition, the training programs had a significant 
influence on the incidence of MetS  
 
This study aimed to compare outcomes of our training program based on AT 
determination (MetSV) to the outcomes of a training program proven in the literature. 
The Leon et al. (1979) training program was chosen for the following reasons: 
x The training program changed in a progressive manner during the training period. 
Our training program was also based on a periodised model. 
x It achieved impressive outcomes with respect to the metabolic syndrome 
components that our study was measuring. 
x The study measured the same variables that our study was investigating. This 
allowed for effective comparison of the two types of training programs. 
x The mode of exercise was the same as our training program. 
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x The training program was very reproducible and easy to implement in our subject 
groups i.e only treadmill velocity and gradient determined intensity (not % of 
maximal calculations). Our training intensity also used treadmill velocity and 
gradient. 
 
This study set our control group as the Non-MetSV group, because our study wanted to 
investigate the exercise responses of individuals with MetS (MetSV group) to those of 
individuals without MetS (Non-MetSV) and of two different exercise programs (MetSV 
vs MetSL). Our focus was not to compare the outcomes of non-exercisers with MetS to 
exercisers with MetS. 
 
Two of the statistically significant differences observed between the MetSL groups and 
the control group in this study are reflective of the definition used to classify MetS (waist 
circumference and systolic blood pressure) (Table 7). The other differences (VO2 peak, 
fasting insulin, OGTT insulin level at 30 minutes and HOMA index) support the findings 
that VO2 peak is lower in persons with MetS (Lakka et al. 2003) and that insulin 
resistance is a major component of MetS (De Fronzo et al. 1991; Eckel et al. 2005), 
respectively. The baseline characteristics of the MetSV group were not significantly 
different to the Non-MetSV group. This could be due to the low sample number, since all 
the diagnostic parameters for MetS were higher in the MetSV group compared to the 
Non-MetSV group, yet did not reach statistical significance. 
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Both training programs used in this study showed favourable training responses. BMI and 
waist circumference decreased significantly in all training groups. Body mass decreased 
significantly only in the groups with MetS (Tables 8, 10 and 12). The decreases in all 
these parameters however, were not significantly different across the three groups at 
week 12 (Tables 15 and 16), but at week 20 the MetSL group decreased their body mass 
and BMI significantly more than that of the Non-MetSV group (Tables 17 and 18). There 
was no significant difference in the change of body mass, BMI and waist circumference 
across the two different training groups (MetSV and MetSL) at weeks 12 and week 20 
(Table 16 and 18). This indicates that the training program utilizing AT had a similar 
effect on these variables with persons with MetS as the training program of Leon et al. 
(1979). When compared though, to a Non-MetS group the Leon et al. (1979) walking 
program seems superior in the outcomes of body mass and BMI.  
  
The importance of decreasing body mass, BMI and waist circumference in persons with 
metabolic disease has been highlighted (Carroll et al. 2004; Haffner et al. 2003; Lemieux 
et al. 2000). There is contradictory evidence whether exercise alone causes changes in 
body mass in persons with MetS. Some studies have found no changes (Katzel et al. 
1997; Lavrencic et al. 2000; Smutok et al. 1993) while others have shown decreases in 
body mass (Dengel et al. 1998; Kraus et al. 2002, Wing et al. 1998). Differences in the 
exercise program frequency and intensity used by these studies may contribute to these 
contradictory results. The STTRIDE studies aimed to address this issue and investigated 
the effect of different exercise amounts and intensities in sedentary, obese, dyslipidaemic 
participants (Slentz et al. 2005; Slentz et al. 2007). These studies showed that body mass 
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and visceral fat responded in a dose-dependent manner. The greater the amount of 
exercise the greater the decrease in these parameters. The present study also found a 
dose-response with respect to body mass - loss. At 19 kcal.kg-1.wk-1 and  
36 kcal.kg-1.wk-1 energy expenditure for the MetSV and MetSL groups respectively, the 
body mass - loss was 4.3% and 8.7% respectively at week 20 (Table 18). The absolute 
body mass - loss that occurred in the groups with metabolic syndrome after the training 
programs used in this study (2.1 – 10 kg) (Table 14) was greater than that reported in the 
review of Carroll et al. (2004) (1.5 – 1.9 kg). 
 
The measures of VO2 peak and AT were used as measures of cardio-respiratory fitness. 
AT improved significantly in all training groups (Table 8, 10 and 12). VO2 peak though, 
improved significantly only in the MetS groups and did not change significantly in the 
group without MetS (Table 9). Studies by Weltman et al. (1992) and Weltman (1995) 
have demonstrated that it is possible for AT to improve without VO2 peak changing. 
Furthermore, many studies have also reported that the workload and VO2 associated with 
AT improve to a greater degree with training than does VO2 max (Denis et al. 1982; 
Hurley et al. 1984; Sjodin et al. 1982; Yoshida et al. 1982). In addition, the VO2 peak 
response in this study indicates a difference in cardio-vascular responses to this training 
program between persons with MetS and those without MetS. The central training 
adaptations were more evident in the MetS groups than in the Non-MetS groups. 
 
The only significant difference in the change of VO2 peak and AT across the three groups 
was in VO2 peak at week 20 and specifically between the Non-MetSV and MetSL groups 
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(Table 16 and 18). Similar to the response of body mass, BMI and waist circumference 
there was no significant difference in the changes that occurred in VO2 peak and AT 
between the MetSV and MetSL groups (Table 16 and 18). This indicates that the training 
program utilizing AT was as effective in improving the cardio-respiratory fitness of 
persons with MetS as the training program of Leon et al. (1979). The training program 
using AT though achieved this improvement at a third of the exercise energy expenditure 
of the training program not using AT (Table 20). 
 
The improvement in VO2 peak with MetS persons after an exercise program has also 
been shown by other studies that ranged from a 9-19% increase in this variable (Dengel 
et al. 1998; Juneau et al. 1987; Katzel et al. 1997; Katzmarzyk et al. 2003; Smutok et al. 
1993). The present study showed an increase in VO2 peak of 19% (week 12) and 31% 
(week 20) in the group using the training program by AT and 16% (week 12) and 35% 
(week 20) in the group using the Leon et al. (1997) program (Tables 16 and 18). These 
changes in VO2 peak were consistent and greater in week 20 than the range (1-25%) 
reported by the review of Carroll et al. (2004). 
 
To our knowledge there are no studies that have shown the response of AT to a training 
program in persons with MetS. These data show a favourable response indicative of an 
increase in cardio-respiratory fitness. The training program using AT and the Leon et al. 
program elicited similar improvements in this parameter. There was no significant 
difference in the improvement in velocity at AT across the three groups (Table 16 and 
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18). This suggests that persons with MetS and persons without MetS have a similar blood 
lactate response to endurance exercise.  
 
Endurance training has been shown to reduce blood lactate concentrations at any given 
VO2 (MacRae et al. 1992; Stanley et al. 1985). These researchers suggested that training 
results in a diminished blood lactate response during exercise by decreasing the rate of 
lactate production or increasing the rate of lactate clearance or both. The decrease in 
blood lactate production may be related to the reduced carbohydrate utilization during 
exercise after endurance training (Saltin et al. 1976). It has also been suggested that a 
training intensity that approximates AT is optimal in eliciting the local training adaptation 
changes in muscle metabolism (Kindermann, 1979; Sjodin et al. 1982; Tanaka et al. 
1986).  
The research of Weltman et al. (1992) showed that the increase in physical activity 
associated with the onset of endurance training is sufficient to elicit a training effect 
provided the initial training intensity is at or above LT (55% to 81% of VO2 max). The 
current study did not find that training at AT improved the velocity at AT to a greater 
degree than training without using AT to set intensity in persons with MetS (Table 16 and 
18). Furthermore, there was no difference in the response to exercise between MetS and 
Non-MetS individuals with respect to AT.   
 
The regression analyses (Table 19) suggest that the improvement in VO2 peak was 
associated with age, baseline VO2 peak, the decrease in waist circumference and the 
decrease in fasting insulin levels that occurred as adaptations to the training programs. 
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The improvement in velocity at AT with training is associated with baseline BLTT levels 
only. These analyses support data from the previous chapter that demonstrated the 
influence of waist circumference on VO2 peak. Furthermore, waist circumference is a 
proxy indicator of visceral fat mass (Pouliot et al. 1994) and this body fat depot is a 
negative regulator of whole body insulin sensitivity (Ross, 2002). This may also explain 
the association of the change in fasting insulin with the change in VO2 peak. It may be 
argued that expressing and analysing VO2 peak as ml.min-1kg-1 may have polluted the 
regeression analysis because if mass and waist girth are highly correlated, then waist girth 
and V02 peak  (in ml.min-1kg-1) will be highly correlated. However if that was true, mass 
would have come through in the final regeression analysis. This did not occur. 
 
Systolic and diastolic blood pressure decreased significantly in the MetSL group (Table 
13). This change was significantly different between the MetSL and Non-MetSV groups 
at week 20 (Tables 17 and 18). At week 12, only the change in systolic blood pressure 
was significantly different across these groups (Tables 15 and 16). In addition, only 
diastolic blood pressure decreased significantly in the MetSV group (Table 10). The 
changes that occurred with blood pressure variables were not significantly different 
across the two groups with MetS (Tables 16 and 18). There was no change in blood 
pressures within the Non-MetSV group (Table 8). This may once more allude to 
differences in adaptations to endurance training in persons with MetS as opposed to those 
without MetS. This may be due to the fact that the latter group had normal baseline blood 
pressures. The training groups with MetS had elevated blood pressure values (Table 7). 
Studies by Dengel et al. (1998), Katzmarzyk et al. (2003) and the review by Carroll et al. 
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(2004) have also reported the beneficial effect of exercise on blood pressure. In contrast, 
some studies have shown no changes in blood pressure after exercise intervention (Katzel 
et al. 1997; Smutok et al. 1993; Watkins et al. 2003). All these studies involved 
participants that had components of the MetS. 
 
The MetSV group showed significant intra-group changes in metabolic parameters. 
Fasting insulin and the HOMA index fell at week 20 (Table 11). Thus, insulin sensitivity 
may have been positively influenced by the training program using AT to set intensity. 
No such improvements were noted in the Non-MetSV group, but fasting insulin and 
HOMA levels did fall in the MetSL group to a magnitude similar to that seen in the 
MetSV group, however these falls were not statistically significant. The insulinogenic 
index was not affected by the training program using AT. More specific tests and a 
greater number of participants would be needed to confirm this result.  It is speculated 
that exercise training at the AT may improve insulin sensitivity due to increases in Glut-4 
transports related to an increase in the demand for glucose when training at the AT. This 
speculation is based on the finding that exercise has been shown to increase the Glut-4 
isoform of the glucose transporter which in turn results in a more rapid glucose uptake 
(Holloszy, 2008). This speculation will need to be addressed with further research. 
 
Research in this area has been contradictory with some studies showing improved 
glucose tolerance and reduced insulin responses to oral glucose as training adaptations 
(Dengel et al. 1998; Kraus et al. 2002; McAuley et al. 2002; Ross et al. 2000; Smutok et 
al. 1993; Watkins et al. 2003), and other studies finding no change in this parameter 
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(Katzel et al. 1997; Potteiger et al. 2002; Stefanick et al. 1998). The current study showed 
that at week 12, the 2 hour glucose levels decreased relative to baseline in the MetSL 
group but increased in the MetSV group, and both these changes were significantly 
different to those observed in the Non-MetSV group, where glucose levels fell (Table 
16). These differences were not significant at week 20 (Table 18). These results may have 
also been influenced by the very low fasting glucose levels at baseline of the MetSV 
group (Table 7). 
 
This study’s training programs did not affect any lipoprotein levels (Table 9, 11 and 13). 
The studies of Smutok et al. (1993); Katzel et al. (1997) and Watkins et al. (2003) are in 
agreement with this finding. Yet, some researchers have shown improvements in 
lipoprotein levels after exercise intervention (Dengel et al. 1998; Katzmarzyk et al. 2003; 
Kraus et al. 2002). A longer training period with attention to body mass - loss via dietary 
interventions in this study may have elicited improved lipoprotein profiles. This was 
highlighted by the research of Katzel et al. (1997) and Anderssen et al. (1998). The lack 
of change in lipoprotein levels may also be due to the relatively normal values in all three 
groups at baseline. However, it should be noted that at week 20, (Table 18) the 
percentage change in each of the 4 different lipid types was higher in the MetSV group 
than either of the other 2 groups, although these differences were not statistically 
significant.  
 
This study used the Leon et al. (1979) exercise program and applied it to a group with 
MetS (MetSL group). The Leon et al. (1979) study used a 16-week walking program to 
 135
train obese men aged 19 – 31 years (without MetS). These researchers showed that the 
walking program reduced body mass (4.9 – 6kg); increased the HDL/ LDL ratio; reduced 
fasting blood glucose; reduced the ratio of plasma insulin / glucose concentrations. Thus 
exercising 5 times per week, 7.5h/wk, at an intensity eliciting 1100 kcal/session 
(4602J/session), suggested a reversal of metabolic disease. A limitation of the Leon et al. 
study is that no control group was investigated. The effect of this exercise program on a 
group with MetS elicited similar results in body mass - loss (Table 12) yet not in any 
metabolic parameters (Table 13). Thus, the metabolic response to the training program 
was different to that elicited in a younger group of obese men without MetS. The 
difference may be in the lower caloric expenditure per exercise session (1100 vs 799 
kcal; 4602 vs 3343 J) of this study’s metabolic group.  
 
Carroll et al. (2004), in their review of metabolic abnormalities and exercise, concluded 
that there is now more evidence that long-term exercise, without body mass reduction, 
modestly decreases abdominal adipose tissue and improves insulin action among 
overweight/obese adults. In addition, exercise alone is effective in improving impaired 
glucose control and reducing the incidence of type 2 diabetes in both sexes. Furthermore, 
exercise alone was associated with modest but clinically relevant lipoprotein profile 
improvements in raising HDL-C and lowering triglycerides. More often than not, though, 
exercise did not alter total cholesterol or LDL-C concentrations. The review also found 
that exercise alone modestly reduces blood pressure with greatest changes evident in 
overweight individuals with hypertension. The majority of the randomised controlled 
studies that Carroll et al. (2004) analysed have suggested aerobic endurance activity, 3-5 
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days/wk, 30-60 minutes per session at moderate to moderately vigorous intensity (40-
80% VO 2 max with median weekly energy expenditure of 1600 kcal/wk). The authors 
did however state that more trials are needed to establish the lower threshold for exercise 
amount and intensity for metabolic outcomes. The present study found that median 
weekly energy expenditure as low as 1238 kcal/wk (Table 20) produced substantial 
physical changes in persons with MetS, and some metabolic changes. 
 
Yamaoka et al. (2012) also performed a systematic review and meta-analysis of lifestyle 
modification interventions (LMI) effects on individuals with MetS. Their analysis 
however included “diet only” and “diet and exercise” randomised, controlled trials as 
opposed to the Carroll et al. (2004) review that analysed “exercise only” interventions. 
Like the Carroll et al. (2004) review, the Yamaoka et al. (2012) review also showed that 
LMI decreases the prevalence of MetS and associated abnormalities of MetS. Yamaoka 
et al. (2012) though suggested that their review indicates that dietary modifications may 
be more effective than exercise interventions. 
 
The training programs used in this study had a significant influence on the incidence of 
MetS. There was a marked reduction in the number of individuals that were still 
diagnosed with MetS after the training program (Fig 3 and 4). The research of 
Katzmarzyk et al. (2003) supports this finding. It should be noted that the MetSV group 
at baseline had no significant differences in the absolute levels of anthropometric and 
metabolic factors when compared to the Non-MetSV group. However, they did differ in 
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terms of the prevalence of the individual components of the MetS, and it was these 
prevalence levels that fell in response to the exercise programme.   
 
The nutritional intake of the participants in this study did not change significantly 
throughout the training period (Table 22) and there was no difference in caloric intake 
across the groups throughout the training period. Thus, exercise was the main effector of 
the reported outcomes of this study. 
 
It should also be noted that a post hoc sample size calculation showed that in order to 
observe significant differences across groups for a percentage change in waist 
circumference, an n of 18 participants per group would be required.  Thus, our study was 
under -powered to observe changes in waist across the groups. A sample size calculation 
based on percentage change in BMI gave an n of 8 per group, which is close to the actual 
number used in this study. It is therefore possible that the small sample size used in the 
current investigation was not large enough to observe significant changes in all the 
variables analysed.  
 
3.7 Conclusion 
When comparing the endurance exercise program using AT to set intensity with the 
walking program of Leon et al. (1997), the latter led to greater falls in blood pressure and 
anthropometric variables whilst the former led to greater falls in cholesterol and 
triglycerides and higher increases in HDL, although none of these changes were 
significantly different between the 2 groups. The program using AT significantly reduced 
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insulin resistance whilst the fall in this parameter in the MetSL group was not significant. 
The AT-based exercise program led to greater increases in VO2 peak and greater falls in 
insulin resistance in subjects with MetS than in those without.  
 
An important finding of this research was that a smaller percent of individuals were still 
diagnosed with MetS after a 12 week training period in the MetS group using AT to set 
intensity, as opposed to the MetS group not using AT to set intensity, although this 
difference was not statistically significant. The main advantage of the training program 
using AT is that its effects occurred at a reduced exercise frequency and lower exercise 
energy expenditure than that of the walking program. The data also indicated that 12 
weeks can elicit such a result and that an effective training program would not have to 
last for 20 weeks. 
 
Length of training program, dietary intervention and subject profile may be factors 
influencing this output. 
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CHAPTER 4 
FACTORS THAT INFLUENCE VO2 PEAK , BLOOD LACTATE TRANSITION 
THRESHOLDS AND THE COMPONENTS OF METABOLIC SYNDROME 
 
4.1 Abstract 
Background  
The role of cardio-respiratory fitness in the attenuation of the metabolic syndrome (MetS) 
has been noted in the literature. However, the determinants of cardio-respiratory fitness 
measurements such as VO2 peak and anaerobic threshold (AT) have not been investigated 
in persons with MetS. This study developed multiple regression models to find the 
variables that correlated with these measurements of cardio-respiratory fitness in persons 
with MetS. Regression models were also developed to investigate whether cardio-
respiratory fitness measurements were associated with the individual metabolic and 
cardiovascular components of the metabolic syndrome.  
Methods  
Thirty one males diagnosed with MetS and twenty-four healthy male participants each 
performed a VO2 peak and a blood lactate transition thresholds (BLTT) test. Height, body 
mass, waist circumference, blood pressure, fasting plasma triglyceride, total cholesterol, 
HDL-cholesterol and insulin levels were also measured. In addition, oral glucose 
tolerance tests (OGTT) were administered to all participants and HOMA indices were 
calculated. Separate multiple regression models were developed in which VO2 peak, AT 
and components of MetS were the dependent variables.  
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Results 
 MetS, waist circumference (indirect relationship) and AT (direct relationship) were 
found to correlate with VO2 peak and VO2 peak had a strong correlation with AT (direct 
relationship). Age (direct relationship) and body mass (direct relationship) were found to 
correlate with fasting glucose, whilst only age (direct relationship) correlated with HDL-
cholesterol. Age (direct relationship) and VO2 peak (indirect relationship) both correlated 
with systolic blood pressure but only VO2 peak (indirect relationship) correlated with 
diastolic blood pressure. 
 Conclusion  
The lower VO2 peak of participants with MetS is associated with their higher waist 
circumference. The VO2 peak, in turn, was shown to correlate strongly with anaerobic 
threshold. Therefore, reducing waist circumference in persons with MetS needs to be a 
focus of intervention programs for such a group. This study also found that both diastolic 
and systolic blood pressures were associated with cardio-respiratory fitness (VO2 peak). 
This further supports the benefit of increasing cardio-respiratory fitness in persons with 
MetS. 
 
4.2 Introduction 
Researchers have shown an inverse relationship between cardio-respiratory fitness and 
the incidence of MetS (Carroll et al. 2000; Irwin et al. 2002; Kullo et al. 2002; Lakka et 
al. 2003; LaMonte et al. 2005; Whaley et al. 1999). Katzmarzyk et al. (2004) showed that 
cardio-respiratory fitness has a strong protective effect against all-cause and cardio-
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vascular disease mortality in healthy men and in men with MetS. However, the 
determinants of cardio-respiratory fitness measurements such as VO2 peak and AT in 
persons with MetS have not been identified. Therefore, this study sought to develop 
multiple regression models to find variables that had strong relationships with cardio-
respiratory fitness measures. The importance of identifying these variables lies in 
intervention programs targeting the determinants to increase cardio-respiratory fitness in 
such a group. In addition, regression models were developed to investigate whether the 
measurements of cardio-respiratory fitness were associated with the individual metabolic 
and cardiovascular components of the metabolic syndrome. The hypothesis of this study  
was that cardio-respiratory fitness measurements correlate with the individual 
components of MetS.  
 
4.3 Methods 
The Human Ethics Committee of the University of the Witwatersrand, Johannesburg, 
South Africa, approved the study protocol (MO61104). 
 
4.3.1 Participants and definition of metabolic syndrome 
Thirty one (31) males diagnosed with metabolic syndrome (MetS) and twenty-four (24) 
healthy male subjects each performed a VO2 peak and a BLTT test. All healthy 
participants were age-matched with the patient group and had one or no components of 
the MetS. Patients were diagnosed with MetS by clinicians using the harmonised 
guidelines (Alberti, 2009). The presence of any 3 of the 5 criteria denoted below 
constituted a diagnosis of MetS: waist circumference (>94 cm); triglycerides (>1.7 
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mmol.L-1) or drug treatment for high triglycerides; HDL-cholesterol (<1.0 mmol.L-1) or 
drug treatment for reduced HDL-cholesterol; elevated blood pressure (> 130/85) or on 
anti-hypertensive drug treatment; elevated fasting glucose (>5.6mmol.L-1) or drug 
treatment for glucose intolerance. Any individuals taking lipid lowering agents, anti-
hypertensive drugs or treatments for dysglycaemia were not included in this study. 
 
4.3.2 Measurements 
All participants underwent an OGTT for the detection of undiagnosed diabetes. Fasting 
and two hour glucose levels were measured using a glucose oxidase method (Roche 
Diagnostics, Mannheim, Germany, measured on the Architect i2000 Abbott 
autoanalyser). Plasma triglyceride, total cholesterol and HDL-cholesterol levels were 
assayed using enzymatic assay methods (Roche Diagnostics, Mannheim, Germany, 
measured on the Architect i2000 Abbott autoanalyser). Fasting insulin levels were also 
measured on the Architect i2000 Abbott instrument using the Chemiluminescent 
Microparticle Immunoassay. The HOMA-IR (Matthews et al. 1985) was calculated to 
assess insulin sensitivity. Fasting blood samples were analysed by a pathology laboratory 
(Lancet Laboratories, Richmond, Johannesburg) as part of the diagnosis. 
 
Height was measured to the nearest millimetre using a Seca Stadiometer [Hamburg, 
Germany]. Body mass was measured to the nearest gram by a Charder electronic scale 
[Taiwan, China]. Waist circumference was taken as the greatest reading around the girth, 
midway between lateral lower ribs and the iliac crests. Blood pressure was measured by a 
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Honsun sphygmomanometer [Shanghai, China], sitting and using the average of two 
readings.  
 
4.3.3 The blood lactate transition thresholds test 
The BLTT test used an initial treadmill speed of 2.5 kph at a 5% gradient with speed 
increments every 4 minutes. The treadmill speed was modified depending on the 
response of a participant to ensure the collection of at least six blood samples for lactate 
analysis. After signalling impending exhaustion, participants were encouraged to 
continue to complete the 30 seconds period already begun. Electrocardiographic 
responses and oxygen consumption (VO2) were measured at the same time (Cortex 
Biophysik Metalyzer 3b CPX system, Leipzig, Germany). The ECG was used to monitor 
electrocardiographic responses during testing of the participants. Testing was stopped if 
any ECG abnormalities were observed. VO2 at exhaustion was recorded as the VO2 peak. 
No abnormalities in ECG readings were observed. This protocol was designed taking into 
consideration the low level of physical conditioning of persons with MetS. All 
participants were requested not to exercise for at least 12 hours before the testing session. 
 
Lactate concentration was measured from whole-blood samples taken from the fingertip 
using the Lactate Scout automated analyser (Lactate Scout, SensLab, Leipzig). Blood 
samples (collected from finger capillary vessels using a lancet) were taken at the end of 
each exercise period within 30 – 40 seconds of the participants standing still on the 
treadmill. The fingertip was first wiped with water to remove the sweat and then it was 
 150
dried before the blood sample was collected. The participant continued exercising within 
one minute of standing. 
 
4.3.4 Determination of anaerobic threshold 
The blood lactate transition threshold (BLTT) that was determined for each participant 
will be defined in this study, for purposes of terminology, as anaerobic threshold (AT). 
AT, in this study, will be defined as the workload (treadmill velocity given as km.h-1) 
marked by a rapid rise in blood lactate denoting the upper limit of equilibrium between 
lactate production and clearance (Bourdon, 2000). The treadmill velocity at AT for the 
BLTT tests was determined using the ADAPT method (Cheng et al. 1992). 
 
The ADAPT method determines AT from the individual shape of the velocity – blood 
lactate curve (not from a fixed blood lactate concentration) and is based on the Dmax mod 
method (Cheng et al. 1992).  A modification of the ADAPT method was used for 
determining AT in this study and has been discussed in our previous investigation (Torres 
et al. 2013). 
 
4.4 Statistical analysis 
Data distribution was analysed using Shapiro-Wilk’s W test, and any variables that were 
found to be significantly skewed were log transformed to normality. ANOVA was used 
to compare variables between the MetS and non-MetS groups. Waist circumference and 
body mass were found to differ between these groups and therefore an ANCOVA was set 
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up in which waist was included as an independent variable and a second ANCOVA was 
performed in which body mass was included with waist as independent variable.  
Pearson correlation analyses were used to determine the principal correlates of the VO2 
peak, AT and the metabolic and cardiovascular components of the metabolic syndrome 
(MetS). The variables included in the correlation matrices were chosen based on evidence 
from the literature and that relationships were physiologically feasible. Variables that 
gave significant correlations in the univariate analyses with (p<0.1) were then used as 
independent variables in separate multiple regression models in which VO2 peak, AT and 
components of MetS were the dependent variables. Backward, stepwise regression 
analysis was then performed until only variables with p<0.05 remained in the model.  
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4.5 Results 
4.5.1 Participants 
Table 23 Physical and biochemical characteristics of study participants 
 
Variables MetS (n= 31) Non-MetS (n=24) 
Age (years) 43.8 ± 7.91 42.7 ± 6.93 
Body mass (kg) 99.8 (25.1) 101 (21.3)* 
BMI (kg.m-2) 32.2 (5.20) 30.3 (7.00) 
Waist circumference (cm) 115 (9.00) 105 (16.8)*** 
Triglycerides (mmol.L-1) 1.75 ± 0.54 1.32 ±0.49
** 
Total cholesterol (mmol.L-1) 5.58 ± 1.37 5.50 ± 1.11 
HDL (mmol.L-1) 0.94 ± 0.22 1.11 ± 0.17
* 
Systolic blood pressure 
(mmHg) 
137 ± 12.2 121 ± 10.4*** 
Diastolic blood pressure 
(mmHg) 
87.7 ± 6.60 81.7 ± 6.88** 
Fasting glucose (mmol.L-1) 5.30 (1.00) 5.10 (0.45) 
2 hour glucose (mmol.L-1) 5.60 (3.40) 5.35 (1.80) 
Fasting insulin (ȝU.ml-1) 12.2 (7.40) 8.50 (2.20) 
HOMA index 2.81 (1.67) 2.09 (0.65) 
VO2 Peak (ml.min-1.kg-1) 27.9 (8.00) 35.0 (13.0)
*** 
Velocity at AT (km.h-1) 5.21 (1.31) 5.94 (2.75)
* 
Data is given as mean ± SD or median (IQR); *p< 0.05; **p< 0.005; ***p<0.0005 vs MetS 
HOMA index = glucose×insulin/22.5.  
HDL= High-density lipoproteins 
 
 
 
 
 
 
 
 
 
 
 153
Table 24 ANOVA and ANCOVA results for comparison of data between the MetS and Non-
MetS groups 
 
Variables Results of ANOVA Results of ANCOVA
(adjusted for waist) 
Results of 
ANCOVA 
(adjusted for 
body mass and 
waist) 
Triglycerides  
(mmol.L-1) 
9.02 (0.004) 11.3 (0.002) 14.7 (0.0004) 
Total cholesterol 
(mmol.L-1) 
0.06 (0.81) 0.32 (0.57) 0.31 (0.58) 
HDL (mmol.L-1) 9.38 (0.03) 12.9 (0.0007) 12.3 (0.0009) 
Systolic blood pressure 
(mmHg) 
25.5 (0.00001) 15.5 (0.0002) 15.6 (0.0002) 
Diastolic blood 
pressure (mmHg) 
11.0 (0.002) 5.69 (0.02) 4.83 (0.03) 
Fasting glucose 
(mmol.L-1) 
0.84 (0.36) 0.28 (0.60) 0.14 (0.71) 
2 hour glucose  
(mmol.L-1) 
0.01 (0.90) 0.76 (0.39) 0.40 (0.53) 
Fasting insulin  
(ȝU.ml-1) 
1.88 (0.18) 1.14 (0.30) 1.33 (0.26) 
HOMA index 1.84 (0.18) 0.60 (0.44) 0.79 (0.38) 
VO2 peak 
(ml.min-1.kg-1) 
21.7 (0.0002) 5.91 (0.02) 5.79 (0.02) 
Velocity at AT (km.h-1) 7.96 (0.007) 1.76 (0.19) 0.28 (0.60) 
Data is given as F-value (p-value) 
HOMA index = glucose×insulin/22.5.  
HDL= High-density lipoproteins 
 
 
 
Table 23 describes the study participants’ baseline characteristics. Significant differences 
between the non-MetS and MetS groups were found for body mass, waist circumference, 
triglycerides, HDL, systolic and diastolic blood pressure AT and VO2 peak. Waist 
circumference is known to be a major determinant of these variables and therefore 
ANCOVAs were performed comparing the metabolic, cardiovascular and fitness 
variables between the two groups with waist circumference included as an independent 
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variable. The results are shown in Table 24. Adjusting for waist circumference, 
strengthened the significant p-values for triglycerides and HDL-cholesterol and 
weakened the significant p-values for systolic, diastolic blood pressure and VO2 peak. 
Velocity at AT was no longer significantly different between the groups, once adjusted 
for waist circumference. Adding body mass to the ANCOVA with waist circumference, 
had no effect on HDL, systolic and diastolic blood pressure and VO2 peak, however, it 
increased the F- and decreased the p-values for triglycerides. In addition, adding body 
mass to the ANCOVA with waist circumference further attenuated the F and p-values for 
velocity at AT. This may be due to the strong correlation between velocity at AT and 
VO2 max (see Table 27) and the strong correlations of waist and BMI with VO2 max 
(see Table 25). Therefore an ANCOVA was set up for velocity at AT, with VO2 max as 
an independent variable. The F- and p-values were 2.69 and 0.11 respectively. Adding 
body mass and waist to the model had a minimal effect on the F- (2.60) and the p-value 
(0.11).   
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4.5.2 Univariate correlation and multiple regression analyses for VO2 peak and AT 
Table 25 Univariate correlations between VO2 peak and selected variables 
 
Variables VO2 peak 
Metabolic syndrome† -0.56 (<0.0001) 
Age -0.21 (0.15) 
Body Mass -0.63 (<0.0001) 
BMI -0.69 (<0.0001) 
Waist circumference -0.76 (<0.0001) 
Diastolic blood pressure -0.36 (0.10) 
Systolic blood pressure -0.46 (0.001) 
Fasting glucose level -0.26 (0.07) 
OGTT glucose level at 2 hours -0.24 (0.12) 
Velocity at AT 0.78 (<0.0001) 
Fasting insulin level -0.12 (0.46) 
HOMA index -0.21 (0.21) 
†Presence of the metabolic syndrome was coded as 1 and absence was coded as 0; data given as  
r-value (p-value). r-values were obtained from Pearson correlation analysis.  
OGTT = Oral glucose tolerance test 
HOMA index = glucose×insulin/22.5.  
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Table 26 Univariate correlations between velocity at AT (anaerobic threshold) and selected 
variables 
 
Variables Velocity at AT 
Metabolic syndrome† -0.34 (0.01) 
Age -0.12 (0.39) 
Body mass -0.65 (<0.0001) 
BMI -0.58 (<0.0001) 
Waist circumference -0.66 (<0.0001) 
Diastolic blood pressure -0.25 (0.07) 
Systolic blood pressure -0.28 (0.04) 
Fasting glucose level -0.16 (0.23) 
OGTT glucose level at 2 hours -0.17 (0.24) 
VO2 peak 0.78 (<0.0001) 
Fasting insulin level -0.07 (0.67) 
HOMA index -0.12 (0.44) 
†Presence of the metabolic syndrome was coded as 1 and absence was coded as 0; data given as  
r-value (p-value). r-values were obtained from Pearson correlation analysis 
OGTT = Oral glucose tolerance test 
HOMA index = glucose×insulin/22.5.  
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Table 27 Results of backward, stepwise multiple regression analyses for isolating principle 
determinants of VO2 peak and anaerobic threshold (AT)  
Regression 
model number 
Dependent 
variable 
Independent variables with 
standardised beta coefficient and (p-
value) 
R2 for full 
model with p-
value 
1 VO2 peak (log) Metabolic syndrome†: -0.24 (0.005) 
Waist: -0.33 (0.003) 
Anaerobic threshold (log): 0.48 (<0.0001) 
0.77 
(<0.0001) 
2 Anaerobic 
threshold (log) 
VO2 peak (log): 0.78 (<0.0001) 0.61 
(<0.0001) 
†Presence of the metabolic syndrome was coded as 1 and absence was coded as 0 
R2 values were obtained from backward stepwise multiple linear regression analyses  
 
Pearson correlation analysis demonstrated that the VO2 peak correlated with the 
following variables: body mass, BMI, waist circumference, diastolic and systolic blood 
pressure, fasting glucose levels and AT (Table 25). Velocity at AT correlated with the 
following variables: body mass, BMI, waist circumference, diastolic and systolic blood 
pressure and VO2 peak (Table 26). These variables, as well as coding variables for the 
presence/absence of metabolic syndrome, were then included as independent variables in 
two separate backward, stepwise regression models in which VO2 peak and AT were the 
dependent variables. In the first regression model, metabolic syndrome (negative 
relationship), waist circumference (negative relationship) and AT (positive relationship) 
were found to correlate with VO2 peak (Table 27). In the second regression model, VO2 
peak (positive relationship) was the only correlate of AT (Table 27). The variable VO2 
peak is expressed per kg body mass. Body mass and waist are strongly correlated with 
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each other (r=0.88, p<0.0001 from Pearson univariate analysis) and therefore the relation 
between VO2 peak and waist observed in Table 27 may be due to confounding from 
body mass. Body mass was therefore placed into model 1 as an independent variable. 
Body mass did not displace waist from the model, as would be expected if the former 
variable was a confounder. Body mass was in fact not correlated with VO2 peak 
(beta=0.33, p=0.054) whereas the correlation of waist with VO2 peak was strengthened 
by the addition of body mass (beta=-0.62, p=0.0007).    
 
4.5.3 Univariate correlation and multiple regression analyses for components of MetS 
and HOMA 
Pearson correlation analysis was also performed for components of MetS that are used in 
diagnosis of this syndrome (Tables 28 – 31). Fasting glucose levels correlated with age, 
body mass, BMI, and waist circumference, with a close-to-significant correlation with 
VO2 peak and fasting insulin (Table 28).  
Table 28 Univariate correlations between fasting blood glucose levels and selected variables 
 
Variables Fasting blood glucose 
Age 0.50 (0.0001) 
Body mass 0.37 (0.005) 
BMI 0.27 (0.05) 
Waist circumference 0.38 (0.004) 
VO2 peak -0.26 (0.07) 
Velocity at AT -0.16 (0.23) 
Fasting insulin level 0.29 (0.06) 
Data is given as r-value (p-value). r-values were obtained from Pearson correlation analysis 
AT= Anaerobic Threshold 
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HDL-cholesterol correlated only with age (Table 29). Our analysis did not find any 
variables correlating with plasma triglycerides (Table 30).  
 
Table 29 Univariate correlations between HDL-cholesterol and selected variables 
 
Variables HDL-cholesterol 
Age 0.29 (0.03) 
Body mass 0.05 (0.74) 
BMI 0.04 (0.75) 
Waist circumference 0.01 (0.94) 
Triglycerides -0.18 (0.19) 
VO2 peak -0.08 (0.57) 
Velocity at AT 0.07 (0.64) 
Fasting insulin level -0.08 (0.59) 
HOMA index 0.03 (0.84) 
Data given as r-value (p-value). r-values were obtained from Pearson correlation analysis 
HOMA index = glucose×insulin/22.5.  
AT= Anaerobic Threshold 
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Table 30 Univariate correlations between plasma triglycerides and selected variables 
 
Variables Plasma triglycerides 
Age -0.17 (0.22) 
Body mass 0.08 (0.58) 
BMI -0.002 (0.99) 
Waist circumference 0.002 (0.99) 
HDL-cholesterol -0.18 (0.19) 
VO2 peak 0.01 (0.93) 
Velocity at AT 0.06 (0.66) 
Fasting insulin level 0.01 (0.94) 
HOMA index 0.02 (0.92) 
Data given as r-value (p-value). r-values were obtained from Pearson correlation analysis 
HOMA index = glucose×insulin/22.5. AT= Anaerobic Threshold 
 
 
 
Correlation coefficients for the blood pressures are shown in Table 31. Systolic blood 
pressure correlated with age, body mass, BMI, waist circumference, VO2 peak and AT 
and a close-to-significant correlation with HOMA (Table 31). Diastolic blood pressure 
correlated with body mass, BMI, waist circumference, VO2 peak and AT (Table 31). 
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Table 31 Univariate correlations between systolic and diastolic blood pressure and selected 
variables 
 
Variables Systolic blood pressure Diastolic blood pressure 
Age 0.35 (0.008) 0.16 (0.25) 
Body mass 0.33 (0.01) 0.29 (0.03) 
BMI 0.36 (0.007) 0.33 (0.01) 
Waist circumference 0.38 (0.004) 0.33 (0.02) 
HDL-cholesterol 0.03 (0.81) -0.09 (0.52) 
Triglycerides -0.03 (0.86) 0.05 (0.70) 
VO2 peak -0.46 (0. 001) -0.37 (0.01) 
Velocity at AT -0.28 (0.04) -0.25 (0.07) 
Fasting insulin 0.24 (0.13) 0.19 (0.23) 
HOMA index 0.28 (0.07) 0.18 (0.25) 
Data given as r-value (p-value). r-values were obtained from Pearson correlation analysis 
HOMA index = glucose×insulin/22.5.  
AT= Anaerobic Threshold 
 
 
Insulin resistance has been identified as one of the possible causes of MetS (Eckel 2005). 
 
Therefore, this study also set up a regression model for HOMA to determine the variables 
that correlated with this measure of insulin resistance. Correlation coefficients for HOMA 
are shown in Table 32. HOMA correlated with body mass and waist circumference with 
p=0.1 (Table 32). 
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Table 32 Univariate correlations between HOMA index and selected variables 
 
Variables Homa 
Age 0.17 (0.28) 
Body mass 0.25 (0.10) 
BMI -0.07 (0.66) 
Waist circumference 0.25 (0.10) 
VO2 peak -0.21 (0.20) 
Velocity at AT -0.12 (0.44) 
Data is given as r-value (p-value). r-values were obtained from Pearson correlation analysis 
AT= Anaerobic Threshold 
 
Correlating variables were included as independent variables in separate backward, 
stepwise regression models in which components of the MetS and HOMA were the 
dependent variables (Table 33). In the first regression model, age and body mass were 
found to correlate with fasting glucose (positive relationships). The second regression 
model showed age to correlate with HDL-cholesterol (positive relationship). In the third 
and fourth model, age (direct relationship) and VO2 peak (negative relationship) both 
correlated with systolic blood pressure whilst in the fourth model, only VO2 peak was 
related to diastolic blood pressure (negtive relationship). In the last regression model, no 
variables were retained (Table 33). 
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Table 33 Results of backward, stepwise multiple regression analyses for isolating principle 
determinants of components of the metabolic syndrome and HOMA 
Regression 
model number 
Dependent 
variable 
Independent variables with 
standardised beta coefficient (p-
value) 
R2 for full 
model (p-
value) 
1 Glucose (log) Body mass (log): 0.16 (0.06) 
Age: 0.003 (0.001) 
0.54 
(<0.0001) 
2 HDL-cholesterol Age: 0.01 (0.03) 0.30 (<0.05) 
3 Systolic blood 
pressure 
Age: 0.47 (0.05) 
VO2 peak (log): -46.3 (0.003) 
0.53 
(<0.0005) 
4 Diastolic blood 
pressure 
VO2 peak (log): -21.9 (0.01) 0.36 (<0.01) 
HDL = High-density lipoproteins.  
R2 values were obtained from backward stepwise multiple linear regression analyses 
 
4.6 Discussion 
The majority of differences in metabolic, cardiovascular and physical characteristics 
between the 2 subject groups of this study agree with the diagnosis criteria for MetS. The 
reason for including the non-MetS group in this study was so that we could identify 
variables that differed between the two groups and which may therefore be possible 
factors involved in the aetiology of the disease.  
The VO2 peak was lower in participants with MetS. Multiple regression analysis found 
that the lower VO2 peak of participants with MetS is associated with their higher waist 
circumference. The VO2 peak, in turn, was shown to correlate strongly with anaerobic 
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threshold. This study also found that both diastolic and systolic blood pressures were the 
only MetS components associated with cardio-respiratory fitness (VO2 peak). 
 
The MetS group in this study had higher body mass and waist circumference, higher 
triglyceride and blood pressure levels and lower HDL-cholesterol levels when compared 
to the healthy group. When adjusted for waist circumference in an ANCOVA (Table 25), 
the differences in systolic and diastolic blood pressure between the 2 subject groups 
became less significant suggesting that waist circumference explains some of the 
difference in blood pressures between MetS participants and healthy participants. The 
same was evident with VO2 peak and AT (Table 25). However, in the multiple regression 
analysis waist circumference did not correlate with AT, and only correlated with VO2 
peak. This suggests that the reason adjusting for waist circumference in the ANCOVA for 
AT makes the p-value less significant is because of the correlation of waist circumference 
with VO2 peak. In addition, adjusting for waist circumference made the p-value for 
HDL-cholesterol much more significant and also slightly strengthened the p-level for 
triglycerides. This suggests that correcting for waist circumference uncovers unknown 
factors that cause HDL-cholesterol to be much lower in MetS than control participants.     
 
Adding body mass to the ANCOVA with waist circumference had little effect on the F- 
and p-values for HDL-cholesterol, showing that waist is the main variable responsible for 
the difference in HDL-cholesterol between the two subject groups. This was also the case 
for systolic and diastolic blood pressure measures and VO2 peak. The finding further 
highlights the importance of reducing waist circumference in a person with MetS. For 
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triglycerides, adding body mass to the waist-adjusted ANCOVA increased the F- and 
reduced the p-value. This suggests that waist and body mass adjustment uncovers other 
variables that affect triglycerides levels and that are associated with waist and body mass. 
For velocity at AT, both waist and body mass attenuated the F- and increased the p-
values in the ANCOVA comparing healthy and MetS participants. This shows that these 
variables may be responsible for the difference in AT between the two groups. However, 
neither waist or body mass correlated with AT in the multiple regression model for AT. 
However, waist and body mass did correlate with VO2 peak, which in turn correlated 
strongly with AT in a multiple regression model. This suggests that the effect of waist 
and body mass on the ANCOVA for AT was principally due to their correlation with 
VO2 peak. This was confirmed by performing an ANCOVA for AT with VO2 peak as the 
independent variable. Adding body mass and waist circumference to this ANCOVA had 
minimal effect on the F- and p-values. 
 
Even when corrected for waist circumference (and body mass) the MetS group had a 
significantly lower VO2 peak than the non-MetS group (Table 24). This demonstares that 
waist is not the sole reason for the lower VO2 peak in subjects with MetS. This finding 
agrees with the Kuoppio study (Lakka et al. 2003) that found directly determined VO2 
max to be lower in persons with MetS. Also, Laaksonen et al. (2002) showed that men 
with a VO2 max of < 29.1 ml.min-1.kg-1 were 3 – 4 times more likely to have MetS than 
those with VO2 max of  35.5ml.min-1.kg-1. These 2 values are in agreement with the 
VO2 peak values of the subject groups in this study (Table 25). Furthermore, researchers 
have also found an inverse relationship between cardio-respiratory fitness and the 
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incidence of MetS (Carroll et al. 2000; Irwin et al. 2002; LaMonte et al. 2005). The 
difference in VO2 peak between the two groups cannot be due to the healthy group 
training more than the MetS group, because all participants in the study had not exercised 
regularly for a minimum of 4 weeks prior to the testing. Adjusting for body mass had no 
effect on the ANCOVA for VO2 peak, which suggests that the difference in VO2 peak 
between the 2 groups is due to waist circumference and not to total body mass . 
 
The regression analysis using VO2 peak as the dependent variable (Table 27) suggests 
that the lower VO2 peak of participants with metabolic syndrome is associated with their 
higher waist circumference. This was confirmed in an ANCOVA comparing VO2 peak 
between the two participant groups, where waist circumference was added as a covariate. 
This attenuated the F-value from 21.7 to 5.91 and the p-value from 0.0002 to 0.02 (Table 
24). This finding confirms the data from chapter 2 that demonstrated that waist 
circumference correlates with VO2 peak, and highlights the importance of reducing waist 
circumference in individuals with MetS, in order to improve energy production and 
health. It is interesting to note that both longitudinal (Eisenmann et al. 2005) and cross 
sectional studies (Jago et al. 2010) have shown that, of all anthropometric variables 
measured, only waist circumference was negatively correlated with level of fitness. It is 
not known why waist circumference specifically influences VO2 peak. However, waist 
circumference is a proxy indicator of visceral fat mass (Pouliot et al. 1994) and this body 
fat depot is a negative regulator of whole body insulin sensitivity (Ross, 2002) and may 
therefore limit glucose metabolism in skeletal muscle.  
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The current study did not show a relationship between insulin resistance, as measured 
using HOMA, and VO2 peak, however it did show that MetS was associated with VO2 
peak independently of waist circumference. A number of studies (Bogardus et al. 1985; 
Brochu et al. 2000; Goodpaster et al. 1997; Nyholm et al. 1996; Rosenthal et al. 1983) 
did identify a negative relationship between insulin resistance and VO2 peak. Our 
divergent results may be due to differing profiles of the study participants. The limited 
range of  VO2 max achieved in sedentary participants (like those recruited into our study) 
may reduce the correlation between VO2 max and insulin sensitivity (Smith, 1981). In 
addition, the relationship between VO2 max and insulin sensitivity may be less apparent 
in obese individuals as the effect of adiposity becomes dominant (Toth et al. 2001). It is 
also possible that our study is insufficiently powered to pick up a relationship between 
HOMA and MetS and a larger cohort of participants is necessary to further investigate 
the correlation of MetS with VO2 peak, particularly looking at MetS-related variables 
such as HOMA or visceral fat mass. 
 
The regression model using HOMA as the dependent variable did not show any 
significant relationships with the included variables. This may be a result of the small 
sample number. The only variables included in the initial regression model were body 
mass and waist circumference, each having p=0.1 in the univariate analysis.  These 
variables have been shown to have strong relationships with insulin resistance in many 
studies.  
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The regression analysis data using AT as the dependent variable demonstrated that the 
lower AT values in participants with the metabolic syndrome is largely associated with 
their lower VO2 peak levels. This finding supports the notion of a lower level of aerobic 
fitness in patients with MetS, as has been demonstrated in other studies (Church, 2009; 
Eisenmann, 2007). Also, the higher velocity attained at AT by the healthy participants 
when compared to the participants with MetS, confirms the observation that persons with 
MetS exhibit a lower level of physical conditioning than their healthier counterparts 
(Lakka et al. 2003). This finding also agrees with the data of the study in a previous 
chapter (Chapter 2). 
 
Aunola et al. (1988) constructed a factor model for aerobic work capacity. The model 
showed that maximal aerobic power (VO2 max) correlated strongly with AT and vice-
versa (r=0.92).  This is also a reason why AT was included in the regression model for 
VO2 peak and VO2 peak was included in the regression model for AT. The model agrees 
with our findings and showed that AT correlated strongly with VO2 max.   
Another reason for the reciprocal inclusion of these parameters in the regression models, 
is that if AT changes, VO2 peak or max does not necessarily change and if VO2 peak or 
max changes, AT does not necessarily change. 
 
Comparing the regression models for VO2 peak and AT shown in Table 27 to those for 
the same dependent variables in Table 4 of Chapter 2, it can be seen that R2 values are 
slightly higher for both models in Table 27. Furthermore, AT appears as a significant 
correlate of VO2 peak in this study but not in the previous study, and body mass occurs as 
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a correlate of AT in the earlier study, but not in this study. These differences are most 
likely due to the higher N (55) in the current study (Table 27), as compared to 30 in the 
study from Chapter 2. The higher N will lead to a wider range for all variables.      
 
Body mass and age were the only variables associated with fasting glucose in this study 
(Table 29). The cardio-respiratory parameters were not associated with this component of 
MetS.  VO2 max has been shown to be a significant predictor of total and non-oxidative 
glucose disposal (Toth et al. 2001). Furthermore, this measure of cardio-respiratory 
fitness has been found to be a stronger determinant of variation in glucose disposal than 
adiposity or caloric expenditure from physical activity in healthy individuals (Bogardus 
et al. 1985; Toth et al. 2001). However, the cited studies did not measure blood glucose 
levels but used the hyperinsulinemic euglycemic clamp and glucose dilution technique to 
assess glucose disposal (mg.kg fat-free mass (FFM)-1.min-1). 
 
Age correlated with three of the five metabolic syndrome components (glucose, HDL-
cholesterol and systolic blood pressure). This agrees with the finding that MetS is 
diagnosed in the latter years of life (Carroll et al. 2004). 
 
Cardio-respiratory fitness (VO2 peak) was shown to be associated with the MetS 
components of systolic and diastolic blood pressure. VO2 peak is equal to cardiac output 
x arterio-venous oxygen difference and cardiac output is equal to mean arterial blood 
pressure / total peripheral resistance. These equations indicate that there is a degree of 
association between mean blood pressure and VO2 peak. Mean arterial blood pressure 
 170
(MAP) obviously consists of elements of both systolic (SBP) and diastolic blood 
pressure(DBP) [MAP = (SBP/3-DBP/3)+DBP]. This highlights the involvement of 
systolic and diastolic blood pressure in the central cardio-vascular component of maximal 
aerobic capacity.  
 
4.7 Conclusions 
Multiple regression analysis found that the lower VO2 peak of participants with MetS is 
associated with their higher waist circumference. The VO2 peak, in turn, was shown to 
correlate with anaerobic threshold. This highlights the importance of reducing waist 
circumference in the treatment of MetS. Furthermore, increasing cardio-respiratory 
fitness in persons with MetS may positively influence their systolic and diastolic blood 
pressures. Also, the relationship observed here between waist and VO2 peak is confirmed 
by the observation in Chapter 3 that an improvement of VO2 peak is related to a fall in 
waist circumference.  
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CHAPTER 5  
5.1 Conclusions 
The main aim of this thesis was to design an exercise program to optimize the effects on 
the metabolic profile of persons with MetS by using AT to set the exercise intensity. The 
study thus, firstly showed that AT is reproducible in persons with metabolic syndrome; 
AT tests can be used to set the exercise load for persons with MetS and that the Mader 
and ADAPT methods of determining the AT were similarly reproducible. The study then 
showed that an exercise program using AT to set exercise intensity was effective in 
improving the metabolic profile of persons with MetS. The exercise program using AT 
had similar outcomes on persons with MetS as the training program not using AT. The 
training program using AT however positively influenced insulin sensitivity. This was 
not evident in the other training groups. Furthermore, a smaller percent of individuals 
were still diagnosed with MetS after the training period in the training group using AT, as 
opposed to the training group not using AT. The training program using AT produced 
these outcomes at a training volume that was less than the training program not using AT. 
Thus, the training program designed in this study positively influenced the physical, 
physiological and metabolic profile of persons with MetS at a training volume that is 
practically possible in such a cohort. Our data also indicated that a 12 week training 
period is as effective in eliciting such improvements as a 20 week training duration. 
 
A unique finding of this thesis was that the lower VO2 peak and velocity at AT in 
individuals with MetS was associated with a greater waist circumference and a lower 
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VO2 peak respectively. A decrease in waist circumference was also found to be 
associated with the improvement in VO2 peak. This was confirmed by the regression 
model in the third study (Chapter 4) of this thesis which showed that waist circumference 
correlated with VO2 peak. Therefore, reducing waist circumference in persons with MetS 
should be an important aim of an intervention program for the syndrome. 
 
Another unique finding was that with training, VO2 peak improved significantly only in 
the MetS groups and did not change significantly in the group without MetS. This 
indicates central training adaptation differences between these groups. In addition, the 
thesis found that increasing cardio-respiratory fitness in persons with MetS may 
positively influence their systolic and diastolic blood pressures and that a median weekly 
energy expenditure as low as 1238 kcal/wk produced substantial physical changes in 
persons with MetS, and some metabolic changes. 
 
The BLTT test and modified ADAPT method of determining AT are simple, low-cost, 
reproducible ways of setting exercise intensity for persons with MetS that can be 
incorporated in the routine cardio-respiratory fitness assessment of an individual (e.g. can 
be done during the routine stress electro-cardiogram test). The test is a more specific 
cardio-respiratory fitness test for the person with MetS that can also be used by the health 
and fitness professional to design an exercise program and monitor progress. 
 
Current blood lactate analysers (like the Nova biomedical lactate plus machine) 
(www.novabiomedical.com/products/lactate-plus) make testing additionally easier by 
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using very small capillary blood samples (0.7 ȝL as opposed to the 25 ȝL required by the 
lactate analyser used in this thesis), taking 13 seconds (as opposed to 60 seconds) for 
analysis and not requiring calibration codes for the testing strips which eliminates a 
source of measurement error. The pricing of these analysers has also reduced due to 
many types now becoming available in the market place.  
 
The training program using AT can also be applied where there is no access to a gym 
facility.  This can be done by using the heart rate (instead of the treadmill velocity) at 
which AT occurred in the BLTT test. Thus, pace of walking/jogging or inclined terrain 
can be used to increase heart rate into the required training zone. The training program 
using AT has a simple periodization that can be implemented in any setting using 
exercise intervention programs for MetS. 
 
5.2 Limitations of the thesis 
All participants in the three studies of this thesis were white males, and thus it cannot be 
assumed that the results will be the same for other ethnic groups and/ or females. 
 
The second and third study had low numbers in each group, due to the subject drop-out 
rate. However, despite this limitation we were able to pick up significant trends in the 
data. The second study (Chapter 3) also did not have a non-exercising control group or a 
group without MetS that undertook the Leon et al. exercise programme (these groups 
were originally included in the study, but had to be removed due to financial constraints). 
The low N and the lack of sufficient control groups in the second study mean that the 
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conclusions drawn from this study must be treated with some reservation. Despite this, 
the training program using AT did produce comparable results to the walking program 
but at a lower training volume.  
 
The nutritional intervention was not performed intensively. Furthermore, the study did 
not measure other MetS related factors e.g. inflammatory markers, markers of fibrinolysis 
and coagulation, endothelial markers etc. Visceral and subcutaneous fat mass were also 
not measured in this thesis. In addition the MetSV group in Chapter 3 did not differ in a 
statistically significant degree to the Non-MetS group in terms of metabolic or 
anthropometric parameters despite each subject in the former group being diagnosed with 
MetS. This may be a result of the small n numbers.  
 
Also, the second study (Chapter 3) compared against only one other exercise regime 
(Leon et al. 1979) and insulin sensitivity was measured using HOMA and not the gold 
standard method (euglycaemic, hyperinsulinaemic clamp).  
Furthermore, all blood lactate measures were taken on a portable machine rather than a 
laboratory autoanalyser. Also, the average of two blood pressure readings was used in the 
second study. The white-coat effect may have influenced the readings. 
 
This was a cross sectional study and therefore causative agents could not be identified. 
Furthermore, regression models were used to find variables that correlated with a 
selection of different outcome variables, however such models can only identify 
correlations and cannot pinpoint causative factors. Furthermore, the current study did not 
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investigate the mechanisms involved by direct experimentation but used correlation 
analyses. Correlations can only show associations and do not demonstrate causality. 
Future experiments are required to determine whether the findings from correlation 
analysis are true causative. 
 
5.3 Future research 
A larger cohort of participants needs to be investigated with the inclusion of a non-
exercising control group and a group without MetS that undertake an exercise program 
not using AT.  Also, the MetSV training program needs to be compared to other training 
programs that are of different methodology to the Leon et al. 1979 program.  
 
The response of women and other ethnic groups to such training programs needs to also 
be determined.  In addition, the applicability of this method of exercise design to a large 
population group using primary health care facilities needs to be investigated.  
 
The influence of psychological intervention programs in lifestyle modification therapies 
for MetS on exercise adherence levels needs further investigation. 
 
 A larger cohort of participants and more specific tests (i.e euglycemic clamp, muscle 
biopsies and MRI scans) are also necessary to further investigate the correlation of MetS 
with VO2 peak, particularly looking at MetS-related variables such as HOMA, and 
visceral fat mass. The relationship between exercise training at the AT, insulin sensitivity 
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and skeletal muscle Glut-4 transporter levels also needs to be addressed with further 
research. 
 
Analysis of waist circumference, visceral fat mass, insulin sensitivity measures and 
markers of skeletal muscle glucose metabolism and their relationship to different levels 
of VO2 peak may help investigate why the relationship between waist circumference and 
VO2 peak exists. 
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APPENDIX 
A. Standardized nutrition program used in study of chapter 3 
 
Nutrition programme  
 
Follow the programme 6 days per week – one day free! 
 
• Alcohol intake: preferably not more than 4 drinks a week 
 
• No cakes/chocolates/sweets/fruit juice (unless very diluted)/sugar 
 
Examples 
 
Breakfast: 
1 large Boiled/poached/scrambled egg 
1 piece of Low GI or rye toast – lightly buttered 
Tomato/mushroom/onion 
 
OR 
 
Poached haddock/smoked kippers/sardines 
1 piece of Low GI or rye toast – lightly buttered 
 182
Tomato 
 
OR 
 
½ papino or few berries 
Pure Whey Protein powder- 1 scoop  
1 tablespoon plain yoghurt (optional) 
½ glass water, ½ glass milk low fat 
Blend together into a smoothie 
 
OR 
 
Small bowl of Oats + Whey Protein powder  
+/- milk  
Can add 1 tablespoon ground seeds 
 
OR 
 
Lean mince meat 
1 piece Low GI or rye toast – lightly buttered 
Tomato 
 
OR 
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½ tub cottage cheese 
1 piece low GI or rye toast-lighly buttered 
Tomato/few slices of avo 
 
LUNCH: 
• Protein: ie. Chicken breast or tuna (1/2 – 1 tin) 
• Salad ingredients – eg.Greens/tomato/cucumber/peppers/ 
/mushrooms/nuts/olives/sprouts/grated carrot/ 
• Add ½ an avocado 
• Add Low fat cheese – mozzarella/cottage/feta/halloumi/ 
• Always have olive oil and may have other dressing 
• May have a piece of Low Gi or rye bread or 2 provitas 
 
OR 
 
Cold lean meat – preferably not processed 
Salad 
Avocado 
Olive Oil dressing 
2 provita or 1 ryvita or Low Gi bread 
 
SUPPER 
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Lean meat/chicken/fish (any sort) Red meat twice a week 
Variety of salads and vegetables 
 
NO starch at night or a little brown rice/sweet potato/new potato/quinoa 
 
*************** 
 
Snacks between meals: ie 11am and 3-4pm 
• Nuts (any except peanuts). Almonds best. Small handful. 
• Cottage cheese with tomato/cucumber/or berries 
• Hummous with carrots 
• Cold chicken, cold meat or Pickled fish 
• Biltong. Only 30g. lean, low salt. 
• NOT more than 2 fruit per day!!!! Try to combine protein eg. Nuts (5-7 
almonds).Best fruit: strawberries, cherries, plums. Pears, apple, citrus 
 
Ideas for Vegetables: 
 
• Spinach – particularly baby spinach leaves 
• Broccoli/cauliflower 
• peas 
• Baby marrow 
• Green beans 
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• Gem squash 
• Patty pans – green or yellow 
• Asparagus 
• Tomato/ peppers 
• Butternut/pumpkin/carrot/corn – watch quantities! 
May grill veg with olive oil and herbs or have with hummous/pesto/avo/pine nuts. 
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B: The Willett food frequency questionnaire 
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C: 24 hour eating record used for study of chapter 3 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
D: Copy of published paper: 
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